BIOTECH IN BAVARIA
RESPONSIVE IN CHALLENGING TIMES

REPORT
2019/20
including more than 350 company profiles
Personalised healthcare is possible.

Today’s medical knowledge, technology and data science offer an enormous promise: the right treatment for the right patient at the right time. If we work together, we can make this a reality for patients worldwide.
BioM – central point of contact for pharma and biotechnology in Munich and Bavaria

- consulting for founders-to-be, start-ups & SMEs
- grant & seed financing support
- pre-seed incubation & m⁴ award
- matchmaking, networking & partnering
- events, conferences & training
- representing Bavarian biotechnology world-wide
- investment opportunities
- central online platform: job exchange, company database and much more

www.bio-m.org
Never stop exploring.
Be part of the digital future.

Right this way for R&D

Bavaria is the leading biotech and pharma location in Germany. With a high number of international pharma companies and new rising biotech stars, Bavaria offers the right environment and infrastructure for your company – especially when it comes to R&D.

In Bavaria you’ll find the right ingredients: a wealth of potential partners and customers throughout the entire industry value chain and highly qualified personnel. Bavaria is the home of digital future and your perfect business location.

Discover the benefits of expanding your business to Bavaria. We do everything to get your business started: From arranging contacts with relevant players to identifying the perfect location for your company.

Our service is confidential and free of charge. Get in touch with us!

→ www.invest-in-bavaria.com
**Content**

**Greeting**
Bavarian Ministry of Economic Affairs

**Preface – Corona – The Hour of Truth for the Biotech Industry**
Prof. Horst Domdey – Spokesman Bavarian Biotechnology Cluster

**Company Development**
Strong Growth in Employment

**Bavarian Biotechnology in the Fight against COVID-19**
Bavaria’s Efforts in Dealing with the Coronavirus Pandemic

**COVID-19 Company Survey**
Challenges and Opportunities – a Snapshot of the Bavarian Cluster

**Professional Translation**
A Guest Contribution from Dr. Siegfried Bialojan

**Start-ups for the Medicine of the Future**
Tailor-made Programs for Bavarian Founders

**DigiMed Bayern**
For the Medicine of the Future

**International Affairs**
German-Japanese Cooperation for global Innovation

**Scientific Excellence in Biomedicine in Bavaria**
Focus on Cellular Therapy

**Innovation Centers in Bavaria**
Regional Networks in Life Sciences

**Company Profiles**

---

**About this Study:**
For the Bavarian Biotech Report, a biotechnology company has been defined as a company which develops and/or manufactures products on the basis of state-of-the-art molecular biological methods.

The biotechnology companies were classified according to the location of the headquarter as ‘international’ or ‘native Bavarian’. The classification into OECD and non-OECD biotech companies as found in previous reports has been dispensed with, as this does not accurately portray the diversity of the biotech pharma ecosystem.

Part of the data were collected in cooperation with BioDeutschland e.V. It was possible to achieve a response rate to the survey of more than 50% in the core group. Possible deviations from previously published figures are the result of additional data gathered in this survey that also may refer to previous years. The period under review for this report is 2019.

There are about 350 company profiles listed in the appendix of this brochure (pp. 41). Not every company listed is also considered in facts and figures in this survey, for example some companies with very specific services, or selected medical engineering companies. Furthermore, some Bavarian biotech and pharma companies are included in the survey but have not activated their listing in appendix. Also more than 500 Bavarian companies in medical engineering are not included in this survey (by numbers or with profiles).

Published in July, 2020
Lab experts at your side

From 6 pharma lab locations in the heart of Europe, we offer worldwide solutions in high and reliable quality for:

- Biologics
- Cosmetics
- Foods for Special Medical Purposes (FSMPs)
- Release & Stability
- Pharmaceuticals
- Medical Devices
- Technical Regulatory & Regulatory Affairs

All services from a single source, even for complex requirements.

pharma@synlab.com | www.synlab.de
A current review of 2019 and the first months of 2020 would not be complete without considering the current coronavirus pandemic. Cutbacks and changes affect not only the entire Bavarian economy and scientific institutions, but also all areas of public life and thus every individual in our society.

The medium and long-term economic consequences for the industry are at present still difficult to predict, and the Bavarian biotechnology sector will certainly not be spared, too. We have indeed heard that many companies have already suffered a dramatic drop in revenues. Staying afloat and maintaining supply chains is proving to be a huge challenge.

With its emergency financial aid program, the Bavarian State Government is doing its best to help employers, employees and businesses to weather the storm and to be ideally prepared for making a new start.

At the same time, we are delighted at the speed and dynamism with which the Bavarian biotechnology sector has already responded to the challenge. Diagnostic companies and device developers have been very quick to adapt, further develop, and deliver their products. Various biotech and pharmaceutical companies are currently developing new therapeutic and vaccine candidates. CROs are supporting an increasing number of clinical trials on COVID-19 which are being conducted in Germany and Bavaria. Some Bavarian companies have delivered highly specific antibody tests at impressive speed. Network organizations, in particular, have an important role to play in this crisis by handling projects in clusters and interlinking research projects.

Even if only a fraction of companies ultimately emerge stronger from the crisis, e.g., with revenue gains, the Bavarian biotechnology sector has reacted quickly and has been a great help right from the beginning of the present coronavirus crisis. We are in no doubt that the interplay of outstanding scientific institutions and dynamic entrepreneurial spirit offers enormous potential, which we as the State Government shall continue to support and promote. We aim to strengthen the global competitiveness of our attractive locations all over Bavaria.

Eventually we hope that we can soon welcome international visitors again and look forward to showing them what Bavaria and its excellent biotechnology sector have to offer.
Developing Targeted Radionuclide Therapies in Precision Oncology.

www.itm.ag

PRECISELY FOR ME.

Dedicated to giving cancer patients better answers than “maybe”.
like all other industries – and is still fighting a hard battle to survive in the current difficult situation. This is the not all too astonishing result of a recent survey which was carried out by BioM. The pandemic has, as we all know, brought immense suffering to our society, the percentage of deaths among infected people, especially in countries with a less well-developed health-care system, has made us shudder. The economic consequences of the world-wide shut-downs of most of the industries and also of most of the academic institutions with their research labs has struck the biotech industry more or less completely unprepared. Fortunately, the political decision makers in Germany and Bavaria have made a lot of wise and mostly correct decisions. On the other hand, they have not (yet) fully recognized where the rescue out of the pandemic can come from, where it has to come from, namely from the pharma and biotech industries. What needs to be done is to put these two industries - along with our excellent health care system - at the forefront of the battle against COVID-19.

Still, I believe that this can and will be the hour of truth for the international and also local biotech companies, because they now have the unique opportunity to prove their real significance in situations like this. The developers of fast and safe, first-class diagnostic tools have already passed their test and they will further optimize, possibly even revolutionize, the existing repertoire in the coming months. And although we have to keep in mind that the development of antiviral vaccines is – in retrospect – not a genuine success story, we will nevertheless continue to hope that safe vaccines will be developed to protect us from a possibly fatal infection. Finally, the therapeutic treatment of infected people with not only repurposed but also newly developed innovative drugs might eventually turn out to become the most successful path to get out of the current devastating situation. Taking everything together it seems that we are currently experiencing not only one of the biggest crises but also one of the most crucial moments in the history of the modern biotech industry, in other words its moment of truth.

Sincerely yours,

Prof. Horst Domdey
COMPANY DEVELOPMENT

Strong Growth in Employment

Number of Companies

In 2019, a total of 400 companies were operating in the biotechnology and pharmaceutical industry in Bavaria. The pharma group (totaling around 60) includes traditional pharmaceutical companies that have existed in Bavaria for decades, global players such as Astellas Pharma, GSK, Baxter, Daiichi Sankyo, Merck, Sharp & Dohme (MSD), and others that have their German or European headquarters in the region. Another important pillar of the biopharma ecosystem comprises 66 contract research organizations (CROs) which contribute with their expertise to preclinical research and development or analytics as well as in setting up and monitoring clinical trials. These organizations are service providers for both local and international drug developers, making Munich a leading center for clinical trials and drug development.

Bavarian biotech SMEs are the main target group of BioM’s networking activities and funding initiatives. These companies focus on the development of new therapeutics and diagnostics, a field in which roughly 66 companies are active. The area is further strengthened by 39 providers of technology platforms, mainly assisting drug development. As digital technology is a main driver in health innovation – and not everything can be categorized as ‘bioinformatics’ – many new companies working in ‘digital health,’ accounting for 23 in total, have been added to this category.

Likewise, the area of biotech devices and reagents is highly advanced and features 27 companies delivering specialized laboratory equipment, assay systems and measuring instruments for research, among other things. In addition, biotech SMEs are active in the fields of industrial biotechnology (22), agriculture, food, and other specific areas. Lastly, 30 suppliers of materials such as lab, electronics or microscopy consumables complete our ecosystem.

Newly founded Companies

In 2019, the momentum for start-ups in Bavaria was very strong. Overall, the number of new companies in the biotech/pharma arena reached an all-time high of +16 (one of which was ‘pharma,’ so our ‘biotech’ community grew by 15 new members). Only one of the 15 biotech additions entailed a relocation: Ipsen Pharma chose Munich as the new site for its German headquarters; 14 genuinely started from zero, supported by many helping hands and organizations. The BioM network is renowned in this regard, connecting scientists, founders, experienced entrepreneurs, investors, lawyers, real estate and many other qualifications for getting a new venture started (an introduction to all the advisory services offered by BioM can be found...
THE BAVARIAN BIOPHARMA SECTOR

Number of Companies

60 Pharma

244 Biotech

30 Suppliers

66 CROs

185 Bavarian Biotech (SME)

59 International Biotech

+ 14 new biotech foundations

40 Therapeutics

26 Diagnostics

39 Technology Platforms

27 Devices and Reagents

22 Industrial Biotech

23 Bioinformatics & Digital Health

8 Other

400 Companies
Among the ‘native Bavarian biotechs,’ most are small and medium-sized companies. A small but growing number (20) of them have more than 100 employees. MorphoSys ranks first with over 400. The largest biotechnology company in Bavaria is the global player Roche, operating one of the largest European biopharmaceutical plants in Penzberg near Munich. The company is growing steadily both in terms of workforce and buildings at its Penzberg site, where more than 6,400 employees are involved in researching and producing biopharmaceutics and diagnostics.

With 16,130 employees (+5%, +700 people) across all 244 biotech companies, Bavaria showed strong growth in 2019. In terms of the ‘native Bavarian biotechs,’ there has been an even more impressive increase in employment by +12% (+530 people) to around 5,000 staff at the 185 SMEs. The number of employees has been growing for many years, recently amounting to more than +20% in the group of SMEs in the period from 2017 to 2019, making the sector an interesting employer offering highly qualified jobs. This growth is a clear indicator of global competitiveness, which is impressively underlined by predominantly small and medium-sized companies in Bavaria. Combined with around 19,000 employees in pharmaceutical companies, CROs, service providers, production and supplier companies, approximately 35,000 people

<table>
<thead>
<tr>
<th>COMPANY</th>
<th>CATEGORY</th>
<th>LOCATION</th>
<th>WEBSITE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cherry Biolabs GmbH</td>
<td>Therapeutics</td>
<td>Würzburg</td>
<td><a href="http://www.cherrybiolabs.com">www.cherrybiolabs.com</a></td>
</tr>
<tr>
<td>Ebenbuild GmbH</td>
<td>Bioinformatics/Digital</td>
<td>Munich</td>
<td><a href="http://www.ebenbuild.com">www.ebenbuild.com</a></td>
</tr>
<tr>
<td>Eisbach Bio GmbH</td>
<td>Therapeutics</td>
<td>Martinsried</td>
<td><a href="http://www.eisbach.bio">www.eisbach.bio</a></td>
</tr>
<tr>
<td>Evanium Healthcare GmbH</td>
<td>Pharma/Food</td>
<td>Munich</td>
<td><a href="http://www.evanium.de">www.evanium.de</a></td>
</tr>
<tr>
<td>Fluics GmbH</td>
<td>Devices &amp; Reagents</td>
<td>Munich</td>
<td><a href="http://www.fluics.com">www.fluics.com</a></td>
</tr>
<tr>
<td>Genesurge GmbH</td>
<td>Diagnostics</td>
<td>Munich</td>
<td><a href="http://www.genesurge.com">www.genesurge.com</a></td>
</tr>
<tr>
<td>Incyton</td>
<td>Devices &amp; Reagents</td>
<td>Martinsried</td>
<td><a href="http://www.incyton.com">www.incyton.com</a></td>
</tr>
<tr>
<td>Independent Data Lab UG</td>
<td>Bioinformatics/Digital</td>
<td>Munich</td>
<td><a href="http://www.independentdatalab.com">www.independentdatalab.com</a></td>
</tr>
<tr>
<td>OmicEra Diagnostics GmbH</td>
<td>DNA/Protein Analytics</td>
<td>Martinsried</td>
<td><a href="http://www.omicera.com">www.omicera.com</a></td>
</tr>
<tr>
<td>Promove Biotech GmbH</td>
<td>Regenerative Medicine</td>
<td>Nürnberg</td>
<td>–</td>
</tr>
<tr>
<td>res mechanica GmbH</td>
<td>Bioinformatics/Digital</td>
<td>Munich</td>
<td><a href="http://www.resmechanica.com">www.resmechanica.com</a></td>
</tr>
<tr>
<td>Sirana Pharma GmbH</td>
<td>Therapeutics</td>
<td>Martinsried</td>
<td><a href="http://www.sirana-pharma.com">www.sirana-pharma.com</a></td>
</tr>
<tr>
<td>Tubulis GmbH</td>
<td>Therapeutics</td>
<td>Munich</td>
<td><a href="http://www.tubulis.com">www.tubulis.com</a></td>
</tr>
<tr>
<td>Velvio GmbH</td>
<td>Therapeutics</td>
<td>Regensburg</td>
<td><a href="http://www.velvio.com">www.velvio.com</a></td>
</tr>
</tbody>
</table>
THE BAVARIAN BIOPHARMA SECTOR
Employment

Employees in Biopharma Companies
35,000

Employees in Life Sciences Research
10,000

13,000 Pharma
16,000 Biotech
3,000 Suppliers
3,000 CROs

5,000 Bavarian Biotech (SME)
11,000 International Biotech

+5%
+12%
As a developer of drugs and diagnostics for the personalized treatment of cardiovascular diseases, Martinsried based AdvanceCOR has a human Fc fusion protein in the pipeline, Revacept, which binds to arterial lesions like a vascular patch to prevent blood clots in arteries. A phase II study showed that fewer cerebral infarctions occurred when Revacept was given. In the Revacept group 46% fewer new brain infarcts were determined by magnetic resonance imaging (MRI) and 36% fewer patients had new strokes or transient ischemic attacks than the placebo-treated patients.

In autoimmune diseases, MorphoSys and Immunic Therapeutics are especially active. Listed on Nasdaq since the beginning of 2019, Immunic is developing selective immunology therapies against chronic inflammatory and autoimmune diseases. Ten of Morphosys’ candidates have already reached phase III of clinical development.

Bavarian Nordic leads the way in the research and development of drugs against infectious diseases. It accounts for six out of the total of 12 projects in the Bavarian drug pipeline. Headquartered in Denmark, the company maintains its strong research site in Martinsried near Munich with around 150 employees, developing cancer immunotherapies and vaccines against infectious diseases such as, among others, smallpox and Ebola.

So far, Bavarian biotech companies have brought eleven drugs to market or delivered the innovative molecules as part of approvals obtained by others.

Bavaria’s biotechnology sector is also making an active contribution with promising projects and concepts in the fight against COVID-19. A special section on the Corona pandemic can be found on page 16.

Financing / Company News
In 2019, financing activities in Germany’s biotech community were strongly dominated by a massive pre-IPO private equity investment of EUR 290 million followed by the EUR 140 million IPO from the very same company,
DRUG PIPELINE OF BAVARIAN BIOTECH SMEs
Number of Projects by Phase and Indication

<table>
<thead>
<tr>
<th>Indications</th>
<th>R&amp;D</th>
<th>Preclinical</th>
<th>Phase I</th>
<th>Phase II</th>
<th>Phase III</th>
</tr>
</thead>
<tbody>
<tr>
<td>Autoimmune</td>
<td>12</td>
<td>3</td>
<td>44</td>
<td>14</td>
<td>3</td>
</tr>
<tr>
<td>Infectious Diseases</td>
<td>98</td>
<td>60</td>
<td>58</td>
<td>29</td>
<td>10</td>
</tr>
<tr>
<td>Oncology</td>
<td>1</td>
<td>11</td>
<td>30</td>
<td>6</td>
<td>5</td>
</tr>
<tr>
<td>Cardiovascular</td>
<td>26</td>
<td>2</td>
<td>2</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>other</td>
<td>12</td>
<td>2</td>
<td>1</td>
<td>2</td>
<td>1</td>
</tr>
</tbody>
</table>

As of April 2020. Not included are more than 80 different non-clinical drug candidates of MorphoSys.

Marketed Drugs (derived from SMEs)

- Autoimmune: 12
- Infectious Diseases: 98
- Oncology: 1
- Cardiovascular: 26
- other: 12
BioNTech (Mainz). In total, financing (private and public equity added) in Germany reached a substantial EUR 856 million in 2019 (according to EY reporting).

In Bavaria, the US IPO from MorphoSys in 2018 of EUR 240 million and other follow-on offerings, amounting to almost EUR 300 million (in 2018), resulted in attenuation in 2019. Nevertheless, private and public financing in Bavarian biotech in 2019 came to a total of around EUR 160 million (approx. EUR 70 million public equity and EUR 90 million private equity), which accounts for roughly 20% of the entire financing volume in Germany. A large number of companies (13) benefited from this financing (i.e. private equity), indicating the diversity of innovative companies and building a broad fundament for future development. Some examples are highlighted in this chapter. Besides financing, we witnessed various mergers & acquisitions and a strong deal flow with renowned international partners, proving the attractiveness of the Bavarian biotech ecosystem.

"Like everyone else, the Corona pandemic hit us unexpectedly. Besides restrictions, new and promising opportunities evolved for us. For example, with the help of our digital lung twin and AI methods we want to make a valuable contribution to personalized and optimized mechanical ventilation of patients in intensive care units."

DR. KEI MÜLLER
CEO, Ebenbuild

Funding

Invex received another investment of EUR 17 million. This investment, the largest to date in the Munich-based start-up, will be used to start series production of its AI-supported laboratory automation system and make the diagnosis of cancer even faster and safer in the future.

In August 2019, Martinsried-based molecular diagnostics company GNA Biosolutions announced the completion of a financing round of EUR 12 million. Some of its new investors, including GreyBird Ventures, Occident and Wachtumsfonds Bayern, were introduced to GNA Biosolutions at the BioM BioAngels Pitch Event.

Immunic Therapeutics successfully joined the Nasdaq after merging with Nasdaq-listed Vital Therapies in early 2019. As part of the listing on the New York Stock Exchange, the start-up’s existing investors invested another EUR 26.7 million. In addition, the company has just completed a capital increase, raising a further USD 25 million through the issuance of additional shares.

Deals

Medigene, which focuses on the development of immuno-oncological therapies, has once again achieved a mega-deal with a financial promise for future activities. A licensing agreement with the newly founded Cytovant Sciences (founded by Hong Kong-based Roivant Sciences and South Korean Sinovant Sciences) has provided the Martinsried-based biotech company with a total of up to USD 1 billion. Cytovant has secured the development, manufacturing and marketing rights for a total of four cancer immunotherapy projects for the treatment of Asian patients.

SIRION Biotech has concluded a mega-deal with the US company Denali and opened a US subsidiary in Boston. SIRION has been a reliable partner for products and services in the cell and gene therapy industry for over ten years. The Munich-based company will receive a refund on its development costs and substantial cash advances from Nasdaq-listed Denali Therapeutics Inc. in the USA.

Munich-based biotech company Tubulis, founded in 2019, has signed a research and feasibility agreement with the immuno-oncology company Glycotope in Berlin. Glycotope thus has access to Tubulis’ proprietary antibody-drug conjugate technologies for the development of novel cancer drugs. In October 2017, the Tubulis research team (LMU Munich and FMP Berlin) won the m$^4$ Award pre-seed competition (see page 24).

Proteros biostructures announced in late 2019 that Rodin Therapeutics, a Boston-based biotech company developing novel small molecule therapeutics for synaptic diseases, had been acquired by Alkermes, a global biopharmaceutical company headquartered in Dublin, Ireland. Rodin was co-founded by Proteros in 2013. Rodin’s former security holders received an upfront payment of USD 100 million and are eligible to receive future payments of up to USD 850 million on reaching certain milestones.

BioNTech (Mainz). In total, financing (private and public equity added) in Germany reached a substantial EUR 856 million in 2019 (according to EY reporting).

In Bavaria, the US IPO from MorphoSys in 2018 of EUR 240 million and other follow-on offerings, amounting to almost EUR 300 million (in 2018), resulted in attenuation in 2019. Nevertheless, private and public financing in Bavarian biotech in 2019 came to a total of around EUR 160 million (approx. EUR 70 million public equity and EUR 90 million private equity), which accounts for roughly 20% of the entire financing volume in Germany. A large number of companies (13) benefited from this financing (i.e. private equity), indicating the diversity of innovative companies and building a broad fundament for future development. Some examples are highlighted in this chapter. Besides financing, we witnessed various mergers & acquisitions and a strong deal flow with renowned international partners, proving the attractiveness of the Bavarian biotech ecosystem.

"Like everyone else, the Corona pandemic hit us unexpectedly. Besides restrictions, new and promising opportunities evolved for us. For example, with the help of our digital lung twin and AI methods we want to make a valuable contribution to personalized and optimized mechanical ventilation of patients in intensive care units."

DR. KEI MÜLLER
CEO, Ebenbuild

Funding

Invex received another investment of EUR 17 million. This investment, the largest to date in the Munich-based start-up, will be used to start series production of its AI-supported laboratory automation system and make the diagnosis of cancer even faster and safer in the future.

In August 2019, Martinsried-based molecular diagnostics company GNA Biosolutions announced the completion of a financing round of EUR 12 million. Some of its new investors, including GreyBird Ventures, Occident and Wachtumsfonds Bayern, were introduced to GNA Biosolutions at the BioM BioAngels Pitch Event.

Immunic Therapeutics successfully joined the Nasdaq after merging with Nasdaq-listed Vital Therapies in early 2019. As part of the listing on the New York Stock Exchange, the start-up’s existing investors invested another EUR 26.7 million. In addition, the company has just completed a capital increase, raising a further USD 25 million through the issuance of additional shares.

Deals

Medigene, which focuses on the development of immuno-oncological therapies, has once again achieved a mega-deal with a financial promise for future activities. A licensing agreement with the newly founded Cytovant Sciences (founded by Hong Kong-based Roivant Sciences and South Korean Sinovant Sciences) has provided the Martinsried-based biotech company with a total of up to USD 1 billion. Cytovant has secured the development, manufacturing and marketing rights for a total of four cancer immunotherapy projects for the treatment of Asian patients.

SIRION Biotech has concluded a mega-deal with the US company Denali and opened a US subsidiary in Boston. SIRION has been a reliable partner for products and services in the cell and gene therapy industry for over ten years. The Munich-based company will receive a refund on its development costs and substantial cash advances from Nasdaq-listed Denali Therapeutics Inc. in the USA.

Munich-based biotech company Tubulis, founded in 2019, has signed a research and feasibility agreement with the immuno-oncology company Glycotope in Berlin. Glycotope thus has access to Tubulis’ proprietary antibody-drug conjugate technologies for the development of novel cancer drugs. In October 2017, the Tubulis research team (LMU Munich and FMP Berlin) won the m$^4$ Award pre-seed competition (see page 24).

Proteros biostructures announced in late 2019 that Rodin Therapeutics, a Boston-based biotech company developing novel small molecule therapeutics for synaptic diseases, had been acquired by Alkermes, a global biopharmaceutical company headquartered in Dublin, Ireland. Rodin was co-founded by Proteros in 2013. Rodin’s former security holders received an upfront payment of USD 100 million and are eligible to receive future payments of up to USD 850 million on reaching certain milestones.
**MorphoSys and Incyte Corporation** have entered into a collaboration and licensing agreement to further develop and globally commercialize MorphoSys’ proprietary anti-CD19 antibody MOR208. The agreement has resulted in MorphoSys receiving an upfront payment of USD 750 million plus potential milestone payments of up to USD 1.1 billion.

**Acquisitions**

At the beginning of 2019, the Japanese company Hitachi Chemical Co., Ltd. acquired apceth Biopharma, based in Ottobrunn/Munich, for the sum of EUR 75 million. Furthermore, apceth Biopharma became a commercial manufacturer in Europe for Zynteglo® (formerly LentiGlobin), a gene therapy from the US American company bluebird bio which is approved for the treatment of transfusion-dependent beta-thalassemia.

Mainz-based BioNTech acquired the operational antibody production unit of MAB Discovery, in early 2019, thereby leveraging the Munich-based biotech company’s proprietary technologies to generate therapeutic monoclonal antibodies.

Based at BioPark Regensburg, 2bind and its partners came first in the EU call for Eureka Eurostars. The consortium will thus receive funding for the next three years for its development of new cancer diagnostics, which should enable patients to receive improved and individualized therapy. 2bind is a service provider for analytical methods, having started with the distribution of NanoTemper instruments.

**Eisbach Bio** was the winner of the BIO-Europe 2019 Startup Slam in Hamburg. Founded in 2019, Eisbach Bio is a spin-off of the Biomedical Center Munich of the LMU, developing novel drugs that target chromatin regulatory mechanisms essential to tumors.

Mainz-based BioNTech acquired the operational antibody production unit of MAB Discovery, in early 2019, thereby leveraging the Munich-based biotech company’s proprietary technologies to generate therapeutic monoclonal antibodies.

**Talend MedTech** acquired the operational antibody production unit of MAB Discovery, in early 2019, thereby leveraging the Munich-based biotech company’s proprietary technologies to generate therapeutic monoclonal antibodies.

**Company Highlights – and a Glimpse into Science**

**Bavarian Nordic**, a Danish-Bavarian enterprise with a workforce of 150 in Martinsried, has received FDA approval for its vaccine against smallpox and monkeypox in adults who are at high risk of developing either infection. The vaccine is the only approved non-replicating smallpox vaccine in the USA and the only approved vaccine against monkeypox worldwide.

Bavaria’s oldest Biotech company, Mikrogen, celebrated its 30th anniversary at the end of May 2019. Founded as a spin-off of the Max von Pettenkofer Institute of the Ludwig-Maximilians-Universität München (LMU), Mikrogen develops, produces, and distributes test systems based on recombinant antigens. Mikrogen has also launched tests for the detection of coronavirus infections (see page 16).
BAVARIAN BIOTECHNOLOGY
IN THE FIGHT AGAINST COVID-19
Bavaria‘s Efforts in Dealing with the Coronavirus Pandemic

The coronavirus pandemic has placed unprecedented constraints on public life and the economy. Companies and academic research teams worldwide are attempting to contain this pandemic and its far-reaching medical and social consequences. Companies and research institutions in Bavaria are also working intensively at present to develop safe and reliable diagnostics, effective therapies, and vaccines. In the fight against the coronavirus pandemic, Bavarian biotech companies and research institutions have reacted swiftly, conducting research into vaccines, testing existing drugs for their effect against COVID-19, developing new drugs, and bringing tests for acute or previous illness to market. Even companies not previously active in this sector have been quick to adapt and review their past technologies and products so that they too can contribute to the management of the COVID-19 pandemic. Supported by their cluster management organization BioM, Bavarian biotechnology companies are doing tremendous pioneering work to this end.

BioM’s Project Call
To exploit the enormous potential of the entire Bavarian biotechnology industry, BioM launched a call mid-March for innovative contributions from companies and research groups in solving the COVID-19 crisis. BioM selected the most promising of the numerous project proposals and is now supporting them during implementation, both by connecting them with suitable partners and by helping in the search for funding or capital.

15-min Coronavirus rapid Test
Progress has certainly already been made. The Martinsried biotech company GNA Biosolutions, a spin-off of the Ludwig-Maximilians-Universität München, was quick to secure considerable funding from the Free State of Bavaria to bring the ultra-fast COVID-19 test to series-production maturity and hence to large-scale production. Within 15 minutes, this test delivers a reliable positive result of acute infection with the SARS-CoV-2 virus. It also offers the advantage of being a battery-powered, portable device.

SARS-CoV-2 Antibody Detection
Bavaria is also at the forefront in the detection of antibodies produced in response to a SARS-CoV-2 infection: In addition to the RT-PCR test available since March, a highly specific antibody detection test was launched by Mikrogen in Neuried near Munich at the beginning of April. The cluster organization has also provided the biotech company with support for its activities in many ways – especially when faced with lockdown and difficult trade routes from Asia. Roche in Penzberg also launched a SARS-CoV-2 antibody test in early May. In addition, it announced an investment of EUR 250 million in a new hub in Penzberg over the next four years, where research and development activities for diagnostic tests will be combined and pooled.

Drugs – Vaccines – Digital Health
In addition to the optimization of diagnostic procedures, the development of drugs and vaccines is of utmost importance: it is the only sustainable means of combating the pandemic. Numerous companies are working on solutions against COVID-19 in Germany. As is the case worldwide, efforts are being made by the Bavarian biotechnology industry to develop a vaccine against SARS-CoV-2. LEUKOCARE, for example, is developing a novel adenoviral, vector-based vaccine against COVID-19 with its partners Univercells (Belgium) and ReiThera (Italy). LEUKOCARE is contributing to the drug development process with a liquid vaccine formulation. Clinical studies are scheduled to start this summer. Munich-based company Baseclick has successfully enhanced the so-called click
chemistry for the purpose of modifying messenger RNA (mRNA), which can thus be used to also develop an mRNA vaccine against SARS-CoV-2. Baseclick was founded in 2008 as a spin-off of the Ludwig-Maximilians-Universität München (LMU). Another company working in this field of vaccine research against SARS-CoV-2 which is very experienced in the development of vaccines is Bavarian Nordic, based in Martinsried near Munich.

Various biotechnology companies are working on highly innovative approaches, moreover, that directly target the novel coronavirus. One good example is Ethris, which develops mRNA-based drugs, the end products of which are antibodies produced by the recipient. Cfm Oskar Tropitzsch and Iris Biotech from Marktredwitz in northern Bavaria are working on a new antiviral agent against SARS-CoV-2, and are already in close contact with leading research institutes. In addition, Cfm Oskar Tropitzsch has another product in the value-added chain of a large diagnostics company and supports the company in securing raw materials for its test kits. In May, Martinsried-based Immunic Therapeutics, which focuses mainly on the development of therapies for the treatment of autoimmune diseases, announced the start of a new clinical development program with its advanced drug candidate IMU-838 (a DHODH inhibitor), which has revealed antiviral activity against the RNA virus SARS-CoV-2 in cellular experiments.

Bavaria is also well represented in the digital health sector. For example, the start-up Ebenbuild, a spin-off of the Technical University of Munich (TUM), has developed a digital twin of the lung. Improved mechanical ventilation of critically ill COVID-19 patients is facilitated by artificial intelligence in the analysis of lung imaging.

**BioM-COVID-19 Platform**

BioM’s call for projects also showed that there is great interest in sharing information, expertise, technologies and capacities within the scope of COVID-19 research projects. BioM has therefore launched the national BioM-COVID-19 platform for companies, research institutions and clinics. Almost 100 offers and requests have already been posted on the platform. Initial success is already evident: BioM used the COVID-19 platform, for example, to organize difficult-to-obtain samples from coronavirus-infected patients for biotechnology companies working on new diagnostic detection systems. Various productive partnerships between industry and research institutions or academic groups have also been established through the platform.

**Academic Approaches**

Academic institutions in Bavaria are also involved, of course, in the fight against the coronavirus pandemic. To better understand the spread of the virus, the Munich Tropical Institute at the LMU University Hospital Munich, headed by Prof. Michael Hölscher, is coordinating the „Prospective COVID-19 Cohort Munich“ (KoCo19) project together with the Bavarian State Government. In the Munich area, the infection status of around 3,000 representatively selected households is being investigated at various time intervals. The study aims to determine the number of undetected cases of COVID-19 in individuals who have not been tested due to the absence or low level of symptoms. The university hospitals of Regensburg and Erlangen have also started a large antibody study in the district of Tirschenreuth, which had a comparatively high number of
reported COVID-19 cases. Through the detection of virus-specific antibodies, study directors Prof. Wagner of the University of Regensburg and Prof. Überla of Friedrich-Alexander-Universität Erlangen-Nürnberg, aim to demonstrate, based on at least 3,600 adults, how many people in the district of Tirschenreuth have been infected with the virus. The study “COVID Kids Bavaria” addresses the pandemic situation in children. Launched at the beginning of July 2020 by the six Bavarian university hospitals in Munich, Erlangen, Würzburg, Augsburg and Regensburg, the study focuses on the risk of infection by SARS-CoV-2 as well as general child health issues. To this end, the medical team led by Prof. Christoph Klein and Prof. Johannes Hübner from Dr. von Hauner Children’s Hospital of the LMU University Hospital Munich will examine around 150 selected childcare facilities throughout Bavaria by January 2021. For many years, the Dr. von Hauner Children’s Hospital has had a special focus on the scientific investigation of the child’s immune system.

A promising approach to finding a suitable drug against COVID-19 is to use existing and approved drugs to combat the virus. To determine which existing drugs might be suitable for this purpose, a research team led by Prof. Jan Baumbach, Chair of Experimental Bioinformatics (ExBio) at the Weißenstephan Science Center of the Technical University Munich, has developed the first online data analysis platform.

Another concept for treating COVID-19 is to use antibodies from convalescent plasma. University Hospital Erlangen was one of the first institutions in Germany to receive official approval to produce therapeutic plasma for treating seriously ill COVID-19 patients. Antibodies produced in response to COVID-19 can be obtained from donor blood and administered to patients with severe COVID-19 to mitigate life-threatening conditions.

The biotechnology sector and research institutions in Bavaria are making a strong contribution to the fight against COVID-19, responding with speed and flexibility as well as enormous team spirit. An extraordinarily large number of players wish to actively contribute to the fight against the coronavirus crisis, working very openly and cooperatively, also on a supra-regional level.
found a new gene scissors?

www.baypat.de we help to make them shine!
Since the discovery of the SARS-CoV-2 virus and its worldwide spread, biotechnology has very much been in the public eye. Both politics and society have great expectations for the industry. The development of diagnostic methods, effective medicines, and not least a vaccine, should help to overcome the COVID-19 pandemic. Some Bavarian biotechnology companies have already made remarkable progress in this direction. But what impact will the crisis have on the Bavarian biotech sector as a whole? What are the challenges, and where can opportunities be found? What support is required to swiftly achieve the goals that have been set, and how many companies are in fact engaged in the issue of COVID-19? To get an idea, BioM surveyed all the companies in the Bavarian biotechnology cluster in May 2020.

Companies surveyed
A total of 94 questionnaires were evaluated, corresponding to a response rate of 27% among the companies surveyed. The responses were received mainly from companies in the biotechnology and pharmaceutical sector – with a further distinction being made between diagnostic and therapeutic developers, technology platforms/devices, and biotech/pharma in general – followed by CROs, medical technology companies, vendors, and digital health companies. Small companies with a maximum of 20 employees accounted for 65% of these responses.

A total of 64% of the responding companies are involved in the development, production or distribution of products, vendor parts, or services that can be used in association with COVID-19. The development of active substances (23%) and diagnostics (19%) as well as laboratory analytics (20%) account for the majority; 11% of the companies are involved in vaccine development.

Challenges and Actions
In general, 55% of the respondents expressed concern about the coronavirus pandemic and the potential consequences for their business. Organizing childcare, home-working and workflows and handling hygiene measures at the company, along with delays to clinical trials, supply bottlenecks and capital procurement, were perceived as the main challenges during the crisis. On the one hand, the action taken by the companies was focused on production: 13% increased and 12% decreased their production output, while 10% adapted supply chains or production channels. On the other hand, personnel changes were made: 6% of the companies surveyed increased their workforce while 22% reduced working hours of their staff; 2% had to lay off staff for operational reasons.

Sales Development and Financing
Whereas 50% of the responding companies reported no impact or even an increase in sales, the other 50% were experiencing a downturn and in some cases even a dramatic decline in sales. Therefore, 26% had applied for financial aid from the Free State of Bavaria or the Federal Government.

Partnerships
Of the companies that responded to the survey, 20% were looking for partners with whom to develop products or services relevant to COVID-19. Various platforms were being used to connect with potential partners. The BioM COVID-19 platform has over 90 entries, providing impressive proof of the willingness of companies in the Bavarian biotechnology cluster to collaborate.

The insights gained from this survey help the BioM cluster management to tailor offers to demand; they have also been shared with political stakeholders at federal and state level as an important basis for decision-making. The BioM team continues to address individual questions directly concerning how to cope with the special challenges posed by the pandemic.

The complete analysis can be found at: www.bio-m.org/covid19-company-survey-en
How concerned are you with the Consequences of the Coronavirus for your Company?

55% of the responding companies are concerned about the coronavirus pandemic

- Extremly concerned: 3%
- Very concerned: 17%
- Relatively concerned: 40%
- Not so concerned: 35%
- Not concerned at all: 5%

COVID-19 relevant Products/Services
(Multiple answers were possible)

- Ventilators/other hardware: 2%
- Protective equipment/disinfectants: 1%
- Digital tools: 2%
- Laboratory analytics: 20%
- Pivotal studies: 10%
- Vaccines development: 11%
- Diagnostics development: 19%
- Drug development: 23%
- No: 36%
- Other: 6%

64% of the responding companies are involved in COVID-19 product development

Sales Development

- Decline in sales existential: 5%
- Decline in sales (up to 50%): 12%
- Decline in sales (up to 20%): 15%
- Decline in sales (up to 5%): 18%
- Sales increase: 13%
- No changes: 37%

50% of the responding companies had declining sales
13% of the responding companies had increasing sales
PROFESSIONAL TRANSLATION
A Guest contribution from Dr. Siegfried Bialojan

Risk Reduction on the Road towards Innovations

Biotechnology has recently experienced a significant upsurge as the foundation and driving force for urgently needed diagnostic and therapeutic solutions – not least due to the current COVID-19 pandemic. The tremendous potentials that biotechnology has already demonstrated with extreme speed in response to this situation are impressive: 229 therapeutic concepts are already available globally (many based on repurposing of known active substances); in addition, 149 coronavirus vaccines are in the pipeline (on many different platforms), and over 650 diagnostic tests are on their way to the market (source: WHO and EY analysis).

In this respect, Germany, and Bavaria in particular, is certainly in the spotlight with extremely interesting contributions: around 60 companies are working on solutions associated with COVID-19 (source: Bio DE).

The most pressing challenges in all these activities are effectiveness and efficiency, i.e., the assurance of quality and efficacy while driving development of the solutions as quickly as possible towards marketing authorization.

However, biotech in Germany is struggling to translate this positive potential into marketable products. Difficulty accessing equity and a risk-averse mindset, in particular, are the obstacles frequently mentioned.

A recent study by EY (EY Start-up Barometer 2020) noted, however, that equity for start-ups is by all means available – in 2019 alone, start-ups in Germany received a total of EUR 6.2 billion. If only 1.5% (EUR 95 million) of this amount benefits biotech, then this not only demonstrates a marked imbalance in capital allocation but also immediately exposes the reasons: the allocation of capital flows is clearly inversely correlated with the respective risk profiles of the sectors – biotech, with an inherently high risk, thus falls sharply behind in the distribution of capital.

A rethink is therefore necessary: How can the risk in the development of biotechnological assets be significantly reduced? Which risk screws can be turned?

Taking a more professional approach to translation could prove to be an important lever and screwdriver, i.e., how to recognize the quality of the ideas early on, and how to generate value from these ideas more rapidly? Effectiveness and efficiency – as mentioned above – are again the drivers here.

The latest EY Biotech Report specifically addresses this aspect. The theory is that, owing to concepts/projects that are better qualified, professional translation would not only reduce the financing risk and thus improve access to capital but it would also lessen the entrepreneurial risk, thereby adding dynamism to the start-up structure. In this way it effectively acts as a catalyst, reducing the “activation energy” (= risk hurdle) on the road from idea to innovation.

The analysis of translational facilities in Germany undertaken in this regard delivered some important insights: Most of the incubators sailing under the translation flag focus on the identification, evaluation and “industry-oriented maturation” of academic ideas – undoubtedly an essential aspect – with the aim of guiding them ultimately towards commercialization.

Initiatives in Bavaria, such as the qualitatively well-positioned scouting program inQlab from BioM, also play a pivotal role in the identification of promising ideas.

However, there are clear deficits in the subsequent phase when start-ups, once founded, encounter risks of at least equal magnitude during their initial development phase: financing, management experience and professional business administration, as well as business planning and business development. Though
established technology parks are available in many regional clusters, what they essentially offer is space in an inspiring science environment and a range of coaching services. The full-service support of successful incubators in the US (e.g. BioLabs/LabCentral) is completely lacking in Germany. While it is by no means possible to replicate the US approach 1:1 in Germany, Track Record – in 2017 alone, 10% of early-phase venture capital in the US went to start-ups in or from this incubator – should help drive similar, professional entrepreneurial developments forward here in Germany too. The intentions in Heidelberg (BioLabs HD) in this respect are an important experiment.

The translational support offered by investors has improved immensely: among these, notably, the corporate venture funds (e.g. Boehringer Ingelheim Venture Fund), certain other early-stage investors (good examples include MPM and Kurma in Munich), and HTGF have recognized the importance of professional company building and are very actively involved on a professional level during the early phase.

In addition, more constructive activities are certainly taking place in the area of TTOs, as innovation enablers who actively support ideas with professional project management while also promoting project funds dedicated to company building.

Recent financing rounds and partnerships have demonstrated that these considerations are not merely theoretical: professionally nurtured ideas and start-ups do indeed lead to more successful business development – significant financing rounds for start-ups supported directly by the investors mentioned above (BIVF, MPM, HTGF) are a solid testament to this fact: Munich has again been a pioneer here, with MPM being the first to invest in iQmix. The latest examples stem from BIVF, which has been involved in 50% of its portfolio companies from the very beginning.

Thus, we can remain hopeful that a momentum has emerged here which will help to counteract the frequent excuse of the “risk-averse mindset” and “risk-averse capital” with risk-reducing initiatives.

Although the two criteria of “effectiveness and efficiency” in translating existing potentials in Germany are still conditional, we can be all the more hopeful that precisely because of the crisis the need to strive for more professional translation, as discussed above, must be given greater consideration and also be pursued long-term (after the crisis).

About EY:
EY is a globally connected, multidisciplinary professional services organization with headquarters in London, UK. The organization is one of the market leaders in auditing, tax consulting, transaction consulting and management consulting. EY is present at 20 locations in Germany.
The vision of the Bavarian biotechnology cluster is to establish itself in the long term as one of the world’s leading locations for precision medicine - the medicine of the future.

The biotechnology start-up sector in Bavaria has generally developed successfully. In 2019, the start-up dynamics in Bavaria were positive, with 14 new companies being founded in the Free State (see page 10). As in other areas, digitization and, in turn, the use of digital technologies and formats is also becoming increasingly important in biotechnology. Thus, in addition to therapeutics and diagnostics, which still dominate, the number of biotech start-ups in Bavaria in the field of digital health is also growing.

From Idea to Success

Start-ups are the powerhouses of innovation. Offering support to founders and biotech start-ups has always been a central task at BioM. Founded in 1997, BioM started out as a regional development agency while also acting as a start-up coach and active biotech seed investor, thereby attracting substantial private capital and establishing the now very successful Biotech Cluster in Bavaria. Leaving the seed financing part to newly established players such as HTGF and Bayern Kapital, BioM ceased its investment activities in 2014 and has since focused on the development of a unique and tailor-made support program for aspiring start-ups and entrepreneurs in the life-sciences sector. The BioM inQlab virtual incubator supports start-ups at every stage of establishing their business. In total, BioM has supported more than 200 start-up companies over the last 20 years.

BioM inQlab

To optimally support Bavarian founders in the field of biotechnology, BioM offers a range of valuable, tailor-made start-up programs in its inQlab:

- In addition to the Start-up Coaching by the BioM team, support is also provided by external experts. The Mentor Circle comprises a pool of around 70 experienced biotech and life-science experts who provide voluntary support to young founders and to anyone interested in starting their own company.

- In personal Pitch Doctor sessions, start-up teams can fine-tune their presentations and obtain open, constructive feedback.

- Teams of founders can validate their business ideas at intensive BioEntrepreneur Bootcamp trainings, which last several weeks and offer them the opportunity to engage with their first customers and key opinion leaders, as well as meet industry representatives and investors.

- At the BioEntrepreneur Lounge, informal gatherings are held several times a year for founders to exchange ideas among themselves and learn from those with more experience.

- BioM’s longstanding investor network increases the chances of finding a suitable financing partner. Two to three times a year, pre-selected and well-prepared start-up teams have the opportunity to present their business ideas to around 30 investment representatives at the BioAngels Pitch Event.

- Every other year, BioM also coordinates the m4 Award, the Bavarian pre-seed funding program which focuses on medical biotechnology. The award ceremony takes place during the inspirational BioM BioEntrepreneurship Summit.

"Winning the m4 Award was a big step for us towards the successful start of our company. In the meantime, despite our short history, we have built up an experienced and dynamic team of 25 people with multidisciplinary expertise in assay development, product development, quality control, and commercialization."

DR. GARWIN PICHLER
CEO, PreOmics
m4 Award: Five calls – nine Spin-offs

Since 2011, the Bavarian State Ministry of Economic Affairs, State Development and Energy has supported the m4 Award, which was initiated by BioM. This pre-seed competition is aimed at Bavarian academic research projects with spin-off potential in the field of biomedicine.

With grant money of up to EUR 500,000 for two years, the competition supports the development and validation of the respective project with a view to creating a spin-off. The scientists receive not only financial support but also active support from BioM and other partners as well as industry experts. Out of five calls, a total of 23 research projects with spin-off potential have been awarded. Nine promising start-ups have been founded so far, highlighting the success of the pre-seed award and importance of this initiative.

PreOmics is one of the m4 Award success stories. In 2013, the team from the Max Planck Institute of Biochemistry in Martinsried won the m4 Award with its pre-seed project, leading to the foundation of PreOmics in 2016 by Dr. Nils A. Kulak and Dr. Garwin Pichler. The start-up develops and produces innovative technologies for pre-analysis of samples for mass spectrometry. PreOmics successfully secured series A financing and is already selling its products while expanding sales globally.

Two further recent successes show the innovative strength of Bavaria: Having achieved the m4 Award in 2019, the research team headed by Prof. Stephan Sieber, Technical University of Munich (TUM), received a special honor in mid-July: In recognition of their current efforts to combat antibiotic resistance, Sieber and his team were awarded the Merck Future Insight Prize 2020. The researchers aim to use the prize money of EUR 1 million to advance the development of new drugs against multi-resistant bacteria and bring them to market.

Just recently, Tubulis, awarded 2017 with the m4 Award, announced the close of a EUR 10.7 million Series A financing round to accelerate the development of a new class of highly stable and efficient antibody-drug conjugates (ADCs) and to support the further growth of the company. The financing round was co-led by BioMedPartners and High-Tech Gründerfonds (HTGF) with support from Seventure Partners, coparion, Bayern Kapital, and OCCIDENT alongside significant contributions by high net worth individuals and the founders. Tubulis was spun out in 2019 from the Leibniz-Forschungsinstitut für Molekulare Pharmakologie in Berlin (FMP) and the Ludwig-Maximilians-Universität München (LMU) with the aim of expanding the therapeutic potential of ADCs for cancer and other disease indications.
BioEntrepreneurship Summit – “Just do it”

Anyone daring to take the plunge into a founder’s life will no doubt find they are entering into uncharted territory. Especially for start-ups, the opportunity to network and exchange information with other start-ups and experienced founders, as well as come into direct contact with investors, is extremely important and beneficial. In addition to its support program, BioM has therefore established the BioEntrepreneurship Summit, a conference with lectures, start-up pitches and networking opportunities designed to bring together all relevant stakeholders in the bioentrepreneurial and health tech ecosystems. The 2019 event, attended by about 200 delegates, proved to be a successful follow-up to the first edition of the BioEntrepreneurship Summit in 2017. Pre-seed teams, start-ups and experienced life science entrepreneurs, life-science entrepreneurs, investors, and industry leaders as well as students and scientists took the opportunity to learn and expand their network in an inspiring setting at TranslaTUM. The next Summit will take place in 2021.

inQlab2023 – from virtual Existence to Bricks and Mortar

To bring founder teams closer together, but also connect them with relevant industry players and investors, BioM plans to further develop the virtual inQlab program to become a real brick-and-mortar incubator for start-ups. BioM’s vision for inQlab2023 is a new infrastructure with state-of-the-art lab facilities, co-working space, a core facility, and event location. As a public-private partnership, the new pre-seed and early start-up incubator aims to foster co-creation between biotech, medtech and deeptech start-ups, while building up and tightening relationships with new industry partners and investors. Initial investors have already confirmed their commitment to the project and various property options are currently being examined. “With its unique programming, interdisciplinary focus and partnership structure, inQlab2023 will become a unique lighthouse structure in the vibrant Bavarian start-up ecosystem,” remarked Prof. Horst Domdey, Managing Director at BioM.

“I found the conference to be very relevant, and extremely informative for current and aspiring biotech entrepreneurs. The information delivered was directly applicable, and the conference format allowed for a perfectly balanced mix of presentations, interactive Q & A, networking, and socializing. Additionally, there was a great mix of attendees - VCs/investors, accelerators, industry, and other interesting, dynamic innovators. I was honored to participate in this important entrepreneurial ecosystem-building activity. Thank you very much for the opportunity.”

MARC FILERMAN
CEO, German Accelerator Life Sciences

From left: Dr. Kiran Dallenbach (BioMedPartners), Dr. Werner Lanthaler (Evotec), Dr. Caroline Man Xu (ViGeneron), Prof. Fabian Theis (Helmholtz Zentrum München) © BioM

Biotech in Bavaria - Report 2019/20
You are looking for suitable laboratories?
We are your specialist!
www.wander-immobilien.de
Office, laboratories and production space
from 250 sqm – 10,000 sqm
We are looking forward to send you
an attractive offer.

BioM inQlab
we guide you from idea to success
virtual incubator for the future of medicine

Startup Coaching
get hands-on support

Mentor Circle
inspired by experience

Pitch Doctor
how to convince investors

BioEntrepreneur Bootcamp
validate your business idea

BioEntrepreneur Lounge
join the community

BioAngels
find the right investor

m4 Award
create the future of medicine

BioEntrepreneurship Summit
connecting the ecosystem

www.bio-m.org
Digitization is transforming our society and has long since reached the medical sector – be it health apps, diagnostic methods based on artificial intelligence, or surgical robots. E-health technologies are aimed at improving disease prevention, diagnosis, and treatment. Especially in personalized medicine, digitization offers physicians and patients new opportunities. The intelligent linking and analysis of huge amounts of data have the potential to draw a holistic picture and thus improve the quality of life of patients in the long term through individual and targeted treatment. This is exactly where the DigiMed Bayern project comes in.

One of the most promising developments in modern medicine is the integration and analysis of population-wide clinical, real-world, and research data, ultimately paving the way for individualised health management. The lighthouse project DigiMed Bayern is aimed at incorporating the concept of the so-called P4 medicine (predictive, preventive, personalized, participatory) in the clinical routine for an improved, holistic, and efficient health care services. Funded by the Bavarian State Ministry of Health and Care, DigiMed Bayern comprises world-leading clinics in the field of cardiovascular diseases, complemented by research institutes focusing on “Omics”-technologies, molecular biology, epidemiology, genetics, medical law and medical ethics. Comprehensive datasets from patients diagnosed with atherosclerotic diseases and with genetic risk factors are enriched with multi-dimensional molecular characterization (genomics, transcriptomics, proteomics and metabolomics) of associated sample material. An ethically and legally compliant, secure IT infrastructure has been set up to support the integrative analysis of the resulting “Big Data”. The greater vision is to support real-life improvements in disease risk prediction, targeted prevention, health care management, diagnostics, and therapy for patients and individuals at risk. DigiMed Bayern also aims to contribute blueprints, concepts and infrastructure to other institutions and disease areas.

Clinical & Scientific
A wide variety of patient samples (whole blood, plasma, tissue) have been collected by the clinical partner sites (WP1-4), and associated pilot studies have been carried out with a view to multi-dimensional, high-throughput experimental analyses (WP5). A digital risk assessment and prevention platform has been conceptualized, including risk score evaluation and individualized long-term risk reduction approaches (WP1.2 & WP4). Large anonymized datasets from German health insurers are analyzed to better characterize coronary heart disease risk profiles, evaluate local medical care, and optimize disease prevention (WP1.3). The “Vroni” study, “Prevention for the early detection of Familial Hypercholesterolemia” (WP3), is designed to start with participant recruitment (n=60,000) in summer 2020.

IT Infrastructure
Requirements and specifications were identified and defined with all partners during the conception phase. Data protection concepts and specified Standard Operating Procedures (SOP) have been iterated and are continuously reflected and optimized within the consortium under the supervision of the Bavarian Data Protection Commissioner (Datenschutzbeauftragter).

ELSI and Public Involvement
In addition to involving ethics committees, ethical, legal, and social implications (ELSI) were discussed in-depth at workshops and public events with experts, as well as with patient representatives and interested citizens. Thoughts and outcomes were partially condensed and published, e.g. https://www.ttn.st.evtheol.uni-muenchen.de/publikationen/ ttn_edition/tnn_edition_2019.pdf (in German).

Stay tuned:
Visit https://www.digimed-bayern.de/en/ for further information and follow us on twitter @DigiMedBayern for news and events.
At Lonza Pharma & Biotech, we provide contract development and manufacturing services that enable pharma and biotech companies to bring medicines to patients in need.

From the gene to the final drug product, our solutions are created to simplify your outsourcing experience and provide a reliable outcome, at the time when you expect it.

Our extensive track record includes the commercialization of pioneering therapies and manufacturing of a wide variety of drugs. We continuously invest to solve not just the current, but also the future challenges.

Together, we can bring your next medicine to life.

Visit pharma.lonza.com
USA +1 201 316 9200
Japan +81 (0) 3 6264 0600
Europe and rest of world +41 61 316 81 11
Email pharma@lonza.com
© 2020 Lonza. All rights reserved.
Interview with Bicoll and Immunic, two Partners of the InnoMuNiCH Project

Since 2017, BioM coordinates the InnoMuNiCH project. The acronym stands for “Innovations through Munich-Nippon Cooperations in Healthcare” and reflects the project’s aim to increase global innovations in the biopharmaceutical industry and to pool German and Japanese expertise in research and development for the benefit of global healthcare.

InnoMuNiCH is part of a funding program for German top clusters, “Internationalization of Leading-Edge Clusters, Forward-Looking Projects and Other, Comparable Networks”. The project was awarded to BioM by Germany’s Federal Ministry of Education and Research (BMBF) in 2017. Amongst other activities, two German-Japanese R&D projects were identified during the conception phase with the help of the Bavarian cluster management. The Munich-based companies Immunic AG and Bicoll GmbH are leading the respective consortia, which will receive co-funding from the BMBF for their projects over three years with a €1.4 mio. (Bicoll) and 1.3 mio. (Immunic) budget.

BioM: InnoMuNiCH provides a platform for German-Japanese cooperation, with the aim to initiate and accelerate bi-national research and development projects. Why was Japan and the InnoMuNiCH program so interesting for your company?

B: Japan is one of the leading countries in the global field of pharmaceutical research. The identification of potential collaborators, and finally concrete project partners becomes more and more challenging. The InnoMuNiCH umbrella offered us the unique opportunity not only to bundle our business development resources, but also to benefit from BioM, which is regarded as a valued cluster in Japan.

I: At Immunic, we also could build up on our long-term, established relationships with Japanese companies and collaboration partners. As an example, we licensed our third development program, IMU-856, from Tokyo-based Daiichi Sankyo. This reflects the value that we place on both the high scientific standards and the level of integrity held by our Japanese partners.

BioM: What challenges did your company face in finding the optimal research and development partners? And how can such a project initiated by your cluster management make a difference?

I: In addition to the important financial funding, the InnoMuNiCH platform facilitates cultural exchange and provides invaluable networking opportunities with business partners and international experts in the areas of drug development, small molecules, immunology, autoimmune diseases and IT, which is not so easily available otherwise in such a compromised form.

B: Finding the optimal research and development partner has never been easy, neither in Japan nor elsewhere. Beforehand, Bicoll had very limited connection to the Japanese market in general and to Japanese people in particular. The first challenge was the market scouting. But also getting an entry and starting business is still very resource demanding and needs significant time investment. With BioM and the InnoMuNiCH...
network, Bicoll has an accessible partner on the local campus in Martinsried, with whom the needs and demands for an ideal matching of collaboration partners could be discussed. That BioM employed a Japanese speaking project manager in the conception phase was the clue to success for the partner search in Japan, and helped with building trust later in the project on both sides.

BioM: What expectations did you have of the BMBF-funded InnoMuNiCH program and how were they met?

B: Our main expectation of getting valuable, risk minimizing support through a representative cluster organization having a reliable name in Japan, was fully met. Furthermore, having access to the local decision makers and – in a best-case scenario – introducing the project also on governmental level was of high importance. The missing points here, which are still not completely solved, are firstly, to persuade the Japanese government to set up a matching program to support the Japanese partners equally, and secondly, to receive further significant support by the cluster, backed up financially by the BMBF, for the establishment of the achieved foothold, not only for Bicoll itself, but also for other companies in the region.

BioM: What success do you hope to achieve by the end of the project and beyond?

I: By combining Immunic’s expertise in targeting intracellular metabolism with the vast experience and resources of each of our partners, a Japanese pharma company, the University of Kyoto and quattro research GmbH, we are hopeful that the results will lead to the development of new therapeutic options for a range of underserved diseases. Additionally, we hope it will lead to the development of qualified biomarkers that enable us to identify patients who may best respond to such therapies.

B: Bicoll aims to have a prototype ready, being able to make individual predictions possible for the best treatment options for patients, and identifying the right compounds for it.

B: For us, the intercultural topic was bumpy at the beginning. Too often, self-announced German Japan-experts are describing the Japanese market as they see it. Unfortunately, this view is often biased – and worse even wrong. We gained significant speed, as we started to include Japanese-born experts sharing their thoughts on German behavior and on the most successful approach. This can still be biased, but here, the Japanese colleagues working for and at BioM really made a difference in explaining us local actors and their behavior. Still, the language remains quite a hurdle in general for further business development in Japan – for sure on both sides.
BioM and Japan – a long-standing Relationship

As the basis for the German-Japanese project InnoMuNiCH, BioM established over the last years a long-standing and valuable relationship with Osaka Prefecture in the Japanese Kansai region. A transnational biotechnology and life sciences cooperation agreement between BioM and Osaka Bio Headquarters includes the exchange of information on new technologies in the respective region, industrial developments and academic potential. As a concrete action, BioM initiated the EU-Japan BioPharma Partnering Event in Osaka, which is now organized annually by the EU-Japan Centre in cooperation with Osaka Prefecture. Numerous Bavarian SMEs already benefited from the partnering event, which conveniently takes place the day before BioJapan starts in Yokohama.

Kawasaki City is a second important partner of BioM. Kawasaki with its world-class open-innovation site King Skyfront is one of the most dynamic cities in Japan. Located in the center of Keihin Industrial Zone, it plays an important role in the growth of the Japanese economy.

In February 2020, the representatives of the Bio-tech Cluster Organizations of Munich and Kawasaki City signed the extension of their Memorandum of Understanding on the Promotion of Business Exchanges. After the first MoU was signed in 2017, a number of successful joint activities followed to initiate and accelerate business cooperation between the life science communities of both regions. The MoU partners offer matching support for cooperation projects between their networks, and exchange best practices in technology transfer and biotech SME support. This will help to identify and strengthen industry-industry and industry-academy partnerships between the two regions.
Cluster Excellence for Business Innovation and Growth in the Health Sector (CE4BIG)

BioM is partner in a new European project, CE4BIG – Cluster Excellence for Business Innovation and Growth in the Health Sector. It was selected to receive funding under the EU COSME “European Cluster Excellence” initiative, which aims to foster cluster collaboration on a European-wide scale. The ultimate objective is to strengthen both, clusters and SMEs, to jointly master global competition and work on the answers to the challenges of personalized medicine.

CE4BIG federates four European healthcare clusters, with similar regional smart specialization strategies supporting the development of advanced therapies for personalized medicine. In addition to BioM, the consortium consists of the project leader, Atlanpole Biotherapies from France, BioWin from Belgium, and Life Science Krakow from Poland.

The project intends to promote business growth and to raise the innovation capacity of SMEs. Professional cluster services will be optimized through targeted activities including the ClusterXchange scheme, which enables and fosters cross-border collaboration between innovation stakeholders in the innovation ecosystems of the project partners. The exchanges aim at helping SMEs within the partnership, design and fine-tune their business models, develop new partnerships, seize new business opportunities abroad, and secure funding for business and innovation to reach proof of technology and grow beyond.

The project will also benefit cluster management and strategic skills through customized training and transnational cluster-to-cluster missions. This will enable the consortium to exchange expertise in topics of common interest for SMEs, and to stimulate the dialogue between SME managers and business/innovation support stakeholders.

The CE4BIG project started on February 2nd and will be funded for 24 months.
A Journey through Bavaria with the “CAR T”

While research into infections, and viruses in particular, has been thrust into the limelight by the coronavirus pandemic, all the topical areas of biomedicine and life sciences are covered by the world-class research activities taking place in Bavaria – frequently combined with special networks for translating and incorporating data into innovations and products. An overview of immunotherapy, and research and application at the university hospitals in Bavaria, is provided below.

Munich

CAR T-cell therapy (chimeric antigen receptor T cells) is considered the great hope in cancer medicine. Clinically, it has proved to be a promising innovative method of treatment for certain advanced types of blood cancer, such as leukemia or lymphoma. The patient’s immune system is thereby genetically modified to fight the cancer. In 2019, the LMU University Hospital Munich became the first center in Germany authorized to use any of the approved drugs. Prof. Marion Subklewe (Medical Clinic and Polyclinic III, LMU University Hospital Munich and the Translational Cancer Immunology working group at the Gene Center Munich) heads the CAR T-cell therapy program at Munich’s university hospital. Initial study results have shown that many patients benefit from the therapy, and about 40 percent are free of lymphoma after two years. Physicians are still working to identify which biomarkers deliver more specific information, and who benefits most from such therapy.

At Klinikum rechts der Isar (Technical University of Munich), Prof. Angela Krackhardt is the senior physician at the oncology day clinic and heads the Tumor Immunology and Translational Immunotherapy working group. She is pleased with the success of CAR T therapy and is herself examining its potential uses. Above all, she is investigating the associated side effects, which are sometimes serious, as well as how to improve their management. Percy Knolle, Professor of Molecular Immunology at the Technical University of Munich (TUM), is interested, moreover, in the mechanisms with which to identify the cells in the tumor tissue that suppress an immune response. The activity of the CD8⁺ T cells, which in fact are also responsible for suppressing cancer in the body, is often found to be reduced in tumor patients. Cancer cells emit signals that slow down the immune system. The TUM research group led by Dr. Bastian Höchst and Prof. Percy Knolle recently identified a degradation product of glucose metabolism that could play a role in this process and works via other cells in the immune system.

Regensburg

University Hospital Regensburg (UKR) is the only medical center in the Lower Bavaria and Oberpfalz region to offer such innovative CAR T-cell therapy. Approximately 20,000 people are diagnosed with cancer every year in eastern Bavaria. CAR T-cell therapy is available only at a few highly specialized centers, such as the UKR’s Clinic and Polyclinic for Internal Medicine III (Hematology and Internal Oncology). Prof. Wolfgang Herr is director of the clinic, and the CAR T-cell program is headed by PD Dr. Simone Thomas. The clinic’s proximity to Regensburg’s Center for Interventional Immunology (RCI) is also a big advantage. Cell programming is the subject of intensive research at both the RCI and the Clinic and Polyclinic for Internal Medicine III of the UKR. The resulting insights are channeled into the clinical studies at UKR, in which the RCI is involved. Several clinical studies are being conducted into this topic at present.
The T-cell receptor study into the treatment of multiple myeloma, acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), for example, which was conceived by Medigene, a biotechnology company based in Martinsried near Munich, is led by Regensburg University Hospital. In addition to the scientists at University Hospital Erlangen, University Hospital Würzburg and other university medical centers (Freiburg, Mainz, Heidelberg, Frankfurt, Dresden) are also taking part in the study investigating a modified approach of CAR T-cell therapy introducing a tumor recognizing receptor into patient’s T-cells.

Erlangen
The development and clinical testing of innovative immunological therapies are also the focus at the German Center for Immunotherapy at Friedrich Alexander Universität Erlangen-Nürnberg. The production of cellular therapeutics is subject to stringent legal requirements and must comply with the guidelines for good manufacturing practice (GMP). An appropriate ultraclean medical laboratory for manufacturing living cell products has been established at University Hospital Erlangen. Using dendritic cells, the lab develops and deploys CAR T-cell therapies, T-cell receptor-based therapies and tumor cell vaccines. Therapies based on antibodies (including immune checkpoint inhibitors), kinase inhibitors, antisense oligonucleotides, or low molecular active ingredients, are also used. The focus lies on the testing of novel therapies in clinical trials and comparing them against conventional treatment concepts to evaluate the safety and efficacy of cell therapies. The clinical facility is therefore an excellent partner in an alliance of international study centers.

This initial clinical trial began in spring 2019 at Medical Clinic 5 – Hematology and Internal Oncology of University Hospital Erlangen, headed by Prof. Andreas Mackensen, who also coordinates this division at the new “Bavarian Cancer Research Center.”

Bavarian Cancer Research Center – an Alliance of six University Hospitals
Despite outstanding basic research, Bavaria also has its deficits in terms of patient-centered cancer research. It is largely conducted on a project-by-project basis, without any sustainable growth in terms of human resources and infrastructures. Excellence is not achieved across the board, but rather only in individual focus areas. Patients derive insufficient benefit from the results of basic research. The future of cancer medicine and research will only be viable based on an alliance of university hospitals at one well-structured center. A fundamental rethink is taking place here. The main idea behind the new Bavarian Cancer Research Center is to develop special expertise and the necessary infrastructures specifically at individual sites which can then be utilized by all sites. To this end, the Bavarian government launched a EUR 150 million funding program to establish an infrastructure alliance and furthermore to network infrastructures in cancer research and the provision of patient care. All six university hospital sites in Bavaria have been integrated; the focus lies in the genuine translation of research results to the benefit of patients. The first light-house projects are due to start in 2020. www.bzkf.de

Würzburg
Not only with CAR T, but also the more specific DAR T (standing for CD123 x CD3 dual affinity re-targeting - DAR T - bi-specific antibody-based molecule), University Hospital Würzburg has demonstrated its prowess in immunotherapy – in both research and application. Researchers in Würzburg have gained special know-how in the handling and design of bispecific linker molecules, which are more effective at bringing the target cell (tumor) and effector cell(s) (T cells, including tumor killer cells) closer together. This expertise is the result of working for many years with the biTE technology developed by Micromet, the Munich-based biotech company acquired by Amgen. Under the name Blyncyo™, this linker molecule is the first novel form of application to have been granted marketing authorization. At the beginning of 2020, the multi-year phase I study currently being conducted at University Hospital Würzburg revealed very good results in patients with advanced multiple myeloma receiving therapy with the new bispecific antibody AMG 420. Bispecific antibodies produced with BiTE technology can bind T cells to the myeloma cells, resulting in their destruction. The study was designed at the clinic headed by Prof. Hermann Einsele with lead investigator Prof. Max Topp; it is here where most of the participants have also been recruited. The bispecific principle works, in this case, as follows: The first target is the B-cell maturation antigen, BMCA, which is mainly found on myeloma cells. The second is CD3, a protein found on the surface of T cells. By binding to these two proteins, AMG 420 attracts and binds T cells to the cancer cells. The killer cells can thus destroy the myeloma cells which would otherwise protect themselves from T-cell infiltration by means of biochemical camouflage.
A special form of CAR T variants is being developed by Dr. Hudecek at University Hospital Würzburg. He has designed a T-cell technology platform to facilitate virus-free gene transfer and optimize the binding of a chimeric antigen receptor to its antigen by utilizing a new and proprietary CAR format. These ideas resulted in the spin-off of the start-up, T-CURX.

Several studies are also investigating new variations of this principle, using new molecules and molecule combinations to better unite the desired target and effector cells. To this end, so-called “hemibodies” were developed by the research team led by Prof. Gernot Stuhler in collaboration with Dr. Thomas Bumm, resulting in the Cherry Biolabs spin-off. The start-up aims to establish a technology platform for developing a variety of novel combinations. This concept has also been recognized with the m4 Award (see p. 24).

**Conclusion:**

With its combination of biotechnology companies, developers of tools for genetically modifying cells, logistics and contract manufacturing companies, and excellent university hospitals, Bavaria occupies a prime position in the research and application of modern immunotherapies.

---

### New Bavarian Research Alliance in combating AMR

*New Strategies Against Multi-Resistant Pathogens by Means of Digital Networking* - bayresq.net

The Bavarian research network “New strategies against multi-resistant pathogens by means of digital networking” builds on novel approaches within basic research to address and counteract the development and spread of resistance in infectious pathogens. An international panel of experts identified six interdisciplinary research groups from the submitted applications. Consisting of two to four academic partners, these project groups are funded by the Bavarian State Ministry of Science and the Arts for a period of five years.

The essence of the program is to gain a deeper understanding of the processes that take place during infection/colonization as well as the interactions between pathogen and host. To achieve this understanding, a common approach based on the systematic use of modern data networks among the bayresq.net projects should enable all users to take immediate advantage of recently collected data. The development and optimization of the data platforms across all projects as well as their user-friendly support will be organized by the bayresq.net administrative offices and operated together with the academic teams, who enter their data into the network. All members of the network and their coworkers can therefore analyze, manage, and share their data via these data platforms.

**Cooperation in challenging times**

Through the projects of this research network, Bavaria will be strengthened in the areas of life sciences and data management. At the same time, the groundwork for improved medical care for future generations is being laid. The bayresq.net research network offers the opportunity to create important conditions for coping with future challenges within and beyond the borders of Bavaria by sustaining and stimulating basic research in areas such as immunology, the microbiome, and infectious diseases. https://www.bayresq.net/
THE SUCCESSFUL INNOVATION CENTRE
MADE IN REGENSBURG

Health Industry of Regensburg

▶ 1.8 billion Euro turnover
▶ 20,000 employees

Cluster BioRegio Regensburg

▶ 55 companies (Life Sciences)
▶ 3,980 employees

BioPark Regensburg

▶ 18,000 sqm area
▶ 38 companies, 608 employees.
▶ 64 start-ups since 1999
▶ flexible leasehold concept & single offices
▶ direct motorway connection
▶ located on the University Campus
▶ own day-care facility
▶ conference rooms and theatre

A company of the City of Regensburg

Member of

CLUSTER BIOTECHNOLOGIE J A Y E B R

BIOPARK
REGensburg GMBH

1999 2019

Am BioPark 13 | D-93053 Regensburg | Phone: +49 941 92046-0 | Fax: -24 | info@biopark-regensburg.de | www.biopark-regensburg.de
In Bavaria, a lively and successful biotech scene has established at five locations. Munich, Regensburg, Würzburg, Straubing and the Nuremberg metropolitan region are among the leading locations in the biotech sector in Germany. The neighborhood of scientific institutions, providers, technology parks and support by cluster organizations creates perfect environments for attracting and founding biotech companies.

The cluster organizations are building a network of companies, universities, research facilities, university hospitals, chambers and associations, investors, funding authorities, advisers, and other players in the clusters.

**Würzburg**
The Innovation and Start-up Center close to the Julius-Maximilians-University offers lab space and has developed a comprehensive program for promoting start-up activities in the region. Cluster organization: Innovation- and Start-up Center (IGZ) Würzburg Incubator: IGZ Würzburg (> 5000 sqm)
www.igz.wuerzburg.de

**Regensburg**
The Innovation center and Start-up Center on the campus of the University of Regensburg offers state-of-the-art laboratories as well as comprehensive technology services. Cluster organization: BioPark Regensburg for BioRegio Regensburg / Healthcare Regensburg managed by BioPark Incubator: BioPark Regensburg (>18,000 sqm)
www.bioregio-regensburg.de

**Munich**
The cluster organization BioM is the central point of contact for the biotechnology sector in Munich and Bavaria and is located in Martinsried, the heart of the Munich Biotech Cluster. The cluster has a strong focus on health, i.e. personalized medicine. BioM offers a wide range of services and events and has developed the comprehensive incubation program “inQlab” for company founders in the field of biotechnology.
www.bio-m.org

**Industrial Biotechnology in Bavaria**
Managed by Industrielle Biotechnologie Bayern Netzwerk GmbH. Established in 2008, IBB Netzwerk GmbH catalyzes the implementation of innovative biotechnological processes and industrial procedures. The main task is to connect partners from large industry, small and medium-sized enterprises, and academia, to implement joint projects in Industrial Biotechnology and sustainable economy.
www.ibbnetzwerk-gmbh.com
Straubing
The BioCampus in the port of Straubing focuses on creating value from biobased resources, biomass logistics and start-up management. In close vicinity to the TUM Campus Straubing for sustainability and industrial biotechnology, it offers lab space, offices, start-up and business support. Cluster Organization: BioCampus Straubing GmbH Incubator: BioCubator (1,200 sqm)
www.hafen-straubing.de

Erlangen and Nuremberg
The European Metropolitan Region Nuremberg is an internationally leading location for medical technology. Cluster organization: Medical Valley Incubator: Medical Valley Centers in Erlangen (>5,000 sqm) and Forchheim (>2,300 sqm)
www.medical-valley-emn.de

IZB Martinsried and Freising
The Innovation and Start-up Center for Biotechnology (IZB) in Planegg-Martinsried (focus on medical biotechnology) and Freising-Weihenstephan (focus on life sciences) has developed into one of the top biotechnology centers in the world and offers young biotech start-ups 26,000 sqm of modern building infrastructure for biotechnology.
www.izb-online.de
Innovation and Entrepreneur Center Würzburg
Where IDEAS become successful STARTUPS

- renting of lab and office space
- coaching of start-ups
- consulting on financing
- support of the management
- networking / business contacts

IGZ Innovations- & Gründerzentrum WÜRZBURG
Friedrich-Bergius-Ring 15
97076 Würzburg, Germany
phone +49 931 780857-0
www.igz.wuerzburg.de
Company Profiles
2bind GmbH
BIOTECH DNA & PROTEIN ANALYTICS

Keywords: Small Molecules, Molecular Diagnostics, Peptide/Protein, Bioanalytics, Drug Development, R&D Service

2bind is a provider for biophysical services in early drug development (hit ID, hit validation and characterization) and antibody Characterization based on the core technologies MST, Dianthus, nanoDSF, BLI and ITC. Our Biotech and Pharma customers benefit from a strong expertise in biophysical methods (certified by NanoTemper for MST, Dianthus and nanoDSF), from customized milestone-based projects with clear timelines and reliable cost structures. Be smart work with the experts!

4SC AG
BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Rare Disease, Orphan Drug, Drug Development, Small Molecules, Oncology

4SC is a clinical-stage biopharmaceutical company developing small-molecule drugs that target key indications in cancer with high unmet medical need. 4SC’s pipeline is protected by a comprehensive portfolio of patients and currently comprises two drug candidates in clinical development: resminostat and domatinostat. 4SC had 44 employees as of 31 December 2019 and is listed on the Prime Standard of the Frankfurt Stock Exchange (FSE Prime Standard: VSC; ISIN: DE000A14KL72).

ABF GmbH
CRO

Keywords: Metabolomics, Analytical Chemistry, Biomarker Discovery & Development

ABF is an accredited (ISO 17025, GLP) bioanalytical contract research laboratory with almost three decades of experience in method development, validation and application in the field of biomarkers and biomonitoring. The lab has particular experience in the analysis of compounds within clinical and toxicological studies by application of LC-MS/MS and GC-MS/MS). Since end of 2001, ABF provides its services to corresponding industry, academic and governmental institutions.
abf diagnostics GmbH

PHARMA SUPPLIER & TRADE

abf diagnostics develops, manufactures and markets products and solutions for the collection, storage and onsite analysis of biological traces and samples. Our strategic focus lies on innovations in pre-analytics and decentralized testing. Our second business area comprises contact-less digital methods for the detection, identification and documentation of biological or chemical traces.

Actarmo Medical GmbH

CRO

Keywords: Respiratory Diseases, Devices, Drug Delivery, Drug Development, Laboratory

Actarmo is a Contract Research Organisation supporting small to mid size pharmaceutical, biopharmaceutical and device companies in development of respiratory products. With our highly experienced team we offer GMP laboratories as well as consultancy activities.

adivo GmbH

PHARMA ANIMAL HEALTH

Keywords: Pain, Oncology, Inflammation, Antibody, Drug Development

adivo is a German biotech company generating species-specific therapeutic antibodies for companion animals. The adivo team aims to initially address high medical needs in dogs including chronic inflammation and cancer, with the potential of expanding activities into the development of therapeutics for other species in the future. Using its fully canine-based antibody library, adivo, either alone or with partners, intends to generate therapeutics for dogs that are well tolerated and efficacious.

advanceCOR GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Cardiovascular Diseases, Peptide/Protein, Drug Development, Inflammation

advanceCOR is a biotech company focusing on personalized medicine in cardiovascular diseases. Revacept, a biological drug (lesion specific inhibitor of atherothrombosis) has completed a phase II trial in patients with stroke and cerebral vascular syndromes. A phase II clinical trial for the treatment of coronary artery disease has completed patient recruitment. Further preclinical candidates are under development. advanceCOR is financed by MIG AG, KfW, Bayernkapital, HTGF, Occident and Bio³M AG.
advanced biolab service Gesellschaft für Laborgeräte, Beratung und Support mbH

DEVICES

advanced biolab service GmbH based in Munich provides maintenance, repair and troubleshooting service for capillary electrophoresis sequencers, Real Time and standard PCR instruments ABI 377, ABI 310, ABI 3100(-Avant), ABI 3130(xl), ABI 3500(xl), ABI 3730(xl), ABI 7300, ABI 7500(Fast), ABI 2700, ABI 2720 and GeneAmp 9700. Remanufactured instruments, service contracts or individual repairs, software and computer upgrades, user training and reagents offered by a small and highly professional team.

ADVITOS GmbH

MEDTECH

Keywords: Multi organ failure, Respiratory Diseases, Hepatology, Devices

ADVITOS has developed the CE-marked & globally patented ADVOS technology (ADVanced Organ Support)® the only therapy worldwide offering multi-organ support integrated in one single device, supporting all 3 main detoxification organs simultaneously: liver, lung and kidney. ADVITOS was founded near Munich in 2005 by renowned nephrology & multi-organ support expert Dr. Bernhard Kreymann who was instrumental in establishing the pervious gold standard of organ support by single-pass albumin dialysis.

Aenova Holding GmbH

BIOTECH & PHARMA PRODUCTION, CMO

With a planned turnover of around EUR 750 million in the current financial year, the Aenova Group is one of the leading companies in the global pharmaceutical and healthcare industry. The group’s portfolio of services covers the entire value chain for the development and production of all the main dosage forms and product groups in the field of medicines and dietary supplements. The Aenova Group high standards of quality, innovative technologies and clear vision for the future have enabled it to become European market leader in the business-to-business field. The company, which has its headquarters near Munich, operates 22 sites in ten countries throughout the world. More than 4,300 employees contribute to the group’s success.

Analytisches Forschungsinstitut für Non-Target Screening GmbH, AFIN-TS

PHARMA & CHEMICAL INDUSTRY

AFIN-TS was founded in 2018 as a spin-off from TUM and provides research as well as important services and consulting around MS based non-target screening. In addition to the detection of known organic compounds in complex samples, non-target screening can be used to characterize unknown/unexpected organic compounds in these or to track changes in the chemical composition (e.g. impurities, fake compounds, and others) along treatment processes (such as drug production and the screen for ‘NIAS’).
Agrobiogen GmbH

BIOTECH AGRO, FOOD, ENVIRONMENT

Keywords: Agrobiotechnology, Bioanalytics, Laboratory

Agrobiogen focuses on and is experienced in the application of molecular-genetic techniques in livestock animals (especially molecular-genetic diagnostics). Detection of pathogens like BVDV, as well as parentage control of animals, SNP genotyping and analysis of DNA markers are offered as a service for breeders, veterinarians and companies.

Agrolytix GmbH

BIOTECH AGRO, FOOD, ENVIRONMENT

Agrolytix is your competent partner around the themes of microencapsulation and micronization. The company specializes in the areas of agrochemicals and cosmetics. We are happy to assist in the development and production of your new products or offer you our technologies as services.

Alexion Pharma Germany GmbH

PHARMA & CHEMICAL INDUSTRY

Alexion (NASDAQ: ALXN) is a global biopharmaceutical company focused on serving patients and families affected by rare diseases through the discovery, development and commercialization of life-changing therapies. Alexion has 2,500 passionate and dedicated employees serving patients in 50 countries around the world. Alexion operates a branch office in Germany to support patients locally. Further information about Alexion can be found at www.alexion.com or at www.alexion.de.

ALGORA Gesellschaft für Medizinstatistik und Vertriebssysteme mbH

CRO

Keywords: Data Management and Biostatistics, Medical Writing, Clinical Trial Management and Monitoring, Infectious Diseases, Oncology, Autoimmune Diseases

Algora offers a broad range of services for phase II-IV clinical trials as well as for observational studies in Germany, with key competencies in study start-up, clinical monitoring, data management, and statistical analysis. Experienced in oncology and infectious diseases since the first days of the company in 1989, we later gained additional expertise in immunology and entered the field of nutritional studies while we continued to cultivate strong relations with the medical community.
Altmann Analytik GmbH & Co. KG

PHARMA SUPPLIER AND TRADE

Keywords: Laboratory, Fine Chemicals/Reagents, Devices, Analytical Chemistry

Specialized distributor for chromatography & lab supply. We provide consumables for HPLC & GC, Spectroscopy (lamps & flow cells) and Sample Prep (syringe filters, vials and caps) as well as chemicals and products for dairy and food industry. On www.analytics-shop.com you can find more than 200,000 lab supply products from high-quality manufacturers, such as Agilent, Chiral Technologies, Grace, Hamilton, Macherey-Nagel, Merck, Millipore, PerkinElmer, Thermo Fisher, Waters, Whatman and YMC.

AMGEN GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Nephrology, Bone/Joint Diseases, Oncology

Amgen is one of the world’s leading biotechnology companies with more than 22,000 employees in nearly 100 countries and a 40-year history. Worldwide, millions of patients with serious or rare diseases benefit from our therapies every year. Our drugs are used in nephrology, cardiology, hematology, oncology, bone health and chronic inflammatory diseases. In addition to original products, our portfolio also includes biosimilars. We have a diverse pipeline. Amgen GmbH in Munich was founded in 1989. Today, almost 650 employees work here with a focus on clinical research, regulatory affairs and the distribution of pharmaceuticals.

AMGEN Research (Munich) GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Immune Therapy, Drug Development, Antibody, Oncology

Amgen Research (Munich) GmbH (formerly Micromet GmbH) located in Munich, Germany has been part of Amgen since March 2012 and is Amgen’s largest R&D site outside of the U.S. The site has about 200 employees and is specialized in the development of the “Bispecific T cell Engager” (BiTE®) antibody constructs for innovative cancer therapies. Amgen is one of the world’s leading biotechnology companies with more than 22,000 employees in nearly 100 countries and a 40-year history.
AmplexDiagnostics GmbH Gesellschaft für molekularbiologische Diagnostik

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Infectious Diseases, In-Vitro-Diagnostics, Molecular Diagnostics, Clinical Diagnostics, PCR

Founded 2002, AmplexDiagnostics is one of the first suppliers for CE IVD diagnostics based on a real-time isothermal amplification technique in a portable device (GENIE II) using lyophilized test reagents for a maximum on user-friendliness and a minimum of hands-on time. With the new eazyplex® system you identify pathogenic bacteria within 15 min, screen swabs for multi-resistant bacteria within 20 min or realise Meningitis diagnostics directly from CSF in 30 min.

AMS Advanced Medical Services

CRO

Keywords: Data Management and Biostatistics, Medical Writing, Clinical Trial Management and Monitoring, R&D Service, Regulatory Affairs, Data Management, Pharmacovigilance

AMS specialises in Global Drug Development, are market leaders in Health Economics and Public Health Benefit Assessments of pharmaceuticals, as well as HTAs and Relative Effectiveness Assessments for medical devices. AMS can provide market access programs in Europe and field force services in German speaking countries. The comprehensive suite of AMS services also include ePRO solutions, strategic consultancy and staff development training.

AMSilk GmbH

BIOTECH NEW MATERIALS AND COMPOUNDS

Keywords: New Materials, Industrial Biotechnology

AMSilk GmbH is the world’s first industrial supplier of synthetic silk biopolymers and has its headquarters in Planegg near Munich, Germany. Sustainably produced using a patented biotechnological process, AMSilk high-performance biopolymers combine the advantages of natural products with the possibility of large scale, industrial production processes. AMSilk’s high-performance biopolymers are distributed in the form of Biosteel® fibers or as a coating solution for medical devices.
amYmed GmbH
Referenzzentrum für Amyloidkrankheiten

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Clinical Diagnostics, Antibody Production Service, Devices, Antibody

We provide high precision immunhistochemical classification of the diverse amyloid diseases with respect to specific and causal treatment as a service for patients and physicians. We are in the process of extending this service by producing and offering test kits in order to enable clinics and institutes of pathology to perform this classification by themselves.

anteris medical GmbH
CRO CONSULTANTS

Keywords: Regulatory Affairs, R&D Service, In-Vitro-Diagnostics, Clinical Diagnostics, Molecular Diagnostics, Devices, Drug Delivery

anteris medical supports Pharma and Biotech companies with the development, quality control and approval of their products. Our expertise in the fields of requirements management, quality control and risks management, usability engineering, Alliance Management as well as approval companies the products through the entire product life cycle. anteris medical brings together the experience of its founders and employees with medical products, combination products and in vitro diagnostics under one roof.

apceth Biopharma GmbH
BIOTECH THERAPEUTICS & DIAGNOSTICS, CDMO

Keywords: Gene Therapy, Cell Therapy, R&D Service, Gene Transfer

apceth Biopharma GmbH, a subsidiary of Hitachi Chemical Co., Ltd., is a pioneering company in regenerative medicine and a leading and certified Contract Development and Manufacturing Organization for cell and gene therapies. We have comprehensive expertise in GMP-compliant manufacturing of various cell types for clinical studies as well as commercial supply. With our partners within the Hitachi Chemical Group, we offer global services for manufacturing and process development.

Assay.Works GmbH
BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Tissue Engineering/Cell Culture, Automation, Small Molecules, Laboratory, Pharmacology, R&D Service, Drug Development

Our mission is to accelerate our partner’s research programs by developing and executing predictive and scalable assays to quantify the bioactivity of novel chemical and biological entities. We combine scientific rigor with our domain expertise in laboratory automation, informatics, and industry best practices to turn challenging assays into quantitative, reproducible results.
Astellas Pharma GmbH

Keywords: Inflammation, Infectious Diseases, Immune Therapy, Autoimmune Diseases, Allergy, Antibiotics, Drug Development

Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to changing tomorrow by improving the health of people around the world. We focus on oncology, anti-infectives, urology and transplantation as prioritized therapeutic areas while advancing new therapeutic areas and discovery research leveraging new technologies and modalities. The German headquarters are based in Munich. Located here are sales, marketing and medical.

ASPHALION, S.L., Zweigniederlassung München

CRO

Keywords: Regulatory Affairs, Pharmacovigilance, Data Management and Biostatistics, Clinical Trial Management and Monitoring, Medical Writing

ASPHALION is a Scientific and Regulatory Affairs consultancy firm with offices in Barcelona, Madrid, Munich and London. Founded in 2000, ASPHALION now consists of a team of over 100 professionals offering services to Pharma and Biotech companies in Drug Development, Regulatory Strategy, Medical and CMC Writing, Regulatory Submissions, eSubmission, Pharmacovigilance and Training. ASPHALION operates in a global environment with regulatory submission expertise mostly in EU and North America.

ATRES engineering biogas

BIOGAS

Keywords: Bioprocessing, Agrobiotechnology

Our top products for the top performance of your biogas plant! Stable biogas production, high effectiveness, high availability of the plant.

Aurigon GmbH

BIOTECH PRECLINICAL SERVICES

Keywords: Pharmacology, Toxicology, Pharmacokinetics, ELISA/EIA, Bioanalytics, Drug Development, R&D Service

AURIGON is an independent CRO offering a full range of in vivo and in vitro non-clinical services. These services include, but are not limited to: PK/PD, ADME, bioanalytics, toxicology and safety pharmacology in all species used in toxicity testing. We’re big enough to provide a full service, but small enough to fully adapt to your needs. AURIGON operates offices in Munich and state-of-the-art GLP- and GMP-compliant facilities at its ATRC Aurigon Toxicological Research Center near Budapest.
Avergen Pharmaceutical GmbH (APG)

BIOTECH THERAPEUTICS & DIAGNOSTICS

Avergen Pharmaceutical GmbH (APG) creates long-term value through internal and collaborative innovative drug discovery programs based on novel drug targets. APG is using a platform to identify and develop protein-protein interaction (PPI) inhibitors. APG is dedicated on its core competences in neurodegenerative disease and oncology research. The location of the company in Munich enables the access to experienced experts in R&D, as well as business development and commercialization.

AMW GmbH, Arzneimittelwerk Warngau

PHARMA & CHEMICAL INDUSTRY

Keywords: Drug Delivery

Intelligent Pharmaceuticals AMW GmbH is an innovative, and steadily growing pharmaceutical company situated nearby Munich, the capital of the Free State of Bavaria in Germany. The base of our technology is to provide a prolonged therapeutic effect with the benefit of having lesser side effects and lower consumption of the active pharmaceutical ingredients. One example from our portfolio is a biodegradable implant, that will be applied subcutaneously by an applicator with an automatic needle-retraction mechanism.

Axolabs GmbH

BIOTECH PRECLINICAL SERVICES

Keywords: RNAi & Antisense, Antisense/Nucleotides, Pharmacology, Bioinformatics, Bioanalytics, Aptamer Technology, Pharmacokinetics

Axolabs is the leading preclinical research organization for oligonucleotide therapeutics and nucleic acid medicines. Based on the foundations of the former Roche Center of Excellence for RNA Therapeutics, we leverage our world-leading know-how and 20 years of experience to provide high-end preclinical solutions and consultancy tailored to your specific needs.

BAP Pharma

PHARMA & CHEMICAL INDUSTRY

BAP Pharma are specialists in the clinical trial supply of comparator drugs, with a global reach. We have extensive experience both in Europe and worldwide. With over 50 years in the industry we are well-placed to understand your clinical trial supply needs. With the newly founded site in Höchstädt, Bavaria, BAP Pharma is even closer to serve customers of the pharma and biotechnology communities.
baseclick GmbH

Keywords: PCR, Nanobiotechnology, Chip/Array Technology,

Baseclick GmbH was founded in 2008 as a spin out of the LMU in Munich by Prof. Dr. Thomas Carell. Baseclick utilizes the “click chemistry”, discovered by the Nobel laureate Prof. Dr. Barry Sharpless, and developed a wide range of nucleic acid modification products, e.g. EdU proliferation kits, labeling of nucleotides and preparation kits for “Next Generation Sequencing” (NGS) and for the development of RNA-based drugs. baseclick GmbH out-licensed this technology to leading companies worldwide.

Basilea Pharmaceutica Deutschland GmbH

Keywords: Drug Development, Antibiotics, Allergy, Dermatology, Infectious Diseases, Oncology

Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland. The company currently focuses on antibiotics and antifungal as well as oncology and dermatology drugs, targeting the medical challenge of rising resistance and non-response to current treatment options in the hospital and specialty care settings. Basilea Pharmaceutica Deutschland was founded 2007 in Munich.

Bavarian Nordic GmbH

Keywords: Infectious Diseases, Vaccines, Drug Development, Immune Therapy, Oncology

Bavarian Nordic (BN) is a fully integrated biotechnology company focused on the development, manufacture and commercialization of life-saving vaccines. We are a global leader in smallpox and monkeypox vaccines. Our commercial product portfolio furthermore contains market-leading vaccines against rabies and tick-borne encephalitis. BN was founded in 1994 and is headquartered in Denmark. The company has more than 500 employees in Europe and USA and is listed on the Copenhagen Stock Exchange.

Baxter Deutschland GmbH

Keywords: Nephrology, Autoimmune Diseases, Oncology, Pain, Immune Therapy, Vaccines, Tissue Engineering/Cell Culture

Baxter International Inc. (NYSE: BAX), through its subsidiaries, develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. As a global, diversified healthcare company, Baxter applies a unique combination of expertise in medical devices, pharmaceuticals and biotechnology to create products that advance patient care worldwide.
Beckman Coulter develops, manufactures and markets products that simplify, automate and innovate complex biomedical testing. Our diagnostic systems are found in hospitals and other critical care settings around the world and produce information used by physicians to diagnose disease, make treatment decisions and monitor patients. Scientists use our life science research instruments to study complex biological problems including causes of disease and potential new therapies or drugs.

Bencard Allergie GmbH

Bencard Allergie GmbH is a subsidiary of the parent company Allergy Therapeutics, an international firm specialized on delivering diagnostic and therapeutic solutions for allergic diseases. With its 19 branches and selling offices, Allergy Therapeutics is represented on the entire globe. In Worthing, a town located in the south of England, the allergen extracts and the formulations for diagnostics and therapeutics are produced according to the highest GMP-Standards.

bene-Arzneimittel GmbH

bene-Arzneimittel GmbH has been producing high quality pharmaceuticals in Munich for 65 years. As a traditional and innovative family business, people are always at the center of our actions. Our branded products are available in 30 countries with the highest standards of quality and compatibility. More than 100 employees are constantly working to develop new products, active ingredients, dosage forms and preparations for our most important goal: human health!

Bernina Plus GmbH

Bernina develops smart oral drug delivery systems for therapeutic peptides. The proprietary technology is based on artificial envelopes created by lipids. In addition, these nano-particle natural and synthetic lipids are used in coating and drug elution processes.
betapharm Arzneimittel GmbH
PHARMA & CHEMICAL INDUSTRY
Keywords: Pain, Drug Development

Betapharm was founded in 1993 in Augsburg. betapharm delivers generic drugs and is one of the leading generic companies in Germany. In 2006 the company was bought by globally active Dr. Reddy Laboratories, Hyderabad, India. With 75 employees Betapharm generates revenues of about EUR 180m.

Bicoll GmbH
BIOTECH THERAPEUTICS & DIAGNOSTICS
Keywords: Natural Compounds, Nutraceuticals, Medicinal Chemistry, Oncology, R&D Service, Agrobiotechnology, Small Molecules

Bicoll is an expert in field of small molecules. It provides fastest and most successful method from initial screening to the animal tests (cycle time <9 months) and products. It provides the most favorable starting points for any innovation campaign to develop one of TOP-200 drugs. High tech plant-derived natural product chemistry is topped up by validated experience in medicinal chemistry. The robust technology serves biological and biochemical high-throughput-screening approaches.

Bind-X GmbH
BIOTECH AGRO, FOOD, ENVIRONMENT
Keywords: New Materials, Agrobiotechnology, R&D Service, Industrial Biotechnology

Bind-X, formerly Dust BioSolutions, is an industrial biotechnology company with core expertise in the development, production and sale of innovative bio-based binders. Bind-X products are capable of solidifying almost any permeable material and providing additional functional properties. Foremost they always increase the sustainability of Bind-X clients in the worldwide mining, agriculture and construction industry.
BIOBANK der Blutspender
Blutspendedienst des BRK

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Clinical Diagnostics, Autoimmune Diseases, Cardiovascular Diseases, Diabetics, Metabolic Diseases, Oncology

With its »Blood Donor BIOBANK«, the Bavarian Red Cross Blood Donor Service offers a unique resource for biomarker research. With a collection of more than 4 Mio plasma samples and a large pool of more than 400,000 active blood donors we are one of the largest blood donor based biobank. The serial, pre-diagnostic blood samples of several thousands of diseased BIOBANK participants per year are a unique resource for investigating markers associated with the onset and progression of diseases.

BioClinica GmbH

CRO

Keywords: Drug Development, Oncology, Neurology, Cardiovascular Diseases, Imaging, Metabolic Diseases, CNS

BioClinica is the global leader in medical imaging core lab services, providing life-science companies with clinical trial support for all phases and across all major indications. Our commitment to service and scientific excellence is focused on advancing our clients’ drug development process. BioClinica’s services create a unique and scalable platform and include Medical Imaging, Cardiac Safety Services, Clinical Event Adjudication Services, Software Solutions, and Drug Safety Solutions.

Biogen GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Rheumatoid Arthritis, Autoimmune Diseases, Dermatology, Neuro-Degeneration, Neurology, Drug Development

Biogen’s mission is clear: We are pioneers in neuroscience. Founded in 1978 as one of the first biotechnology companies, Biogen has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first approved treatment for spinal muscular atrophy, commercializes biosimilars of advanced biologics and is focused on advancing research programs in MS, neuroimmunology, Alzheimer’s disease, neuromuscular and movement disorders and ophthalmology. Biogen German is located in Munich.
Biogents AG

BIOTECH AGRO, FOOD, ENVIRONMENT

Keywords: Infectious Diseases, Natural Compounds, Devices, Agrobiotechnology

Biogents develops, produces & sells innovative trapping systems against mosquitoes & flies, especially against dangerous vectors such as aedes aegypti, aedes albopictus & sand flies. These systems are already being used by leading health organizations (e.g. CDC, USA), several armed forces and other governmental bodies & public entities (incl. quarantine departments, research institutes & universities). Biogents also offers a fee-for-service business for insect repellents and attractants.

BioLink Informationstechnologie GmbH

BIOTECH BIOINFORMATICS

Keywords: Laboratory

The BioLink GmbH, an information-technology company, was founded in 1997 to serve as High Security Internet Provider and as Software Developer for Laboratory-Informations-Management-Systems (LIMS). It was specifically the software-developing business which evolved over the last years. Based on the concept to design and develop personalized LIMS solutions, BioLink put forth a number of softwares aimed to support laboratory processing as well as certain aspects of genetic engineering.

Biomax Informatics AG

BIOTECH BIOINFORMATICS

Keywords: Bioinformatics, Industrial Biotechnology, Data Management, Personalized Medicine, Agrobiotechnology, Informatics, Data Management and Biostatistics

Biomax Informatics provides software solutions for knowledge management in the life science markets: AILANI is a semantic search platform that catalyzes digital change and accelerates the innovation cycle. NeuroXM is the one-stop-shop to decipher brain physiology. The Clinical Integration System ensures access to real world evidence data, which is critical to train Artificial Intelligence to support clinical decisions at the point of care. Biomax is certified according to ISO 9001 and ISO 27001.
**Biomed Labordiagnostik GmbH**  
**BIOTECH THERAPEUTICS & DIAGNOSTICS**  
**Keywords:** In-Vitro-Diagnostics, Bioanalytics  

BIOMED Labordiagnostik GmbH has been known for over 40 years as a reliable and innovative partner for diagnostics in human medicine. Our core competences are diagnostic products and equipment for routine and special laboratories for detection and prevention of diseases. Whether immunology, infectiology, cytology, hematology, safe screening methods or the use of molecular biological methods — we cover a wide range of test methods.

**Biometric GmbH**  
**BIOTECH AGRO, FOOD, ENVIRONMENT**  
**Keywords:** Analytical Chemistry  

Biometric GmbH is a laboratory for microbiological and chemical analysis dealing with the analysis of water, hygienic control and providing microbiological analyses of pharmaceutical products, medical devices, cosmetics and food.

**BIONORICA SE**  
**PHARMA & CHEMICAL INDUSTRY**  
**Keywords:** Neurology, Pain, Respiratory Diseases, Oncology, Analytical Chemistry, Drug Development  

Bionorica SE is one of the leading companies in the area of phytopharmaceuticals worldwide. The product range focuses mainly on diseases of the respiratory tract, urinary tract, gynaecological disorders. Phytoneering combines the huge potential of natural active substances (phytos) with the knowledge and methodology of modern pharmaceutical research (engineering) in order to develop efficient and safe preparations.

**BioNTech Small Molecules GmbH**  
**BIOTECH THERAPEUTICS & DIAGNOSTICS**  
**Keywords:** Immune Therapy, Oncology, Medicinal Chemistry, Analytical Chemistry, Small Molecules, 3D-Structural Analysis, Molecular Modelling  

BioNTech Small Molecules is a 100% subsidiary of BioNTech SE (Mainz, Germany) focusing on discovery and preclinical development of small molecule drugs in immuno-oncology. BNT411, the most advanced compound, is expected to enter clinical development by mid-2020. The research pipeline ranges from hit identification via in silico screening through hit-to-lead and lead optimization to preclinical development. We are offering services in virtual High Throughput Screening and Analytical Chemistry.
**Biontex Laboratories GmbH**

**BIOTECH DEVICES & REAGENTS**

Keywords: Microscopy, Nanobiotechnology, Gene Therapy, RNAi & Antisense, Liposomes, Gene Transfer, Fine Chemicals/Reagents

Biontex Laboratories GmbH is an innovative biotech company with focus on transfection technology, covering the introduction of genetic material and proteins into eukaryotic cells by synthetically produced carrier systems. Current research focuses on the development of completely new strategies for maximising the transfection efficiency for all cell types in vivo or in vitro by utilising synthetic carrier components free from immunological effects.

**Bio-Rad Laboratories GmbH**

**BIOTECH DEVICES & REAGENTS**

Keywords: Chip/Array Technology, Peptide/Protein, Proteomics, Genomics, Gene Transfer, Laboratory, Antibody Production Service

Bio-Rad was founded in 1952. The headquarter is in Hercules, California. Today, Bio-Rad products are used in hospitals, universities, major research institutions, biotechnology companies, reference laboratories, pharmaceutical firms and classrooms around the world. Bio-Rad’s key competencies incl. separation, purification and analysis. The company is a leader in electrophoresis, protein assays, gel image analysis, quality controls, diabetes monitoring, autoimmune testing, blood typing and BSE.

**Biosepar Ges. für Medizin- und Labortechnik mbH**

**PHARMA ANIMAL HEALTH**

BIOSEPAR is driving excellence in sample preparation for parasitologic diagnostics since 1987. With the vision to make parasitologists’ life easier, BIOSEPAR has revolutionized parasitological stool diagnostics with standardized, hygienic, ready-to-use kits and non-toxic, environmentally friendly reagents in both, human and veterinary medicine. The flagship product ParasiTrap® was followed by FixSepar® ECO and while increasing its global reach the company continues driving innovation.

**Biophyll GmbH**

**PHARMA SUPPLIER AND TRADE**

Biophyll has over 25 years of experience in sourcing and manufacturing of biological products of animal, human, and plant origin. We assess the specific needs of our customers to provide tailored product solutions for pharmaceutical, diagnostic, and scientific purposes. - Access to new and rare biological products sourced worldwide - Supply of quality and traceability documentation - Regulatory support in import, export, and registration matters - Individually designed transport logistics concepts
bioVariance GmbH
BIOTECH BIOINFORMATICS

Keywords: Genomics, Bioinformatics, Personalized Medicine, Biomarker Discovery & Development, Informatics, Pharmacogenomics, NGS

BioVariance GmbH offers biomedical data analyses and related software development in the area of precision medicine for the healthcare, pharma and biotech sector. To accelerate the data analytics, we use special algorithms and machine learning to automate complex analytical processes in a customized software pipeline and to develop prediction models. We develop user-friendly interfaces including mobile apps to simplify data collection, processing, visualization and research.

BIOZOL Diagnostica Vertrieb GmbH
BIOTECH DEVICES & REAGENTS

Keywords: Antibody, Peptide/Protein, ELISA/EIA, Proteomics, Small Molecules, Clinical Diagnostics

BIOZOL Diagnostica Vertrieb GmbH markets and distributes products for immunology, cell biology, molecular biology, biochemistry and human and veterinary diagnostics, such as antibodies, recombinant proteins, ELISA/EIA, detection kits, biochemicals and further reagents for cell culture, flow cytometry, immunohistology and cytogenetics. The company represents almost 50 different worldwide known suppliers in Germany. Biozol offers additionally different types of services such as free product search.

Bristol-Myers Squibb GmbH & Co. KGaA
PHARMA & CHEMICAL INDUSTRY

Keywords: Oncology, Autoimmune Diseases, Cardiovascular Diseases, Rheumatoid Arthritis, Hematology

Bristol-Myers Squibb is a global BioPharma company firmly focused on its mission to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. Around the world, our medicines help millions of people in their fight against diseases such as cancer, cardiovascular disease and rheumatoid arthritis.

BSL BIOSERVICE
Scientific Laboratories Munich GmbH
CRO

Keywords: Toxicology, Pharmacology

BSL BIOSERVICE is an internationally active Contract Research Organization. We are offering biological testing services for Pharmaceuticals, Chemicals and Medical Devices. A high degree of customer orientation, high quality and flexibility are core values of our corporate philosophy. A experienced team guarantees acceptance by authorities and supports customers from research until finalization. BSL is certified in accordance with GLP/GMP. We are listed by the WHO and been audited by the FDA.
Carl Zeiss Microscopy GmbH

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Clinical Diagnostics, Microscopy, Tissue Engineering/Cell Culture

ZEISS Research Microscopy Solutions is the world’s only one-stop manufacturer of light, electron, X-ray and ion microscope systems and offers solutions for correlative microscopy. The portfolio comprises of products and services for life sciences, materials and industrial research, as well as education and clinical practice. The unit is headquartered in Jena. ZEISS Research Microscopy Solutions is part of the Industrial Quality & Research segment of the ZEISS Group.

CASCAT GmbH

INDUSTRIAL BIOTECHNOLOGY / CHEMICAL INDUSTRY

CASCAT researches and develops processes for the production of chemicals based on chemical-enzymatic reactions. One focus is the use of renewable resources as a base. The own implementation of these processes as well as working with partners in this case represents the preferred choice of the company. In addition, the consultation of third parties in matters of biotechnology, biocatalysis, renewable resources, sustainability and bioeconomy is a main focus.
catalYm GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, Oncology

CatalYm is developing innovative immunotherapies to transform cancer patients’ lives by effectively engaging their own immune systems to combat this malignant disease. Targeting novel mechanisms that lead to a potent and sustained activation of the immune system within the tumor microenvironment, CatalYm’s goal is to rapidly bring its next-generation immunoncology products to patients in need.

Celgene GmbH - a BMS company

PHARMA & CHEMICAL INDUSTRY

Keywords: Oncology, Drug Delivery, Hematology, Small Molecules, Drug Development

Celgene is a globally acting biopharmaceutical company, founded in New Jersey (USA) in 1986. Celgene is mainly active in developing and distributing drugs in hematology, oncology and immunotherapy. Since 2006, Celgene operates a German subsidiary in Munich-Riem. For further information visit: www.celgene.de

cellasys GmbH

BIOTECH DEVICES & REAGENTS

Keywords: R&D Service, Bioanalytics, Laboratory, In-Vitro-Diagnostics, Biochips, Devices, Toxicology

cellasys delivers system solutions for microphysiometry. These include services such as contract research, research & development, and production & maintenance. Furthermore we offer consulting services in the area of application development, data analysis and data interpretation. Our microphysiometric systems monitor different parameters directly from living cells. These parameters include extracellular acidification (pH), cellular respiration (pO_2) and morphology (impedance).

CellTool GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Microscopy, Devices

CellTool is a company that develops, manufactures and distributes Raman laser microscopes for single cell analysis in suspension, tissue and organoids, 2D and 3D. Multi-omics read out from functional genomics to functional metabolomics (DNA, proteins, lipids, sugars, small molecules).
Centronic GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Analytical Chemistry, Medicinal Chemistry, In-Vitro-Diagnostics, Clinical Diagnostics

Centronic GmbH is a german manufacturer and distributor of a big range of high qualitative clinical chemistry and immunoturbidimetric reagents for the medical diagnosis of enzymes, electrolytes, substrates, lipids and specific proteins. The portfolio is completed with corresponding controls, calibrators, Latex and Salmonella reagents and cleaning solutions for many analysers. Our Quality Management System is certified according EN ISO 13485:2016 by the TÜV.

Cfm Oskar Tropitzsch GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Pharmacology, Antibiotics, Fine Chemicals/Reagents, AntibodyDrugConjugate ADC, Natural Compounds, Drug Development, Drug Delivery

Cfm Oskar Tropitzsch is your reliable and GDP-Certified partner for: Small scale (API) manufacturing (nonGMP/cGMP) Contract synthesis (nonGMP/GMP) Small molecules (> 700 substances) Phytochemicals (> 1000 substances) Phyto-Reference Substances Pharmaceutical raw materials Excipients HPAPIs - Cytotoxins - Payloads for ADCs. Sourcing of APIs Cfm Oskar Tropitzsch GmbH assists the pharmaceutical and biotech industry in sourcing and producing APIs and Excipients.

Charles River Laboratories, Research Models and Services, Deutschland GmbH

CRO

Keywords: Drug Delivery

At Charles River, we understand that the quality of our research models has a direct impact on what truly matters to you - your research. With our core programmes - biosecurity, international standardisation, animal welfare and model quality - you can focus on your work while being assured that you are receiving the highest quality and most reliable models for your research. From standard and disease-specific models to surgically altered animals, you can trust us to be an integral part of your research programmes - now and in the future.
Cherry Biolabs GmbH
BIOTECH THERAPEUTICS & DIAGNOSTICS

Cherry Biolabs GmbH has developed a novel antibody-based platform technology for the treatment of cancers, not amenable by current immune therapies. This is achieved by the combination of two complementary antibody fragments (hemibodies) that assemble "on target" and thus specifically tag tumor cells for lysis by the patient's killer T-cells. While distinct hemibody-combinations against certain tumor types have already been identified, the platform is continuously expanded.

ChromoTek GmbH
BIOTECH DEVICES & REAGENTS

Keywords: Antibody, Proteomics, Imaging, Laboratory

ChromoTek is pioneer and leading supplier of innovative tools, reagents and assays based on alpaka single domain antibodies (also known as nanobodies). Our products simplify, accelerate and improve research applications in biochemistry, proteomics, microscopy and live cell imaging. Nanobodies provide unique properties such as small size, conformational epitope coverage, nano- to picomolar binding affinity and exceptional chemical protein stability. The latest premium tool is the Spot-Tag and Spot-Tag nanobody system - the first peptide-tag/nanobody system for demanding capture and detection applications including high resolution imaging.

Cipla Europe NV
PHARMA & CHEMICAL INDUSTRY

Cipla Europe NV, a 100% subsidiary of Cipla Limited, has presence in several countries in Europe through its partners and own network. Cipla is focused on offering a new pharma concept built on layers of value such as newer products, concepts, formats, information and services to help healthcare providers across Europe. Cipla offers a range of products in Europe — Respiratory, HIV, Vaccines, OTC, API, Plain Generics and Hospital products.

Clariant Produkte (Deutschland) GmbH, Group Biotechnology
PHARMA & CHEMICAL INDUSTRY

Keywords: New Materials, Agrobiotechnology

Clariant is an internationally active specialty chemical company based in Muttenz, Switzerland. Clariant focuses on creating value by investing in future profitable and sustainable growth. The main focus of Clariant Group Biotechnology is on bio-catalysis and bio-refining. The company develops sustainable products and processes for bio-based chemicals and fuels. Clariant has developed a process which uses enzymatic hydrolysis followed by fermentation to produce cellulosic ethanol from agricultural residues.
Climedo Health GmbH

BIOTECH BIOINFORMATICS

Keywords: Automation, Cell Therapy, Oncology, Clinical Trial Management and Monitoring, Devices, Regulatory Affairs, Data Management

Climedo’s mission is to bring the best treatment to every patient by empowering healthcare professionals with intelligent software solutions. Together with Europe’s leading hospitals, they have developed a cloud-based platform for cutting-edge clinical validation and post-market surveillance of medical devices and pharmaceutical products. By digitally connecting all stakeholders (medical device manufacturers, pharma companies, CROs, hospitals and patients), Climedo allows for increased performance, better cost-efficiencies - and ultimately - accelerated medical innovation.

Clinipace GmbH

CRO

Keywords: Drug Development, Regulatory Affairs, Medical Writing, Orphan Drug, Oncology, Clinical Trial Management and Monitoring, Data Management and Biostatistics

Clinipace is a global, mid-size contract research organisation (CRO) providing a comprehensive suite of services, technology, and people. We have the global reach and cutting-edge systems of a large CRO, but the agility and speed of a smaller organisation. Clinipace understands the complexities involved in clinical development and we take a personal and consultative approach through our knowledgeable staff who can navigate both the operational and regulatory challenges that may arise.

Clinrex GmbH

CRO

Clinrex was founded in 2004 by Dr. Dagmar Chase to offer consulting services and training in the of areas GCP, Quality Management and Project Management for clinical trials. GCP/Quality Management Consulting - GCP gap analyses - Inspection readiness/Audits - SOP development/streamlining - Interface sponsor/CRO - Investigator Initiated Trials (IITs) Training (Smart Training® or customised in-house training) - GCP for Sponsors, CROs or On-site Personnel - Project Management/Working with CROs - NIS
ClinTec GmbH

CRO

Keywords: Regulatory Affairs, Drug Development, Oncology, Medical Writing, Data Management and Biostatistics

Covering over 80 countries, we have a strong presence in Europe, USA and Asia-PAC as well as unique markets in Middle East & Africa, providing the global footprint to performing global trials. Clintec has a wealth of experience in conducting clinical trials in oncology and rare disease as well as other therapeutic areas. We use industry leading e-clinical technologies to support our focused, flexible and forward-thinking approach, ensuring excellence at every stage of the trial, everywhere in the world.

COLORIMETRIX GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Colorimetrix GmbH - The lab in your pocket - We turn any smartphone into a portable laboratory using its camera to read diagnostic tests at home. No hardware needed, iOS and Android compatible, very competitive pricing, cloud analytics, trends, insights on the measurements, etc. Check out our first products: https://pearlfertility.app and https://covidrapidtest.app - happy to discuss opportunities, info@colorimetrix.com.

Comphass GmbH

PHARMA SUPPLIER AND TRADE

Keywords: Logistics

Comphass GmbH and Pharmapack Stade GmbH offer a wide range of services in the secondary packaging sector. Our focus is blistering and packaging of capsules and tablets. But we also offer secondary packaging of bottles, cans and special packaging. We are specialized in the packaging of small to medium batch sizes. Certifications according to EU-GMP and manufacturing authorization according to §13 AMG are available.

Conreso GmbH

CRO

Keywords: Vaccines, Oncology, Infectious Diseases, Clinical Trial Management and Monitoring, R&D Service, Data Management and Biostatistics, veterinary clinical trials

Conreso, established in 1990, BVMA member, offers a wide range of medical research services from phase II to late phase, non-interventional and epidemiological studies in humans for pharmaceuticals, vaccines and medical devices. Furthermore, your need for temporary insourcing can be met by Conreso with the permanent permission to temporarily lend staff. Since 2008 the Conreso Department of Veterinary Medicine provides also services for veterinary (field-) studies.
Coriolis Pharma Research GmbH

CRO

Keywords: R&D Service, Peptide/Protein, Vaccines, Antisense/Nucleotides, Analytical Chemistry

Coriolis is a globally operating and world-leading contract research organization in formulation development of (bio)pharmaceutical drugs and vaccines, including proteins, peptides, antibodies, RNA/DNA, VLPs, virus-based ATMPs and GMOs (up to BSL-2). Coriolis is highly experienced in biopharmaceutical characterization by using innovative and state of the art analytical technologies to support trouble-shooting, higher order structure characterization studies, particle forensic and GMP release.

Covance Clinical Development GmbH

CRO

Keywords: Regulatory Affairs, Oncology, Pharmacology, Medical Writing, Laboratory, Clinical Trial Management and Monitoring, Drug Development

Covance Inc. is the world's most comprehensive drug development company. We are dedicated to advancing healthcare and delivering Solutions Made Real® by providing high-quality nonclinical, preclinical, clinical & commercialization services to pharmaceutical and biotechnology companies to help reduce the time and costs associated with drug development. Because of our broad experience and deep knowledge, we are in a unique position to provide insights to our client partners that go above and beyond testing.

Creative Instruments GmbH

BIOTECH DEVICES & REAGENTS

Keywords: PCR, Automation, Devices

Creative Instruments develops and manufactures customized solutions for laboratory automation, automation analysis for diagnostics and biotechnology as well as for measurement technology in close cooperation with the customer. The focus is on precision engineering, chemical and liquid handling, particularly in the optical detection and related evaluation. Its product portfolio includes now analytical devices as Real-time PCR Cycler and temperature control systems.

CRELUX GmbH - a WuXi AppTec company

BIOTECH PRECLINICAL SERVICES

Keywords: Peptide/Protein, R&D Service, Small Molecules, 3D-Structural Analysis

CRELUX is part of HitS platform of WuXi AppTec and provides one-stop solutions for clients seeking premium drug discovery services. We enable early drug discovery, which starts by providing high quality protein and continues with target validation, hit finding (fragment or DNA encoded library screenings) and hit confirmation (biophysics, biochemistry). Importantly, our clients can obtain structural elucidation of their target at atomic precision from X-ray crystallography, Cryo-EM or NMR.
**CRI – The Clinical Research Institute GmbH**

**CRO**

**Keywords:** Devices, Medical Writing, Clinical Trial Management and Monitoring, Data Management and Biostatistics, Logistics, Pharmacovigilance, Regulatory Affairs

We are a full-service Contract Research Organization for clinical studies - controlled trials and observational studies - in all medical indications. We perform clinical projects primarily within Europe with currently >500 contracted hospitals in about 25 countries. The special competence of our 50+ team is large-scaled non-commercial trials, studies with medical devices, and supportive IT solutions like App-based follow-up of patients or data exchange with remote clinical monitoring services.

**CROMSOURCE GmbH**

**CRO**

**Keywords:** Pharmacovigilance, Regulatory Affairs, Medical Writing, Devices, Drug Development, Clinical Trial Management and Monitoring, Data Management and Biostatistics

CROMSOURCE is an ISO-certified international provider of outsourced services to the pharmaceutical, biotechnology and medical device industries, specialized in clinical development and staffing solutions. A well-established full-service CRO, CROMSOURCE is unique in offering an end-to-end guarantee covering trial timelines, enrolment and contract price. This guarantees our clients that their trials are delivered on time and within the contract price with no CRO initiated change orders. CROMSOURCE supports the full spectrum of clinical development via our Pharmaceutical, Medical Device, and Staffing Solutions divisions.

**CryoShop**

**OTHER SERVICES**

**Keywords:** Logistics

SUPPLIER FOR LIQUID NITROGEN EQUIPMENT CryoShop is Munich based consulting and trading company specialising in the field of cryogenic and cold storage applications. CryoShop is offering value added cryogenic solutions. Our portfolio allows us to provide products and solutions along the cryopreservation (standardized) workflow: from preanalytical sample preparation, controlled rate (cell)freezing, temperature controlled transport, cryogenic archiving to controlled/automated thawing devices. Furthermore we are offering special cryogenic personal protective equipment.
CSO Pharma Consulting GmbH

CRO

Keywords: Pharmacology, Data Management, Regulatory Affairs, Pharmacovigilance, Medical Writing, Laboratory

CSO Pharma provides reliable pharmacovigilance services, professional medical affairs support and successful QM/GDP consulting. We run our own quality management system and offer our customers reliable services and processes based on international standards. You can benefit from our extensive experience from audits and inspections and our comprehensive knowledge of present legal requirements.

Curadis GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

The pharmaceutical start-up company located in Erlangen/Regensburg researches and develops steroidal medicines for breast cancer and benign enlargement of the prostate gland. Curadis GmbH was founded in 2008 in Erlangen and has S-Refit AG of Regensburg as one of its investors. The company is developing a novel substance for breast cancer and a substance for prostate cancer.

Cytophorics GbR

BIOTECH DEVICES & REAGENTS

Keywords: Molecular Diagnostics, Devices, Chip/Array Technology, In-Vitro-Diagnostics

The Cytophorics technology enables a variety of applications in the pharmaceutical industry, clinical diagnostics and basic research. Wherever a living cell sample is in interest of investigation, the patented sensor-equipped multi-well plate is able to capture high quality, relevant vital data in real time. The integrated fluidic system allows long-term studies for all kind of cell based assays. The main areas of interest are in personalized medicine in drug developing and in research to investigate basic cell mechanisms.

CYTOX, biologische Sicherheitsprüfungen

BIOTECH DEVICES & REAGENTS

Keywords: Microscopy, ELISA/EIA, Toxicology, Tissue Engineering/Cell Culture

CYTOX provides biological testing service for the medical device and pharmaceutical industry by using in vitro toxicological testing procedures according to ISO 10993 as well as FDA-compliant processes. Next to classical 2D cell culture testing systems we use organotypical 3D cell culture systems especially in the area of skin irritation testing and REACH applications.
DAIICHI SANKYO EUROPE GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Cardiovascular Diseases, Oncology, AntibodyDrugConjugate ADC

Daiichi Sankyo and its 15,000 employees in more than 20 countries are dedicated to the creation and supply of innovative pharmaceutical therapies. In addition to a strong portfolio of medicines for cardiovascular diseases, the Group’s 2025 vision is to become a Global Pharma Innovator with Competitive Advantage in Oncology. Our European headquarters are in Munich, Germany and we have affiliates in 13 European countries.

Data Matrix GmbH

CRO

Keywords: Data Management and Biostatistics, Medical Writing

Data MATRIX’s was established in 2014. With its high-quality software products and professional team Data MATRIX has already successfully completed over 200 projects. Our products automate the processes of clinical trials, and users manage and monitor its progress online. We adjust and validate our software before the project starts in order to do it in the best way. With Data MATRIX products, 6 out of 10 TOP Big Pharma companies reduced their R&D costs by 15%.

Davids Biotechnologie GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Allergy, Immune Therapy, Antibody, Proteomics, ELISA/EIA, Tissue Engineering/Cell Culture, Antibody Production Service

Davids Biotechnologie is a German custom manufacturer for antibodies since 1996. Polyclonal antibodies and monoclonal antibodies. Antibodies and other proteins are produced in HEK and CHO cells after transient transfection as well as in standard E.coli cells. Chromatographic and affinity purification services for purification of protein without a tag and with a tag. Cell based natural killer cell assays for detection of active molecules and for control of human therapies.

DelphiTest GmbH

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Laboratory, Clinical Diagnostics, Genomics, PCR, Analytical Chemistry

The company’s core technology capitalizes on the revolutionary development of DNA analysis, DNA sequencing and DNA fragment analysis. Delphitest focussed on family relationship testing and has an ISO/IEC17025 accreditation. Additional services are paternity tests and genetic tests for dogs, as well as some antibody tests for humans and dogs. Delphitest provides its high level of competence in DNA techniques to scientific partners like universities, hospitals or pharmaceutical companies in Europe.
Denk Pharma GmbH & Co. KG

PHARMA & CHEMICAL INDUSTRY

In a global world it is difficult to know where a product is manufactured. Therefore all Denk Pharma products are: # Manufactured in Germany # Quality controlled in Germany # Registered in Germany.

Denk Pharma, Munich, Germany (www.denkpharma.de) is a globally operating pharmaceutical company with focus on development and marketing of innovative medicine for therapy of infectious and inflammatory disease and broad range generic portfolio. Denk Pharma was founded in Munich, Germany in 1948.

DiaServe Laboratories GmbH

BIOTECH DEVICES & REAGENTS

DiaServe is a primary manufacturer of human and animal blood derived raw materials for diagnostic industry. Based on this raw materials DiaServe also offers tailor-made in vitro controls/calibrators for medical laboratories. The company was established in 1997 with a mission to identify, develop and manufacture in vitro diagnostics mainly on OEM basis for diagnostic manufacturers and clinical laboratories.

Dojindo EU GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Fine Chemicals/Reagents

Dojindo produces over 500 well-known products used by research organizations in the world. Dojindo strives to expand its ability to analyze the future direction of science by maintaining continued interest in new research activities as well as improving its information-gathering network. Dojindo is ready for offering state-of-the-art products because our creative researchers are working continuously to meet tomorrow’s research needs.

DoNatur GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, Rheumatoid Arthritis

DoNatur GmbH develops new therapeutics from herbal extracts with traditionally confirmed therapeutic efficiency. The comprehensive analysis of the genuine extracts, the isolation and structural characterization of the active substances and the test of their pharmacological activities constitutes the main competence of the company. Over the last years DoNatur has successfully developed a new immunomodulatory acting natural substance which has been proved highly efficacious for the therapy of rheumatic diseases.
**Dr. Nibler & Partner**

CRO

Keywords: Medical Writing, Pharmacology, Devices, Drug Development

We provide a complete pharmacovigilance full-service solution:
- 24-hours availability
- Literature screening and -review
- Data entry and MedDRA coding
- Scientific assessment by experienced physicians
- Authority reporting
- SUSAR reporting
- Periodic reports: ASR, DSUR, PSUR
- Risk management plans
- Implementation of pharmacovigilance systems
- Audits and guidance through inspection.

**Dr. Pfleger Arzneimittel GmbH**

PHARMA & CHEMICAL INDUSTRY

Keywords: Dermatology, Antibiotics, Pharmacokinetics, Pharmacology, Drug Delivery

Dr. Pfleger Arzneimittel GmbH is a medium-sized pharmaceutical company with over 390 employees and a sales turnover of nearly 100 million EUR in 2019. Dr. Pfleger markets over 60 non-prescription and prescription medicines for indications in urology, gynaecology, dermatology and areas of self-medication in Germany and selected territories world-wide. The financial surpluses generated by the company are passed onto the Doktor Robert Pfleger-Stiftung.

**Dynamic Biosensors GmbH**

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Antibody, Proteomics, Small Molecules, Peptide/Protein, Chip/Array Technology, Drug Development, Devices

Dynamic Biosensors is a provider of instruments, consumables, and services in the field of analytical systems for the characterization of biomolecules and molecular interactions. The company commercializes the switchSENSE® technology, a groundbreaking platform technology for the analysis of biomolecules with applications in R&D and drug development. The switchSENSE® technology is protected worldwide and only available through Dynamic Biosensors. Further information at www.dynamic-biosensors.com
Ebenbuild GmbH
DIGITAL HEALTH
Keywords: Personalized Medicine, Respiratory Diseases, Pneumology, Biomarker Discovery & Development, Informatics, Imaging, R&D Service

Every year, six million patients worldwide are mechanically ventilated due to Acute Respiratory Distress Syndrome (ARDS), e.g. caused by Corona. Two million die. Ebenbuilds deep-tech software harnesses cutting-edge physics simulation and computer vision to generate unprecedented data of the patients’ lung. A first of a kind precision tool, it will enable physicians to provide better, personalized protective ventilation therapy for ARDS, improving the patients’ odds of survival and recovery.

Eisbach Bio GmbH
BIOTECH DEVICES & REAGENTS

Eisbach develops medicines that target chromatin regulatory mechanisms essential to tumors. Our novel targets and best-in-class drug discovery allow us to develop a pipeline of impactful medicines. Since a tumor’s genome constantly evolves, cancers can be difficult to target. We identified the engines that drive all genome rearrangements. Our unique screening platform has generated first-in-class inhibitors that target the key vulnerability in genetically-defined tumors.

Electrochaea GmbH
BIOTECH AGRO, FOOD, ENVIRONMENT

Electrochaea offers a nationally and internationally patented power-to-methane key technology based on biocatalysis, which cost-effectively recycles CO₂ and at the same time produces carbon-neutral methane that can be stored and used at will from excess electrical energy. The first pilot plant on an industrial scale is operating successfully in Denmark. Further plants were opened in Solothurn, CH, and Colorado, US in 2019. Plants of more than one gigawatt of capacity are targeted by 2025.

ELLA Biotech GmbH
BIOTECH DNA/PROTEIN ANALYTICS
Keywords: Antisense/Nucleotides, Genomics, RNAi & Antisense, Chip/Array Technology, PCR, In-Vitro-Diagnostics

Our expertise is the synthesis of special oligoribonucleotides for random mutagenesis, in-vitro diagnostics, epigenetic sequencing, Aptamer technology and many more following quality standards which you would appreciate and expect in your own lab. Through our validated technology platform, our experienced interdisciplinary team and our resolute attitude towards the highest quality in our products we offer tangible advantages to our customers and partners.
EMFRET Analytics GmbH & Co. KG
BIOTECH DEVICES & REAGENTS

emfret Analytics GmbH (founded 2002) is focussing on production, characterization, derivatization and supply of monoclonal antibodies in biomedical research, namely vascular biology.

EMP Genetech
BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Drug Development, Biomarker Discovery & Development, R&D Service

EMP Genetech is a CDMO in the field of recombinant protein production. Recombinant proteins are expressed from mammalian cells. We develop stable high producer cell lines mainly of human (HEK293 EBNA) origin cells. Protein production is conducted by bioreactor driven high cell cultivation up to 10 L scale with serum free conditions. Gene cloning and single cell clone selection as well as downstream processing are well established methods in our lab. We work successfully since 2000.

EpiGene GmbH
BIOTECH AGRO, FOOD, ENVIRONMENT

Keywords: Agrobiotechnology, Genomics

EpiGene GmbH is a genomics-based research and development company focusing on applications in plant protection. The core competences comprise the molecular characterization of plant-pathogen interactions and the development of high throughput systems for molecular diagnostics of involved genetic factors. In addition, research efforts include investigations of the mode of action of plant protective agents and the identification of mutations or differentially expressed genes in pathogens as potential new targets.

EpiQMAx GmbH
BIOTECH DNA/PROTEIN ANALYTICS

Keywords: R&D Service, Clinical Diagnostics, Molecular Diagnostics, Proteomics, Personalized Medicine

Since 2018, EpiQMAx is a partner for the development of epidrugs and biomarker research in the epigenetic and proteomic field. Headquartered nearby Munich, we operate a state-of-the-art mass spectrometer to facilitate epigenetic screenings into clinical applications. Our technology platform comprises a kit for quick sample preparation, a mass spectrometer for a unique quantitative analysis of modifications and software programs for intuitive and visual reporting of the results.
BUILDING STRONG DRUG DISCOVERY PARTNERSHIPS

Flexible scientific and commercial solutions progressing both small and large molecules from target to IND and high-end CMC
**essentim GmbH**

BIOTECH DEVICES & REAGENTS

essentim lab pursues the goal to improve process, workflow and documentation in laboratories of today and tomorrow. As our first product, essentim lab kit optimizes the documentation of procedures and simplifies the effort for continuous quality control. The scope is meant as mobile wearable device transmitting data in real time being visualized by our lab application. Location and process documentation is easier, more detailed and accomplished with more satisfaction.

Roßmarkt 6  
D-80331 München  
Phone: +49 (0) 89 999 50696  
E-Mail: info@essentim.com  
Internet: www.essentim.com

---

**ethris GmbH**

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Metabolic Diseases, Dermatology, Bone/Joint Diseases, Gene Therapy, Gene Transfer, Tissue Engineering/Cell Culture, Drug Development

Ethris is paving a new path from genes to therapeutic proteins using our proprietary messenger RNA technology. Developed in-house, our integrated platform enables the discovery, design and development of transcript therapies that restore missing functions in patients’ cells and tissues. We will advance transcript therapies to transform the treatment of disease independently and with our partners.

Semmelweisstrasse 3  
D-82152 Planegg  
Phone: +49 (0) 89 8955 788-0  
E-Mail: info@ethris.com  
Internet: www.ethris.com

---

**eticur) GmbH**

BIOTECH THERAPEUTICS & DIAGNOSTICS

Based on the idea that umbilical cord blood contains multipotent adult stem cells, the cord blood is prepared and stored for potential later use. These cells might in future play an important role in therapies including regenerative medicine. eticur) grants the storage of stem cells following the highest quality-standards of the Federal Board of Physicians and the Institute for Sera and Vaccine (Paul-Ehrlich-Institute) and extensive testing by highly qualified personnel.

Landsberger Str. 406  
D-81241 München  
Phone: +49 (0) 89 12 59 81-0  
E-Mail: info@eticur.de  
Internet: www.eticur.de
Eurofins BioPharma Product Testing Munich GmbH

BIOTECH PRECLINICAL SERVICES

Keywords: Pharmacology, Small Molecules, Bioanalytics, Laboratory, Medicinal Chemistry, Toxicology

Eurofins BioPharma Product Testing Munich is part of the world’s largest network of testing laboratories providing comprehensive laboratory services to pharmaceutical, biopharmaceutical and medical device companies. Certified according to GMP, GLP and ISO, Eurofins BioPharma Product Testing Munich supports its customers in the safety testing of drugs, medical devices, chemicals and cosmetics. The company was founded in 1995 and is today represented with around 400 employees in a laboratory and office space of around 14,000 sqm at Planegg near Munich.

Eurofins Genomics

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Genomics, NGS, PCR, Antisense/Nucleotides

Eurofins Genomics is an international provider of genomic services around the core business lines next generation sequencing, genotyping, gene expression, custom DNA sequencing, oligonucleotides, siRNA and gene synthesis.

Evanium Healthcare GmbH

PHARMA & CHEMICAL INDUSTRY

Alcohol consumption and the associated health-risks as well as the Hangover are common problems with a negative impact on the consumer as well as the society. Evanium Healthcare is active in alcohol research, with the company pursuing a dietary approach. By the means of custom galenic formulation of the key ingredients Evanium Healthcare could develop tablets for oral consumption and produce them on a pilot system. Wide-ranging patent applications protect the product from imitation and enable a strong market position.

Evotec (München) GmbH

BIOTECH PRECLINICAL SERVICES

Keywords: Cell Therapy, Metabolomics, Biomarker Discovery & Development, Bioinformatics, Small Molecules, Proteomics, Genomics

Evotec is a leading player in the drug discovery and development field. We operate worldwide providing the highest quality stand-alone and integrated drug discovery solutions, covering all activities from target-to-clinic. The Company’s headquarters are located in Hamburg, Germany with 13 further operational sites in Europe and the USA and more than 2,500 employees worldwide. Evotec (München) GmbH is the Company’s centre of excellence for proteomics, biomarker and metabolomics services.
**ExB Health GmbH**

**IT, DIGITAL HEALTH**

ExB Health is a subsidiary of the ExB Labs GmbH, a Germany based technology incubator and research company in the field of unstructured big data, natural language processing, Cognitive Computing and deep learning. ExB Health draws on the labs mature developments and adapts them for the use in lifescience and healthcare. The knowledge discovery and decision support systems help pharma and healthcare industries to lower costs, speed up the drug-development cycle and improve patient outcomes.

**EXCELLA GmbH**

**PHARMA & CHEMICAL INDUSTRY**

**Keywords: Drug Development, Medicinal Chemistry, Analytical Chemistry, Small Molecules, Oncology**

Excella GmbH & Co. KG has been serving the pharmaceutical industry for more than 35 years with high quality API’s and finished dosage forms. Focused towards high containment manufacturing Excella supplies products to the generic industry and big pharma but also develops processes for innovative API’s and novel solid dosage forms. Services offered from our globally registered and approved site range from early product development through registration support to state-of-the-art manufacturing.

**Exosome Diagnostics GmbH,**

**a Bio-Techne company**

**BIOTECH THERAPEUTICS & DIAGNOSTICS**

**Keywords: Clinical Diagnostics, R&D Service, In-Vitro-Diagnostics, NGS, Biomarker Discovery & Development, Oncology**

Exosome Diagnostics is developing and commercializing biofluid-based diagnostic tests using proprietary technology. The company also offers biopharma services for exploration of exosomal RNA, cell-free DNA, and proteins to identify and validate biomarkers without tissue. The urine-based ExoDx Prostate test is included in the 2019 NCCN Guidelines and will soon be offered as CE-IVD in Europe. Exosome has clinical laboratories in Waltham (US) and Munich (DE) and was acquired by Bio-Techne in 2018.

**F-Select GmbH**

**PHARMA & CHEMICAL INDUSTRY**

The element fluorine plays an increasingly important role in the field of high-performance materials and pharmaceuticals. The production of the necessary chemical substances remains a challenge and F-Select has the solution. F-Select offers selected fluorinating agents as well as a comprehensive know-how in the handling and production of fluorinating agents. The methods developed by F-Select provide resource-saving methods for the production of pharmacological building blocks.
FGK Clinical Research GmbH

CRO

Keywords: CRO/CMO, Drug Development, Cell Therapy, Regulatory Affairs, Devices, Data Management and Biostatistics, Clinical Trial Management and Monitoring

FGK is a Europe-based CRO with offices in DE (HQ), PL, CZ and HU, offering full service for all phases of clinical trials. Our international client base includes biotech, medical device and pharma companies. With extensive experience in all major therapeutic areas and 150+ highly qualified medical, scientific and regulatory experts we can guide you through the clinical development process, from planning and approval up until the final report.

FGK Pharmacovigilance GmbH

CRO

Keywords: CRO/CMO, Medical Writing, Clinical Trial Management and Monitoring, Drug Development, Pharmacovigilance, Data Management and Biostatistics

FGK Pharmacovigilance GmbH is a service provider offering vigilance services in support to pharmaceutical, biotech, and medical device companies’ obligations in managing risk-benefit profile of their products. Services can be added to existing vigilance system of a client on a modular basis or comprise a standalone center of product vigilance on national, international or global level.

FLUICS GmbH

BIOTECH DEVICES & REAGENTS

Keywords: sample tracking, labeling, mobile database

FLUICS CONNECT helps modern research labs to keep their sample inventory up to date. With our mobile app and an internet-ready printer connected to an online database we offer a convenient solution to print and track smear proof, QR-coded cryo labels. It takes just 1 minute to watch how it works: https://go.fluics.com/teaser.

FoodChain ID Testing GmbH

BIOTECH AGRO, FOOD, ENVIRONMENT

Keywords: ELISA/EIA, Genomics, PCR, Laboratory, Agrobiotechnology, NGS

FoodChain ID Testing GmbH provides molecular biological analysis of food and feed, plant material, and animal tissue (GMO analysis, species identification, DNA barcoding, genotyping, custom contract assay development) and immunological detection of allergens in food and feed.
Formycon AG
BIOTECH THERAPEUTICS & DIAGNOSTICS
Keywords: Inflammation, Dermatology, Ophthalmology, Drug Development

Formycon is a leading, independent developer of high-quality follow-on products for biopharmaceutical medicines known as biosimilars. The company focuses on treatments in ophthalmology, immunology and on other key chronic diseases, covering the entire value chain from technical development to the clinical phase III as well as the preparation of dossiers for marketing approval.

Freeline Therapeutics GmbH
BIOTECH THERAPEUTICS & DIAGNOSTICS
Keywords: CGene Therapy, Industrial Biotechnology, Drug Development

Freeline is a leading clinical-stage biotechnology company in GB and Germany. We focus on development and commercialisation of innovative gene therapies to change lives. Our ambitious vision is to create better lives for people suffering from chronic, debilitating disease. We are developing functional cures for a wide range of liver-based diseases which have previously been underserved and incurable.

FRIZ Biochem Gesellschaft für Bioanalytik mbH
BIOTECH DEVICES & REAGENTS
Keywords: Chip/Array Technology, Infectious Diseases, Devices, Clinical Diagnostics

FRIZ will be a provider of novel, disruptive and broadly applicable molecular diagnostic solutions with special emphasis on near-patient applications. The company’s mission is to offer quality diagnostics that immediately link everyone to the care they need. It is on the verge to market entry with its CYCLE® technology. The first applications of CYCLE® True Point-of-Care are MRSA (Methicillin-resistant Staphylococcus aureus) admission and Coronavirus testing.

GATTAAquant GmbH
BIOTECH DEVICES & REAGENTS
Keywords: Microscopy

The worldwide first commercial DNA origami application: The key innovation behind our nanorulers is the application of an elaborate nanotechnology method, which serves as a breadboard to position dye-molecules on the nanometer scale. The used technique, where DNA is folded into predefined shapes, is called DNA origami and allows to attach dye-molecules at will.
GBA PHARMA GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Laboratory, Analytical Chemistry, R&D Service

GBA Pharma Labs run three GMP-certified and FDA-inspected sites in Germany with more than 160 highly qualified employees and over 4,500 m² of lab space. Our locations for analytical services support domestic and international customers, whether from the private industry or research institutions, with scientific and technical solutions for the development, approval process, and quality control throughout every step of the product lifecycle.

GBN Systems GmbH

BIOTECH & MEDTECH DEVICES & REAGENTS

For over 20 years our challenge is to meet the outstanding demands of our clients in the fields of medical technology, biotechnology, the semiconductor industry and automation technology. Our product range: From customized components to complete assemblies and machines from initial vision to serial end production. The Facilities are centrally located near Bavarian capital and airport of Munich. Key competencies in: Concept, development, prototyping, validation, certification, pre-series, main-serial production, quality management, fulfillment, logistics.

YOUR CRO: FLEXIBLE EXPERTS AND RELIABLE SOLUTIONS.

› Customized conduct of clinical trials for biotech and medical device companies
› Highest quality standards, accompanied by frequent and clear communication
› Combined know-how in all major indications through our 140+ in-house experts in Europe

fgk-cro.com

New Branch Office Berlin

Owned and managed by:

Dipl.-Stat. Martin Krauss
+49 89 893 119-25
martin.krauss@fgk-cro.com

Dr. med. Edgar J. Fenzl
+49 89 893 119-22
edgar.fenzl@fgk-cro.com

Delivering Reliability
Genedata Bioinformatik GmbH

BIOTECH BIOINFORMATICS

Genedata is a bioinformatics company that specializes in developing software systems for the comprehensive analysis of genomes, transcriptomes, proteomes, metabolomes, and biochemical compounds. By working closely with key partners, the company combines its extensive product portfolio with expert scientific consulting services to offer tailor-made solutions for specific applications and multiple therapeutic areas. The company’s solutions are key for moving the focus of life science research from high-throughput data acquisition to high-content data interpretation. Founded in 1997 as a spin-off from Novartis, the company is headquartered in Basel (Switzerland) with branch offices in Munich (Germany), San Francisco (USA), Boston (USA), and Tokyo (Japan).

Genedia AG Biotec Services and Products

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Antisense/Nucleotides, Genomics, Medicinal Chemistry

Genedia AG Biotec Services and Products is a provider of DNA testing services including private DNA paternity testing, legal DNA paternity testing as well as other relationship testing services. Another area is DNA genealogy and anthropology, which includes ancestral origin DNA population test, Y-Chromosome Analysis, mt-DNA analysis. The forensic area includes DNA identification and banking services DNA molecular testing of diseases (Factor V and II, MTHFR, CFTR-Mutation).

GeneSurge GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

GeneSurge is your access to individualized diagnostics. Even though we classify tumors according to their place of origin and appearance, each one remains somewhat different at the molecular level. And that is exactly what makes each cancer an individual disease. This fact ultimately creates a need for individual and detailed information to enable personalized treatment that is specific to the individual patient. We provide 3 tests to reach your individual profile.

GENidee

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Molecular Diagnostics, PCR

GENidee is a young and innovative biotech company specialized in the development, production and sales of molecular biological diagnostic kits for the rapid detection of food-borne pathogens in food. Fast and reliable real-time PCR diagnostics is guaranteed by simultaneous analytics suited to the individual customer requirements. GENidee offers DNA-based detection systems of highest quality. Using our kits directly in the production facilities enables the results of molecular food analytics to be supplied much sooner than by conventional diagnostics.
Gen-Plus GmbH & Co. KG
CRO

Keywords: Laboratory, R&D Service, Drug Development

Gen-Plus GmbH & Co.KG provides solutions for challenging needs in pharmaceutical development and is a state-of-the-art CRDO. We develop tailor-made formulation and technology concepts (NCE, value-added-Generics, OTC) for solid/semisolids, non-steril liquids, patches and thin films from early idea to IMP production under GMP. Further in-house capabilities: narcotics & high potent handling (isolators), 2D&3D API printing, high-tech analytics incl. skin permeation.

Gilead Sciences GmbH
BIOTECH THERAPEUTICS & DIAGNOSTICS

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California. For more information on Gilead Sciences, please visit the company’s website at www.gilead.com.

GILYOS GmbH
CRO

Keywords: Small Molecules, Peptide/Protein, Antibody, Nanobiotechnology, Drug Development

GILYOS is a contract development solution provider with more than 20 years of experience in pharmaceutical freeze drying. GILYOS’ key business is consultancy and hands-on development services. Typical services include formulation development of small molecules and proteins, process optimization and analytical characterization. Further, GILYOS has a very strong expertise in scale-up and technical transfer of freeze drying cycles, including troubleshooting of established products (scale down).

gimbio mbH Gesellschaft für Informationsmanagement in der Biotechnologie
BIOTECH BIOINFORMATICS

Keywords: Automation, Data Management

Gimbio GmbH offers innovative products and solutions in bioprocess technology, especially for companies in the food, brewing or biotechnology industry. The guiding principle of the company is, in addition to the information gathering and processing, the development and application of innovative online measurement systems for biotechnical process state variables for the purpose of process design, modeling and simulation, with the ultimate goal of optimizing underlying bioprocesses.
GKM Gesellschaft für Therapieforschung mbH

CRO

Keywords: Regulatory Affairs, Data Management and Biostatistics, Medical Writing, Pharmacovigilance, Clinical Trial Management and Monitoring

GKM Gesellschaft für Therapieforschung is a privately owned full service Contract Research Organisation for planning and conducting clinical trials phase II-IV as well as for non-interventional studies. GKM also provides services for early benefit analyses (AMNOG), vigilance, and medical writing. Since 1981, GKM is a reliable partner for pharmaceutical, biotech and medical device companies. GKM provides flexible, cost-effective services with expert knowledge and dedication to your projects.

Lessingstr. 14
D-80336 München
Phone: +49 (0) 89 209 120-0
E-Mail: mail@gkm-therapieforschung.de
Internet: www.gkm-therapieforschung.de

Creating new ideas is your business.
Protecting these ideas is ours.
GlaxoSmithKline GmbH & Co. KG

PHARMA & CHEMICAL INDUSTRY

Keywords: Antibiotics, Vaccines, CNS, Dermatology, Respiratory Diseases, Urology

GSK is a science-led, globally operating healthcare company with a special purpose: to help people do more, feel better, live longer. Our goal is to be one of the worlds most innovative, best performing and trusted healthcare companies. GSK is setting milestones in healthcare prevention with a comprehensive portfolio of vaccines, respiratory and additionally in Oncology. Via our affiliate ViiV Healthcare, we are also involved in the area of HIV.

GNA Biosolutions GmbH

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Clinical Diagnostics, In-Vitro-Diagnostics, Bioanalytics, Molecular Diagnostics, Devices, New Materials, Other Diagnostics

GNA Biosolutions GmbH was founded in 2010 as a spin-off from Ludwig-Maximilians-Universität, Munich. The company employs 40 people today. GNA develops instruments, consumables and tests for fast molecular diagnostics, based on its proprietary technology, Pulse Controlled Amplification (PCA). PCA can transform molecular diagnostics by enabling the development of testing platforms that can be used outside of the traditional laboratory setting.

Gotham Therapeutics, NY/Munich

BIOTECH THERAPEUTICS & DIAGNOSTICS

Gotham Therapeutics has assembled an exceptional team and network to establish a novel drug class targeting RNA-modifying proteins. By changing the activity of proteins that modify messenger RNA, Gotham aims to develop new treatment options for patients suffering from cancers, auto-immune and neurodegenerative diseases. The team is applying a 360-degree approach to small molecule drug design to build a pipeline based on the promise of this rapidly emerging biopharmaceutical field.
GWK Präzisionstechnik GmbH
BIOTECH DEVICES & REAGENTS

Keywords: Microscopy, Chip/Array Technology, Automation, Analytical Chemistry, Devices

GWK Precision Technology offers laboratory equipment and medical devices. Based in Munich we are a team of 20 specialists and serve industries since 1991. We provide special know-how in technical fields (precision mechanics, optics, image processing, sensors, microfluidics, cutting techniques, lateral flow, 3D-prototyping) and system techniques (automation, handing, electronics and machine control) as well as the certification of equipment and production systems.

Hellsicht GmbH
BIOTECH BIOINFORMATICS

Keywords: Bioinformatics, Imaging, Data Management, Informatics

We build deep learning software to improve medical diagnosis by combining human expertise with machine intelligence in a unique hybrid approach.

Hematri Wound Care GmbH
MEDTECH

Keywords: Devices

Hematri Wound Care GmbH develops, manufactures and markets products in the area of wound care. Our major initial focus is the marketing of hemostatic products to control bleeding. We are experts in the field of hemostasis and wound healing. Our vision is to build up an attractive company together with our investors in this business area.

HWI regulatory services GmbH
CRO

Keywords: Drug Development, Analytical Chemistry, Medical Writing, Pharmacology, Toxicology, Devices, Regulatory Affairs

HWI regulatory services GmbH (former i.DRAS) provides regulatory services for drug substances and products. For medical devices and drug-device combination products we offer clinical evaluation, biological safety assessments and technical documentation writing for certification. Together with HWI group’s services in analytics, development, reference standards, life-cycle management, vigilance and quality we are the one-stop shop for the pharmaceutical, medtech and biotech industries.
HMNC Brain Health GmbH

**BIOTECH THERAPEUTICS & DIAGNOSTICS**

Keywords: Drug Development, Medicinal Chemistry, Personalized Medicine, Laboratory, Biomarker Discovery & Development

HMNC is a biopharma company developing novel treatments for depression and anxiety: Proprietary gene-based companion tests support the decision which drugs optimize treatment effects. Our portfolio includes investigational drugs targeting stress systems in the brain. A novel formulation of ketamine holds promise to become prime option for treatment resistant depression. The myGeneCode1-test informs whether a given antidepressant passes the blood-brain barrier. The test is already on the market.

Human Tissue and Cell Research-Services (HTCR) GmbH

**BIOTECH PRECLINICAL SERVICES**

Keywords: Biomarker Discovery & Development, Bioprocessing, Tissue Engineering/Cell Culture, Toxicology

HTCR-Services (HSG) develops and markets cell culture technology based on human liver cells and other human organs. The cell culture technology is used for prognosing metabolism of novel drugs and for in vitro simulation of liver dysfunctions. With their cutting edge cell and tissue products, HSG provides to the scientific community and pharmaceutical industry an outstanding in vitro test system coming close to the human in vivo conditions. Animal experiments can be replaced to a large extent.

HTI bio-X GmbH

**BIOTECH DEVICES & REAGENTS**

Keywords: Devices, Automation

HTI bio-X GmbH is an engineering supplier for products and technical service. We are developing customized solutions of instruments and automations. Our product portfolio covers e.g. consumables and instruments for DNA-synthesis. The biomagnetic workstation X-Tract facilitates magnetic beads applications. The main focus is a system of instruments and modules for the automation of laboratory processes. The X-TubeProcessor is based on the X-Capper for capping and of screw cap tubes. This device is expandable with many modules e.g. for labelling, barcode reading, filling reagents or powder into individual tubes or dispensing of reagents into all tubes. The X-TubeProcessor is usable for a wide range of tubes. The system will be combined with modules regarding to the market requirements.
Hyglos GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Proteomics, Infectious Diseases, Peptide/Protein, Clinical Diagnostics

Hyglos is BioMérieux’s Endotoxin Center of Excellence based in Bernried, Germany. Our ENDONEXT™ range of recombinant Factor C assays and our ENDOXPERTS™ services provide innovative solutions for endotoxin detection. We aim at revolutionizing the endotoxin detection market through the replacement of historical animal-source based methods by modern, sustainable and ecological techniques, leveraging significant advantages such as accuracy, sensitivity, lot-to-lot consistency, and easy automation.

Hyperthermics Regensburg GmbH

BIOTECH AGRO, FOOD, ENVIRONMENT

Hyperthermics Regensburg GmbH is a biotechnology company developing applications of hyperthermophilic organisms in renewable energy solutions and in industrial processes. In these applications hyperthermophilic microorganisms are the “software”. In the initial phase we are focusing on developing applications together with international industrial partners. In an operational phase we will focus our research activities towards “software development and update”.

ibidi GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Microscopy, Chip/Array Technology, Tissue Engineering/Cell Culture, Nanobiotechnology, Devices

The ibidi product lines includes micro-Dishes, -Slides, and -Plates for the cultivation and high-resolution microscopy of cells, and also cell-based assays for investigating angiogenesis, chemotaxis, wound healing, and cells under flow. ibidi also specializes in instruments, such as stage top incubators for live cell imaging under physiological conditions, plus a unique perfusion system for the simulation of blood vessels. The company also offers reagents and cell lines for live cell imaging.
ImevaX GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Infectious Diseases, Industrial Biotechnology, In-Vitro-Diagnostics, Clinical Diagnostics, Biomarker Discovery & Development

ImevaX GmbH, founded in 2013, is a Munich based life science company focussed on novel infection diagnosis. Current product in development is an innovative H. pylori rapid test that combines unprecedented sensitivity, specificity and speed. It determines the presence of two specific antibodies to H. pylori, FliD and CagA, that allow a risk-stratification into low- and high-risk groups for development of gastric cancer. ImevaX owns the global patent for the detection of antibody marker FliD.

IMGM Laboratories GmbH

BIOTECH & PHARMA PRODUCTION

Keywords: PCR, Laboratory, Genomics, Chip/Array Technology, Pharmacogenetics, Pharmacogenomics

IMGM Laboratories are a GLP and DIN EN ISO / IEC 17025 certified contract service provider for genomic services. Our four service pillars cover biomarker discovery, pharmacogenetics, metagenomics and biodistribution studies of nucleic acid compounds. In close collaboration to our clinical partner, we offer a complete pathology workflow containing the molecular characterization of cancer samples from histology to mutation detection and fusion transcript identification.

immatics biotechnologies GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, Cell Therapy, Personalized Medicine, Immune Therapy, Oncology, Genomics, Proteomic

Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors to enable a robust and specific T cell response against these targets. This deep know-how is the foundation for our pipeline of Adoptive Cell Therapies and TCR Bispecifics as well as our partnerships with global leaders in the pharmaceutical industry. We are committed to delivering the power of T cells - unlocking new avenues for patients in their fight against cancer.
Immumed GmbH
Gesellschaft für angewandte Immunologie

BIOTECH PRECLINICAL SERVICES

Keywords: Laboratory, Inflammation, ELISA/EIA, Clinical Diagnostics

Applied Immunology - Testing Services We offer testing services for scientific samples: - Analysis of cytokines, chemokines and hormones - Cell-characterization - Cytotoxicity. Our team is specialized in measuring multiplex-parameter analysis with Luminex-Technology in various samples like serum, cell cultures, saliva, urine. We perform many applications for flow-cytometry analysis, for example cell phenotyping or cytotoxicity assays, as well as a broad range of metabolic and aging parameters.

Immunic AG

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Small Molecules, Autoimmune Diseases, Inflammation, Drug Development, Immune Therapy

Immunic, Inc. (Nasdaq: IMUX) is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including relapsing-remitting multiple sclerosis, ulcerative colitis, Crohn’s disease, and psoriasis. Immunic, Inc. is headquartered in New York. Its subsidiary, Immunic AG, is based in Planegg-Martinsried, Germany, where the company’s research and development activities are conducted.

immunoGlobe Antikörpertechnik GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Laboratory, Antibody Production Service, Antibody

immunoGlobe®, GmbH, established in 1997, is a privately owned antibody manufacturer. Full service custom antibody services are supplemented by epitope mapping (single amino acid precision) and recombinant antibody technologies in cooperation with different partners. A special focus is on antibodies to posttranslational modifications (PTM), such as combinations of different (de)phosphorylation states of neighboring sites, neo-epitopes (e.g. cleavage sites), isoforms, variants, and point mutations.
Implen GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Proteomics, Nanobiotechnology, Genomics, Chip/Array Technology, Automation, Devices

Implen is a privately held corporation that is a leading supplier for spectroscopy instruments and consumables for the non-destructive analysis of ultra low volume samples. The company focuses on biological, chemical, and pharmaceutical laboratories in industry and research.

Independent Data Lab

BIOTECH BIOINFORMATICS

Genomic data has become an essential part of almost every project in molecular biology and medicine. Unfortunately, high rate of rotation of personnel in academic environment has made it difficult to maintain collaborations for projects that often can last for years. At IDL we are committed to making sure every dataset receives the most thorough attention, and makes it’s contribution to the progression of science.

INCYTON GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Oncology, Drug Development, Toxicology, R&D Service, In-Vitro-Diagnostics, Imaging, Bioanalytics

INCYTON multi-sensor systems monitor different cellular key parameters simultaneously, in real time and label free. Our technology records each event, giving the user full control at every time-point without the need to be constantly present. A highly automated testing process reduces the time spent carrying out even the most complex assays. INCYTON smart technologies are combined in one housing creating a global environment control and reducing the risk of contamination and variations.

Infors GmbH

BIOTECH DEVICES & REAGENTS

INFORS HT is your specialist for bioreactors, shaker incubators and bioprocess software. We offer the right solutions for the cultivation of microorganisms and cell cultures: Customer specific bioreactors and incubation shakers including qualification, parallel bioprocesses, and integration of all your bioprocesses in one software platform. Close customer relationships, high quality, innovation and flexibility are our greatest strengths.
**InGeneron GmbH**

**BIOTECH THERAPEUTICS & DIAGNOSTICS**

**Keywords:** Cell Therapy

InGeneron is elevating the field of regenerative medicine by translating robust science into proven patient benefit. Our purpose is to set new therapeutic standards by enabling physicians to use the patients own regenerative cells at point of care. With the initial focus on key orthopedic and wound healing indications, we will make regenerative cell therapies broadly accessible across multiple medical fields.

**Institut für angewandte Zellkultur Dr. Toni Lindl GmbH**

**BIOTECH DEVICES & REAGENTS**

**Keywords:** Antibody Production Service, Tissue Engineering/Cell Culture

The Institut für angewandte Zellkultur Dr. Toni Lindl offers services in the area of cell culture and tissue culture, training in cell culture work, distribution of cell lines, consulting in cell culture, molecular biology, genetic engineering and development of monoclonal antibodies and in vitro processes. The core competences cover cell culture services and genetic engineering with a product range of recombinant human interleukin-2 and human monoclonal antibodies against rabies.

**Institut Virion\Serion GmbH**

**BIOTECH THERAPEUTICS & DIAGNOSTICS**

**Keywords:** Clinical Diagnostics, ELISA/EIA, Autoimmune Diseases, Infectious Diseases, Respiratory Diseases, Automation

Institut Virion\Serion GmbH is an in-vitro diagnostic company. Our product portfolio for the diagnosis of infectious diseases contains SERION ELISA classic tests for quantified antibody detection in human serum, plasma, and against various viral, bacterial and parasitic infections. Our Complement Fixation Tests are featuring more than 50 different antigens. The latest developments of our particle-based SERION Multianalyt allow simultaneous antibody detection against multiple antigens using flow cytometry.
Intana Bioscience GmbH

BIOTECH PRECLINICAL SERVICES

Keywords: Drug Development, R&D Service

Intana Bioscience GmbH is a privately owned service provider company. We contribute to our clients R&D programs by developing predictive assays and screens, by comprehensively understanding the behavior of their candidates, and by supporting drug discovery and development efforts from target validation to clinical testing. Our services cover target validation, assay development, screening, support of PK/PD studies and target occupancy measurements.

inveox GmbH

IT, DIGITAL HEALTH

Keywords: Other Diagnostics, Data Management, Devices, Clinical Diagnostics, Laboratory, Imaging, Tissue Engineering/Cell Culture

inveox has the goal of making cancer diagnosis faster, safer, and more reliable. In todays labs, tissue samples (biopsies) are at risk of being mixed-up, contaminated or lost. But our products are designed to work as a cohesive unit to make this a thing of the past. We help patients and doctors. In addition, we create the lab of the future by bringing big data, artificial intelligence, and machine learning to labs. This provides better research data for scientists so they can eradicate cancer.

Invitrocue Europe AG

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Bioanalytics, In-Vitro-Diagnostics, Personalized Medicine, 3D-Structural Analysis, Other Diagnostics, Tissue Engineering/Cell Culture, Laboratory

Invitrocue Europe AG is an innovative leading healthcare bio-analytic company, that specialises in ex-vivo 3D cell culture models such PDOs as well as in-vivo models by producing HiMice™ as promising tools for personalized cancer treatment. IVQ imparts to the industry valuable knowledge in creating better, faster and more affordable disease treatments.

Intercept Pharma Deutschland GmbH

PHARMA & CHEMICAL INDUSTRY

Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases. Founded in 2002 in New York, New York, Intercept now has operations in the United States, Europe, and Australia. Founded in 2015, Intercept Pharma Deutschland GmbH based in Munich offers medical sales and marketing support in Germany. The team has set itself the task of continuously providing high quality services to the ‘liver community’.
iOmx Therapeutics GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, RNAi & Antisense, Immune Therapy

iOmx Therapeutics is a biopharmaceutical company focused on developing first-in-class cancer immunotherapies addressing novel immune-checkpoints hijacked by cancer cells. Using the foundational iOTarg discovery platform, iOmx has identified several new tumor-associated immune-checkpoints and is advancing a preclinical stage pipeline of promising drug candidates that have the potential to address cancers that are resistant to current immuno-therapies. For more details, please visit www.iomx.com.

Ipsen Pharma GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Ipsen Pharma GmbH, subsidiary of the Ipsen Group for Germany, Austria and Switzerland, has been commercializing various drugs in the fields of oncology, neuroscience and rare diseases in Germany for more than 40 years. In 2019, the company relocated its headquarters to the competence center Munich. Ipsen would like to utilize the vibrant research landscape, with its numerous universities and clinics, to further promote the innovative spirit and the biotech mindset of within the company.

Iris Biotech GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Fine Chemicals/Reagents, Peptide/Protein, Drug Development, Drug Delivery, Medicinal Chemistry, Combinatorial Chemistry, Natural Compounds

1. Starting materials for peptide synthesis, peptidomimetic and medicinal chemistry: protected amino acids, coupling reagents, linkers and resins, natural and unusual amino acids and natural compounds with physiological properties. 2. Technologies for Drug Delivery: more than 900 different carriers used in polymer therapeutics products (PEGylating reagents, Poly(amino acid)s and Poly(2-oxazoline)s. 3. Custom synthesis in all areas above, especially compounds with one or several chiral centers.

IRUBIS GmbH

BIOTECH DEVICES & REAGENTS

IRUBIS offers an innovative analytical device for the manufacturing of biopharmaceutical drugs. A major challenge in upstream bioprocessing is the optimal nutrient concentration to optimize yield and quality. However, samples extraction is performed manually and only once per day. IRUBIS developed a novel MIR spectroscopy system enables continuous monitoring and control of the nutrient concentration.
ISAR Bioscience GmbH

BIOTECH PRECLINICAL SERVICES

Keywords: Industrial Biotechnology, Drug Development, Tissue Engineering/Cell Culture, Nutraceuticals, Neuro-Degeneration, Cell Therapy, Biomarker Discovery & Development

ISAR Bioscience GmbH is a translational research company. We overcome current limitations of stem cell research in order to advance development of novel therapeutics and industrial biotechnology products. We use human iPSC and genome editing technologies to build the next generation of disease models and cell-based models for biotechnology applications. ISAR forges strategic partnerships with industry partners and translates academic achievements and ideas into industrial solutions and products.

iThera Medical GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Nanobiotechnology, Drug Development, Devices, Cardiovascular Diseases, Inflammation, Oncology

iThera Medical develops and markets a novel in-vivo biomedical imaging technology, “MSOT” = multi-spectral opto-acoustic tomography. MSOT utilizes the photo-acoustic effect to visualize and quantify anatomical, functional and molecular information of living tissue. Today, MSOT allows the early and reliable validation of new substance efficacy in drug discovery (e.g., for oncology, neurology and cardiovascular problems). For the future, MSOT also promises to become a valuable tool for clinical diagnostics.

ITM Isotopen Technologien München AG

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Delivery, Drug Development, Industrial Biotechnology, Personalized Medicine, Oncology

ITM Isotopen Technologien München AG is a privately owned biotechnology and radiopharmaceutical group of companies dedicated to the development, production and global supply of targeted diagnostic and therapeutic radiopharmaceuticals and radioisotopes for use in cancer treatment. ITM’s main objectives are to significantly improve treatment outcomes and quality of life for cancer patients while reducing side effects and improving health economics through a new generation of Targeted Radionuclide Therapies.
Kalbitzer Innovations UG

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: 3D-Structural Analysis, Bioinformatics, Bioanalytics, Drug Development, Oncology

Kalbitzer Innovations is a spin-off from the Institute of Biophysics and Physical Biochemistry (University of Regensburg) that provides novel experimental as well computational methods. It is focused on the application of high pressures on proteins in drug design, drug screening and protein refolding/renaturation. Kalbitzer Innovations develops software for specific application in NMR-based analytics as AUREMOL, a software package for automated protein structure determination.

Kantar GmbH

CRO

Keywords: Logistics, Pharmacovigilance, Oncology, Medical Writing, Clinical Trial Management and Monitoring, Data Management and Biostatistics, Regulatory Affairs

Kantar GmbH Clinical Research conducts phase I-IV clinical trials, retrospective and prospective non-interventional studies, patient reported outcomes and pharmacoeconomic studies. Our services include: protocol and CRF design, eCRF solutions, feasibility and site selection, investigators training, handling of legal and ethical requirements, monitoring and site management, project management, data management, pharmacovigilance, quality assurance, statistical planning and analysis, medical writing.

KLIFO GmbH

CRO

Keywords: Medical Writing, Data Management and Biostatistics, Pharmacovigilance, Clinical Trial Management and Monitoring, Regulatory Affairs, Drug Development

KLIFO owns significant experience in partnering with Biotech and Pharma: At KLIFO, we offer cross-functional consulting and operational solutions across all areas of clinical research, clinical trial supply, CMC development, regulatory affairs, PV and the development of pharmaceutical/biotech products and medical devices. KLIFO operates from Denmark, Sweden and Germany and employs more than 150 highly skilled employees plus senior consultants all with international experience in drug development.
KLIFOVET AG

CRO

Keywords: Pharmacovigilance, Regulatory Affairs, Drug Development, Data Management and Biostatistics, Clinical Trial Management and Monitoring

KLIFOVET AG is a full service veterinary CRO and Regulatory Consultancy and provides the following services: evaluation of research projects, Regulatory Consultancy, Life Cycle Management & PhV, Preclinical and Clinical Studies, Quality Assurance, Data Management and more. Experienced in all species, we manage the development of VMPs & Feed/Feed Additives in every step. Multiple Animal Pharm Awards in 2006, 2015 and ‘Best Service Company’ for 2019 show our long term commitment to our customers.

kmbs

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Genomics, PCR

kmbs care for organismic studies e.g. in Wildlife Biology, Phylogeny, Taxonomy, and Conservation Biology to clear up specimens’ identities by means of DNA analyses (sample preparation, PCR, DNA sequencing) for purposes like identifying species, detecting animal pre-absence, delimiting species boundaries, resolving species relations a.s.o. Off the lab, mapping species inventories or searching for organisms including electro fishing is our business.

Laboklin GmbH & Co KG – Unternehmensbereich Labogen

BIOTECH THERAPEUTICS & DIAGNOSTICS

Our laboratory provides a complete testing service for veterinary surgeons to meet the diagnostic needs of your practice. You can find all important information and our laboratory profiles and screens (microbiology, haematology, allergy, pathology and genetic testing). Furthermore you can download submission forms or order sample collection material. If you are registered you are able to locate your samples, the stage of investigation and much more.
Labor Friedle GmbH

Keywords: Clinical Diagnostics, Medicinal Chemistry, Allergy

Labor Friedle GmbH is an internationally active residue analysis laboratory based in Tegernheim near Regensburg. It focuses on chemical, chemical-physical, microbiological and mycological analyses of food samples, especially fruits and vegetables. Consumer goods, cosmetics, pharmaceuticals, cleaning products and animal feed (pet food) as well as environmental medical issues from human biological matrices are also examined.

Labor L+S AG

Keywords: Laboratory, Clinical Diagnostics, Allergy, Medicinal Chemistry, Molecular Diagnostics, Analytical Chemistry

The Labor LS is one of the leading European CROs for analytics and consulting for pharmaceuticals and medical devices. More than 1000 customers trust in the company’s experience. The range of services covers microbiology, molecular-biology, biochemistry as well as physics and chemistry on raw materials and on finished products. In addition, services in industrial hygiene and clinical-microbiological diagnostic are offered.

LabPMM GmbH

Keywords: Clinical Diagnostics, Molecular Diagnostics

LabPMM (an Invivoscribe® company) is your partner of choice for diagnostic, research, and clinical trial services. Our network of laboratories located in the USA, Europe and Asia specialize in internationally harmonized molecular testing and collectively have CLIA and ISO15189 certifications via CAP and DAkkS. We offer an ever expanding menu of molecular assays, including NGS gene and MRD panels, FLT3 and NPM1 mutation assays, and B- and T-cell clonality and MRD assessment.
Lead Discovery Center GmbH,
LDC - Abteilung Antikörper

BIOTECH PRECLINICAL SERVICES

The lead discovery center GmbH was founded in 2008 by the Max Planck Society in order to exploit the potential of the excellent basic research for the development of new, urgently needed drugs. The Lead Discovery Center collects promising academic research projects and develops them further into pharmaceutical lead structures (Proof-of-concept in model systems). In close collaboration with leading academic and industrial partners the Lead Discovery Center develops an extensive project portfolio in the fields of small molecules (Dortmund) and therapeutic antibodies (Planegg) with high medical and commercial potential.

leon-nanodrugs GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Drug Development, Drug Delivery, Peptide/Protein, Small Molecules

leon is leading the way in expediting APIs to deliver improved stability, increased solubility and enhanced bioavailability, revitalizing forgotten formulations and breathing new life into generics. leon provides complete development services for the international market from concept to CTM and commercial production. leons patented microjet reactor MJR® technology platform offers access to the next generation of SMART nano-particles™ and nano-formulated drugs.

LEUKOCARE AG

BIOTECH DEVICES & REAGENTS

LEUKOCARE provides proprietary formulation technologies and related development services for stabilization and protection of biologics. Our technologies are employed in collaborations with partners in the field of vaccines, therapeutic proteins, and biologic device combination products. They provide manifold benefits as improved shelf-life, Terminal sterilization and Significant production cost savings. LEUKOCARE provides development services based on fee for service during implementation of its technologies.
**lifespin GmbH**

BIOTECH THERAPEUTICS & DIAGNOSTICS

**Keywords:** Biomarker Discovery & Development, Analytical Chemistry, Agrobiotechnology, Laboratory, Bioanalytics, In-Vitro-Diagnostics, R&D Service

Digitize the metabolism - we measure biological processes in medicine and biotechnology: fast, precise, cost-efficient. lifespin offers diagnostic/analytical NMR-services, software solutions and databases, for R&D, routine industrial use, diagnostics and QC in medical research, the pharmaceutical industry, plant research and biotechnology. The portfolio ranges from standardized multiparameter quantification, metabolomics-based classification, to the integration of big data approaches.

**LINDIS Biotech GmbH**

BIOTECH THERAPEUTICS & DIAGNOSTICS

**Keywords:** Drug Development, Antibody

LINDIS Biotech was founded to develop ektomun®, an innovative immuno-therapeutic for the treatment of small cell lung cancer, melanoma and other neuroectodermal cancers that currently lack sufficient treatment options. The company is managed by Horst Lindhofer, inventor of the underlying trifunctional antibody technology and CEO of TRION Pharma.

**LISANDO GmbH**

BIOTECH THERAPEUTICS & DIAGNOSTICS

LYSANDO AG is the world leading company for the development of antimicrobial proteins to combat Gram-positive and Gram-negative pathogens. In a wide range of fields including hygiene, agriculture, domestic and livestock husbandry, medical devices, veterinary and human pharma, LYSANDO AG provides a solution that is right for every customer. LYSANDO AG has been certified by the quality management standards of EN ISO 13485.

**LivImplant GmbH**

BIOTECH THERAPEUTICS & DIAGNOSTICS

**Keywords:** Inflammation, Bone/Joint Diseases, Cell Therapy, Tissue Engineering/Cell Culture

LivImplant GmbH develops innovative cell based therapies for leasons and diseases of tendons, joints, cartilage and bones, focusing on stimulating the self-healing powers of the body by applying stem cells and growth factors. As a spin off from the Ludwig-Maximilians-University of Munich and a close collaboration with the Veterinary Clinic of the University of Giessen, LivImplant benefits from the latest scientific proceedings. First applications are available for curing lameness with horses and dogs.
Loewe® Biochemica GmbH
BIOTECH DEVICES & REAGENTS

Keywords: Agrobiotechnology, ELISA/EIA

LOEWE® is committed to the development and production of high quality reagents for the detection of plant diseases caused by bacteria, fungi, nematodes, and viruses. Furthermore we offer contract testing services for all kinds of crops and ornamentals (ELISA techniques, Immuno Fluorescence Antibody Assays, Blotting, and PCR).

Lophius Biosciences GmbH
BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Clinical Diagnostics, Immune Therapy, Infectious Diseases

Lophius mission is to transform treatment paradigms and patient management with novel molecular diagnostic solutions for life threatening infectious diseases. The core program addresses an unmet clinical need in tuberculosis (TB) with a proprietary blood-based multi-marker solution to improve TB infection detection and enable differential diagnosis. Lophius also markets a clinically validated CE-marked IVD to individualize transplant patient management by personalized CMV risk stratification.

LRE Medical GmbH
MEDTECH

Keywords: R&D Service, Molecular Diagnostics, Other Diagnostics, Automation, Devices, In-Vitro-Diagnostics

LRE Medical GmbH is a leading developer and manufacturer of medical, in vitro diagnostic (IVD) and life sciences instrumentation for OEM customers. For more than 45 years LRE provides full turnkey projects ‘One Stop Shop’ solutions for Point-of-Use and Laboratory incl. MDx (Engineering, Manufacturing, After Sales Service and Lifetime Product Support) for the development and manufacturing of innovative devices in compliance with ISO 13485, IVDR, FDA CFR Part 820 for Class I-III Medical Devices.

Luye Pharma AG
PHARMA & CHEMICAL INDUSTRY

Keywords: Pharmacology, Drug Delivery, Medicinal Chemistry

Luye Pharma AG Miesbach is one of the largest independent manufacturers of transdermal delivery systems in Europe with a product portfolio primarily focused on more sophisticated and higher margin specialty patch categories such as CNS, pain and hormone treatments. Luye Pharma AG also acts as the EU hub for Luye Pharma Group’s development efforts in R&D, manufacturing, international registration, and market promotion of new formulation products to international standards.
Medical Device Services GmbH
PHARMA & CHEMICAL INDUSTRY

Biological Safety of Medical Devices: Our test laboratories at Medical Device Services have been synonymous with success for medical device manufacturers for 20 years.

Medigene AG
BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Oncology, Personalized Medicine, Cell Therapy, Vaccines, Hematology, Immune Therapy, Gene Therapy

Medigene AG is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative immunotherapies to target various forms of cancer. Medigene concentrates on the development of personalized T cell-based therapies, with associated projects currently in pre-clinical and clinical development.

Medizone Germany GmbH
PHARMA & CHEMICAL INDUSTRY

Keywords: Clinical Trial Management and Monitoring, Logistics, R&D Service

Medizone Germany is your trusted and reliable partner regarding sourcing of comparator products for clinical trials and analytical samples for biosimilar development. We are authorized to import comparators into the EU with proper certification through our Qualified Person. With an extensive network of well-established approved suppliers, Medizone prides itself with meticulous quality standards when providing global sourcing services.

Medpace Germany GmbH
CRO

Keywords: Oncology, Metabolic Diseases, Cardiovascular Diseases, Imaging, Pharmacovigilance, Drug Development, Regulatory Affairs

Medpace is a global, full-service clinical CRO providing Phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. Medpace’s mission is to accelerate the global development of safe and effective medical therapeutics through its high-science and disciplined operating approach that leverages local regulatory and deep therapeutic expertise across all major areas including oncology, cardiology, endocrinology, central nervous system and anti-viral.
MedPharmTec GmbH

CRO

Keywords: Medical Writing, Pharmacovigilance, Regulatory Affairs

MedPharmTec is a service provider for pharmaceutical medicine. Our customers: pharmaceutical industry and companies in the biotechnology, medical technology and food industries. Our services: Proofreading / proofreading by specialist and Product information / Creation and maintenance of drug information / Authorization maintenance (e.g. creation of PSURs) / Consulting for pharmacovigilance in Clinical Trials and NIS / Preparation and Submission of Ethical Applications and official registrations

metabion

BIOTECH DEVICES & REAGENTS

Keywords: PCR, Antisense/Nucleotides, Antibody Production Service, Other Diagnostics, NGS, Genomics, Proteomics

metabion is one of the globally leading suppliers of custom nucleic acids renowned for its focus on reliable supplies of consistently high quality products and services. Metabion offers production of a wide range of synthetic DNA and RNA oligonucleotides according to customers’ needs as well as the supply of standard life science products. Successfully translating highest quality standards into daily practice is the core of metabion’s business philosophy and key to its popularity at the same time.

MetaHeps GmbH

BIOTECH PRECLINICAL SERVICES

Keywords: Toxicology, Drug Development

MetaHeps® is an innovative service provider specialized to identify or exclude drug-induced liver injury (DILI) in an individual patient using a blood sample. MetaHeps tackles DILI in clinical trials or postmarketing as a major cause of drug attrition: As a diagnosis of exclusion, DILI suspicion may be incorrect in up to 50% of cases. Now, the MetaHeps technology allows to clear a drug from DILI suspicion, or - in case DILI is confirmed - biomarker development using the cell- and databank.
Metronomia Clinical Research GmbH
CRO

Keywords: Data Management and Biostatistics, Medical Writing, Clinical Trial Management and Monitoring, R&D Service

Metronomia is a specialized CRO for biostatistical consulting, biostatistics, clinical data management and medical writing in Munich. Experience: > 600 projects since foundation in 1990, proven track record in all major therapeutic areas and all clinical phases / NIS. Customers: Biotech-, pharma- and medical device companies, universities, CROs. Commitment: High-quality and reliability of our data, outstanding flexibility and personal service through stable teams, competitive cost-benefit ratio.

Microcoat Biotechnologie GmbH
BIOTECH DEVICES & REAGENTS

Keywords: In-Vitro-Diagnostics, Bioanalytics, PCR, Laboratory, Pharmacokinetics, ELISA/EIA


MIKROGEN GmbH
BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: PCR, Clinical Diagnostics, ELISA/EIA, Infectious Diseases, Automation, Autoimmune Diseases, Chip/Array Technology

MIKROGEN is a global provider of system solutions for medical laboratory diagnostics. We combine excellent genetic engineering know-how with scientific background and consistent customer orientation. The extensive and efficient evaluation of system solutions in collaboration with scientific experts and institutes is the basis for reliable diagnoses. Mikrogen offers a wide range of system solutions for the indirect detection (antibodies) and direct detection (PCR) of pathogen.
Minitüb GmbH

Minitüb is an international established system supplier for assisted reproduction of domestic animals, notably in the areas of A.I., cryobiology and E.T. Through its participation in MWM Biomodels GmbH, a spin-off company of LMU Munich, Minitüb is also engaged in the development and characterization of transgenic large animal models for biomedical research. Current projects focus on genetically modified pigs for xenotransplantation, transgenic pig models of diabetes mellitus, muscular dystrophy and immunodeficiency.

mk2 Biotechnologies

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: R&D Service, Bioanalytics, Industrial Biotechnology

mk2 Biotechnologies develops, produces and investigates peptides at highest purity and quality standards using a revolutionary synthesis technology. We are able to synthesize any kind of peptide, regardless of its physical or chemical properties. We are strongly convinced, that our process has the potential to tackle parts of major social challenges as well as to provide solutions for a known and yet unknown demand for new classes of active substances.

MLL Münchner Leukämie Labor GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Clinical Diagnostics, NGS, Laboratory, Oncology, Hematology, PCR, Genomics

MLL Munich Leukemia Laboratory is a leading institution for leukemia diagnostics and research. An interdisciplinary structure guarantees valid, comprehensive and prompt diagnosis and includes: cytomorphology, chromosome analysis, immunophenotyping, cytogenetics, FISH, and molecular genetics. MLL performs also WGS. Several workflows are already supported by AI. This combination gives medical professionals an essential foundation to ensure ideal patient care.

Molecular Machines & Industries GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Microscopy, Molecular Diagnostics, Devices

MMI Microdissection, Micromanipulation and Imaging MMI is the leading provider of unique technologies for microdissection, micromanipulation, and imaging with a wide range of clinical and research applications. I.e. Capillary-based selective isolation of single cells (CellEctor), Pico-cut laser microdissection to isolate cells in tissue (CellCut), Microscopy-integrated Whole Slide Imaging (CellScan), Optical tweezers to quantify biological forces (CellManipulator).
Molecular Networks GmbH - Computerchemie

BIOTECH BIOINFORMATICS

Keywords: Molecular Modelling, Toxicology, Small Molecules

Molecular Networks and Altamira (MN-AM) offer innovative approaches and solutions for chemoinformatics, computational toxicology and safety/risk assessment of chemical compounds. The ChemTunes-ToxGPS® software platform provides a unique combination of expert-reviewed toxicity databases, MoA-based in silico predictions for human health endpoints and workflows to support, e.g., Read-Across and ICH M7 GTI studies. A rigorous decision theory approach delivers weight of evidence-based final outcomes.

Molekula GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Antibiotics, Analytical Chemistry, New Materials, Medicinal Chemistry, Peptide/Protein, Fine Chemicals/Reagents

Molekula is a leading chemical supplier offering research chemicals and bio-chemicals sourced from production sites across the globe. Our clients ranging from university labs to big industrial players. With offices in the UK, USA, China, Germany and Italy, our global insight into the market keeps us firmly at the forefront of this industry. We hold over 8000 ex-stock products and also have in-house production of tailor-made gases in solutions and Grignard reagents.

MorphoSys AG

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Rheumatoid Arthritis, Inflammation, Drug Development, Antibody, Infectious Diseases, Oncology, Autoimmune Diseases

MorphoSys (FSE & NASDAQ: MOR) is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of exceptional, innovative therapies for patients suffering from serious diseases. MorphoSys’ most advanced proprietary product candidate, tafasitamab (MOR208), is currently under review by the FDA for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL).
MSD SHARP & DOHME GMBH

Keywords: Infectious Diseases, Oncology, Diabetics, Cardiovascular Diseases, Antibiotics, Vaccines

MSD Merck & Co., Inc., in the USA and Canada, with headquarters in Kenilworth, NJ, USA is a leading global healthcare company. MSD’s core business is the discovery, development, production and distribution of prescription medicines, vaccines, biologic therapies and animal health products. In 2017, the company generated sales of approximately 40.1 billion US dollars with approximately 69,000 employees in more than 140 countries. The company has its German headquarters in Haar near Munich.
Twitter: @MSD_Deutschland

multi service monitoring

CRO

Keywords: Oncology, Clinical Trial Management and Monitoring, Autoimmune Diseases, Devices, Regulatory Affairs, Drug Development,

multi-service-monitoring (in the BioPark, founded in 2003, 5 employees) is a clinical research organisation (CRO) that is specialised in monitoring of non-commercial clinical trials and medical clinical trials with devices. All tasks are carried out in accordance with the appropriate national regulations and the international guidelines ICH/GCP and “DIN ISO 14155”.

multimmune GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Imaging, Antibody, Oncology, Immune Therapy, Drug Development, Personalized Medicine, Cell Therapy

multimmune GmbH is a clinical stage biopharmaceutical company delivering new theranostics for tumours expressing surface-bound Hsp70, a tumor-specific marker which is present on about 70% of all cancer entities. Current pipelines include: activated autologous Natural Killer (NK) cells (Phase II for lung cancer), monoclonal antibody-based therapeutics and imaging (preclinical) and inducing tumor-specific apoptosis using recombinant human serine protease (preclinical).
MVZ Martinsried GmbH
BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Clinical Diagnostics, NGS, Genomics, Bioinformatics, Oncology, Personalized Medicine, Laboratory

The Center for Human Genetics and Laboratory Diagnostics in Martinsried continues to broaden its expertise and competencies. The interdisciplinary collaboration between five medical specialist areas - Human genetics, Laboratory Medicine, Microbiology/Virology, Transfusion Medicine, Molecular Oncology/Pathology - enables diagnostic questions to be more efficiently, comprehensively and accurately resolved. Accredited according to DIN EN ISO/IEC 17025 and ISO 15189.

MWM Biomodels GmbH
BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, Pharmacokinetics, Transgenic Animals, Cardiovascular Diseases, Diabetics, Respiratory Diseases

MWM Biomodels GmbH is specialized in the development and characterization of transgenic large animal models for biomedical research. Current projects are focused on genetically modified pigs for xenotransplantation as well as transgenic pig. MWM Biomodels offers support starting from the design of a project, the development of expression and targeting vectors, the generation of genetically modified large animals, their phenotypic characterization and the performance of preclinical studies.

Nanion Technologies GmbH
BIOTECH DEVICES & REAGENTS

Keywords: Nanobiotechnology, Devices

Nanion Technologies is a world leading provider of Automated Patch Clamp (APC) electrophysiology systems, with throughput capabilities ranging from a single cell up to fully automated high throughput screening (HTS). Founded in 2002 as a spin-off from the University of Munich, Center for Nanoscience (CeNS), Nanion’s product range includes in vitro systems for membrane pump/transporter, and bilayer recordings, and confluency and contractility measurements from cells monolayers (impedance/EFP).
nanoSaar AG

NANOTECHNOLOGY

Keywords: Nanobiotechnology

THE POWER OF NANO! nanoSaar AG is a leading provider of tailor-made nanotechnology solutions that give a wide range of partners from the chemical industry a competitive advantage. - Very homogeneous, superior product quality - Continuous, cost-effective production process - Fast, simple scale-up for industrial chemical production - Business opportunities with license or joint venture models - You can find out more at: www.nanosaar.com

NanoTemper Technologies GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Automation, Vaccines, Bioprocessing, Drug Development, Bioanalytics, Device

NanoTemper is a global leader for optical measurements in R&D and biomanufacturing. NanoTemper has a strong customer focus and stands for strong commitment to quality, ease of use and high precision instrumentation. The globally operating team of experts strongly focuses on the user’s benefits by ensuring maximum efficiency for the Pharmaceutical and Biotech industries as well as academic research. With our MST, TRIC & nanoDSF technologies, we provide knowledge about the most difficult targets.

NDA Regulatory Service GmbH

CRO

Keywords: Pharmacovigilance, Drug Development, Medical Writing, R&D Service, Regulatory Affairs

NDA is a leading regulatory consultancy, supporting drug development companies of all sizes on the shortest and most economic path to approval and patient access. Our experienced team of 150 consultants (30 in Munich) provide advice on all phases of development and therapeutic areas, including procedure and submission management, for both US and EU. Our specialist Advisory Board, consisting of very senior ex-regulators, provides independent strategic advice with an inside the agencies view.

Neaspec GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Devices, Analytical Chemistry, Microscopy, Nanobiotechnology, Molecular Diagnostics

Trusted to deliver cutting-edge solutions for nanoscale optical imaging & spectroscopy for research laboratories in industry and academic institutions is central to Neaspecs philosophy. Neaspec developed the neaSNOM microscope that combines the best of two worlds the nanoscale resolution of atomic force microscopy (AFM) with the analytical power of FT-IR infrared imaging & spectroscopy.
**NEOVII Biotech GmbH**

**BIOTECH THERAPEUTICS & DIAGNOSTICS**

Keywords: Oncology, Gene Therapy, Cell Therapy, Antibody, Immune Therapy, Hematology, Drug Development

Neovii Biotech GmbH develops, commercializes and manufactures immunologically active biopharmaceutical therapeutics, especially the medicinal product Grafalon®. Neovii is headquartered in Switzerland (Neovii Pharmaceuticals AG, Zürcherstrasse 19, 8640 Rapperswil, Switzerland (Phone: +41 55 210 05 00; Fax: +41 55 210 55 08; E-mail: info@neovii.com) and part of the Neopharm Group, Israel.

**NeuroProfile GmbH**

**BIOTECH THERAPEUTICS & DIAGNOSTICS**

NeuroProfile is committed to the discovery and development of novel therapeutics for the treatment of Central Nervous System (CNS) diseases. The main objective is the identification and commercialization of novel neuronal drug targets for the most important neurodegenerative diseases Alzheimer and Parkinson and for psychiatric disorders such as schizophrenia and depression. Our targets will be the basics for drugs with new mechanisms of action and improved therapy of the diseases.

**nexttec GmbH**

**BIOTECH DEVICES & REAGENTS**

Keywords: Laboratory, Devices, Genomics, Automation

nexttec1-Step kits for rapid purification of plasmid and genomic DNA from tissue, cell cultures, blood, bacteria and plants. The nexttec1-Step DNA purification system consists of only one buffer system for the lysis of the corresponding samples and nexttecCleanColumns, or nextteccleanPlates96. The nexttec 1-Step DNA purification is a reversal of the usual, well-known DNA purification methods. Here, proteins and other inhibiting substances are adsorbed on a special sorbent surface. The DNA does not bind, passes through the adsorbent layer and is immediately available in the eluate for the applications. This allows purification of the DNA in just 4 minutes.

**NIGU Chemie GmbH c/o AlzChem AG**

**PHARMA & CHEMICAL INDUSTRY**

Nigu offers a full range of high-purity guanidine salts for biotechnological applications, which meet the supreme quality standards set by the biopharmaceutical industry. The product group includes several grades of guanidine hydrochloride for separation and purification of recombinant proteins and antibodies. Guanidine thiocyanate for nucleic acid based diagnostics (test kits for viral RNA/DNA) is another integral part of the portfolio.
Novartis Pharma GmbH

PHARMA

Novartis is reimagining medicines to help improve and extend people’s lives. We use innovation and digital technologies to develop therapies in areas with high unmet medical need. We invest a high share of our turnover in research and development. Our products reach around 800 million people worldwide and we strive to expand access to them. In Germany Novartis employs around 7,400 people at 12 locations and around 109,000 worldwide.

www.novartis.de and www.novartis.com

numares AG

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Cardiovascular Diseases, Metabolomics, Biomarker Discovery & Development, Drug Development, Clinical Diagnostics, Nephrology, Metabolic Diseases

numares AG, based in Regensburg develops and markets innovative diagnostic tests based on NMR metabolomics. Essentially, our tests consist of metabolic constellations that are characteristic of certain diseases. To find these, we apply machine learning to clinical study cohorts measured with our AXINON® NMR system. We have a successful commercial base especially in laboratories in the USA.

Nuvisan GmbH

CRO

Keywords: Oncology, Small Molecules, Peptide/Protein, Pharmacokinetics, PCR, ELISA/EIA

Nuvisan Pharma Services is a global provider of product development and support services to the pharmaceutical, biotechnology and medical device industries. We deliver services ranging from a single test to fully integrated drug development programs. Together with Focus we are pleased to offer our sponsors the complete spectrum of drug development services and assist the sponsor in bringing safe and effective pharmaceutical products to market.

Octamer GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Epigenetic mechanisms promise to open new avenues to drug discovery because they allow interfering with the most basic processes of transcriptional regulation. We research nucleosomes for decades and offer the unique opportunity to provide disease-relevant substrates to epigenetic targets - both for academic research and drug discovery.
Omegametrix GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Prof. C. von Schacky, University of Munich, invented and defined the HS-Omega-3 Index® with a collaborator in 2004. In 2006, von Schacky founded the laboratory Omegametrix GmbH to deal with the ever-growing number of samples. Initially proposed as a risk factor for sudden cardiac death, the HS-Omega-3 Index also indicates risk for total mortality and cardiovascular disease. Other applications encompass, but are not limited to, athletes, cognition, psychiatric diseases or pregnancy and lactation.

OmicEra Diagnostics GmbH

BIOTECH DNA/PROTEIN ANALYTICS

Proteome scans become a universal diagnostic for health and disease. We anticipate that MS-based proteomics becomes a cornerstone of precision medicine over the coming years. For broad applications, a new technology platform must be developed including very large analytical capabilities. We aim to build the best performing platform with the highest capacity for precision medicine.

OmicScouts GmbH

BIOTECH BIOINFORMATICS

Keywords: Pharmacogenomics, Bioinformatics, Proteomics, Drug Development, Biomarker Discovery & Development

OmicScouts is a chemical proteomics company focused on supporting drug and biomarker discovery with its unique expertise and innovative technologies. We provide and develop proteome-wide assays that work with native proteins and enable the identification of small molecule drug targets, target engagement markers, molecular mechanisms of action and drug response biomarkers. OmicScouts supports your drug and biomarker discovery projects with end-to-end solutions tailored to project specific needs.

OncoLead GmbH & Co. KG

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, Clinical Diagnostics, Oncology

Oncolead is a privately owned service provider company. We offer a unique cellular screening of anticancer agents in a panel of 80-200 cancer cell lines. Routine operation and highly standardized processes guarantee our customers the results within 2-4 weeks with outstanding reproducibility for cellular screening. Customers will further benefit from a comprehensive data analysis including correlation of activity profile with mutation status and with activity profile of thousands of known anticancer agents.
Optores GmbH

MEDTECH

Optores GmbH provides the world’s fastest solutions for optical coherence tomography (OCT). With sweep rates of several million OCT A-scans per second, Optores founders coined the term “MHz-OCT”. These ultrahigh speeds are ideal for novel OCT applications, such as real-time surgical guidance, endoscopic OCT, large area surveys, visualization of blood flow, and high-throughput industrial inspection.

origenis GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Combinatorial Chemistry, Medicinal Chemistry, Automation, Combinatorics, Molecular Modelling, Small Molecules

Originis is a privately owned company based in Martinsried, Germany, and a leader in small molecule drug discovery with over 14 years of experience in the field. Originis runs its own patented drug discovery platform MOREsystem®, which combines state-of-the-art drug design, patent analysis, chemical synthesis and biological characterization. Currently focusing on anti-inflammatory and CNS drugs, originis runs research alliances as well as active in-house programs and is offering a variety of out-licensing opportunities via its proprietary patent database Cippix® - www.cippix.com.

Oryx GmbH & Co. KG

BIOTECH THERAPEUTICS & DIAGNOSTICS

ORYX is a privately held Munich based biotech company. The company develops three highly innovative drug candidates for the treatment of a whole range of cancers, originating from leading research institutions like the German Cancer Research Center (DKFZ) and the University of Heidelberg. The ORYX clinical development portfolio consists of an oncolytic virus and two therapeutic cancer vaccines. In 2015, these candidates successfully completed clinical Phase I/IIa trials.

Otsuka Novel Products GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Drug Development, Clinical Diagnostics, Antibiotics, Infectious Diseases

Otsuka Novel Products GmbH (ONGP) est. 2011, is a subsidiary of Otsuka Group Company with an international network of 195 subsidiaries, 47,000 employees in 31 countries. With our corporate philosophy Otsuka-people creating new products for better health worldwide, ONPG focuses on fighting tuberculosis through innovative research and development, equitable access to medicines, collaborations, and capacity building programs that strengthen the quality and delivery of care.
Oxford BioLabs Ltd.

BIOTECH DEVICES & REAGENTS

Oxford Biolabs is a science-routed company that develops and markets naturally-based nutraceuticals and cosmeceuticals aimed at helping people combat unwanted signs of ageing, from androgenetic alopecia, over skin ageing to mild cognitive decline, to name a few. Our goal is to create innovative products that are of high value for its users.

Panacea Biotec GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Panacea Biotec is the third largest biotechnology company (as per ABLE Survey, 2011), as well as among the top 50 pharmaceutical companies (as per ORG IMS March 2010) of India. Panacea Biotec Germany GmbH is located in Munich and delivers and markets products in transplantation, immun-suppression and anti-infection.

PAN Biotech GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Tissue Engineering/Cell Culture, Industrial Biotechnology

PAN-Biotech GmbH, founded in 1988, is a modern company manufacturing and distributing sera, media, serum-free systems, biologicals, reagents and other cell culture products. We deliver our goods to customers from research, clinics and the biopharmaceutical industry. PAN-Biotech has been certified by the international quality management standards of DIN ISO 9001 and the strict EN ISO 13485. Production takes place in its headquarters in Aidenbach, Bavaria: “Quality - Made in Germany!”

PARI Pharma GmbH

MEDTECH

Keywords: Respiratory Diseases, Infectious Diseases, Antibiotics, Analytical Chemistry, Drug Delivery

PARI Pharmas focus is the development and manufacturing of optimized eFlow®-Technology nebulizers in cooperation with partners from the pharmaceutical industry. The eFlow Technology platform is suitable for a wide range of drug formulations and patient populations. It enables short development times for customized drug-specific nebulizers. PARI has a committed team with a considerable track record. As of today, five commercial drug-specific eFlow Technology nebulizers administer specific inhaled medications.
Pelo Biotech GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Laboratory, Tissue Engineering/Cell Culture, Fine Chemicals/Reagents

PELOBIOTECH is competent for cells and offers the broadest portfolio of animal & human cells and media. We bring your research from bench to bedside. You get the whole variety of solutions from tissue dissociation to cryopreservation for research and clinical applications (GMP). Tissue Dissociation Enzymes; Defined & Xeno-free Media; Human & Animal Primary & Stem Cells from healthy & diseased donors; Tagged Cells; ES/iPS Cells, Media, Reprogramming & Small Molecules; 2D/3D Cell Culture Systems.

Pharma Stulln GmbH

PHARMA & CHEMICAL INDUSTRY; CMO

Keywords: Ophthalmology, Respiratory Diseases

Experience in manufacturing of eye drops in bottles and single-doses for almost 40 years. Specialist in manufacturing: Eye drops, Nasal sprays, Respiratory solutions and Lens care products. A modern zone concept fulfills European and international standards in production of sterile fluid pharmaceuticals. Pharma Stulln has approximately fifty well established pharmaceutical customers in Germany, Europe and international countries such as Australia, China, Canada etc.

Pharmalog – Institut für klinische Forschung GmbH

CRO

Pharmalog (TÜV certified and BVMA member) offers full service with an excellent reputation for all phases of clinical trials since 1983. We operate in Germany and all EU/EEU-countries and have performed more than 400 clinical trials in all medical indications for medical products/devices/biotechnology products.
PhaToCon (Pharm/Tox Concept)

BIOTECH PRECLINICAL SERVICES

Keywords: Antibody, Pharmacology, Regulatory Affairs, Toxicology, Drug Development, Drug Delivery, Tissue Engineering/Cell Culture

Safety of Medical Device and Pharma for patients and manufacturers. Our competence are toxicological Assessments (in vitro / in vivo) as well as biocompatibility evaluation and related preclinical study-management. Our support is customized, adapted from international standards like GLP/GMP, ISO, and we support “hands-on”, based on science, evidence, quality and pragmatism. With our network of competence and capabilities we mark the difference to your competitor on your way to success.

Am Klopferspitz 19
D-82152 Planegg-Martinsried
Phone: +49 (0) 89 444 899-41
E-Mail: info@phatocon.com
Internet: www.phatocon.com

Phytochem Referenzsubstanzen GbRmbH

BIOTECH DNA/PROTEIN ANALYTICS

Phytochem (PC) develops, produces and markets pure reference substances for the pharmaceutical industry, research, analytics and authorities and synthesizes or isolates Impurities in remedies for customers needs with best equipment and experience. PC further develops analytical methods and new products mainly focussed on natural sources for Phytopharmaceuticals, Functional Foods as well as Cosmetics. The CEO has also the status of a qualified person acc. § 65 AMG for product release in Pharma.

Krumbacherstr. 9
D-89335 Ichenhausen
Phone: +49 (0) 731 97205-45
E-Mail: phytochem@t-online.de
Internet: www.phytochem-standards.de

Pieris Pharmaceuticals GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Oncology, Respiratory Diseases, Peptide/Protein, Drug Development, Immune Therapy

Pieris Pharmaceuticals is an international Nasdaq-listed (TICKER: PIRS), clinical-stage biotechnology company that discovers and develops Anticalin protein-based drugs to target validated disease pathways in a unique and transformative way. Our pipeline includes immuno-oncology multi-specifics tailored for the tumor microenvironment, an inhaled Anticalin® protein to treat uncontrolled asthma and a half-life-optimized Anticalin® protein to treat anemia.

Zeppelinstrasse 3
D-85399 Hallbergmoos
Phone: +49 (0) 811 12 447-0
E-Mail: info@pieris.com
Internet: www.pieris.com

PIKA Weihenstephan GmbH

BIOTECH AGRO, FOOD, ENVIRONMENT

Keywords: Agrobiotechnology, New Materials, Analytical Chemistry, PCR

PIKA Weihenstephan GmbH, a spin-off from TU München, is specialized in microbiology and DNA analyses for the food and beverage industries including breweries. Besides consultancy and lab service, our portfolio covers development, production and sales of products for on-site testing. Major products for quality control are FastOrange® enrichment media and 4everyone™ Detection kits, besides we supply fresh yeast from our HefeFarm®. PIKA Weihenstephan is certified according to DIN EN ISO 9001:2015.
PolyQuant GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Biomarker Discovery & Development, Peptide/Protein, Laboratory, Clinical Diagnostics, Proteomics, In-Vitro-Diagnostics, R&D Service

PolyQuant provides ISO 9001:2015 certified products, services and bioinformatics support for protein analysis and proteomics covering: Stable isotope-labelled reference standards for absolute protein quantification based on our proprietary QconCAT platform technology, Kits for LC and MS instrument calibration and standardization, entire assay development for proteomics workflows (quantitative/qualitative), comprehensive support for protein analytics (Medtech, Biotech, Life Sciences, Pharma).

Postnova Analytics GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Devices

Postnova is a manufacturer of analytical instruments based on Field-Flow Fractionation. The application range of 1 nm-100 μm and 1000 Da up to many MDa, Postnova provides an analytical tool for the separation/characterization of particles, polymers, proteins, viruses, antibodies, liposomes or exosomes in complex aqueous/organic matrices. Postnova offers the complete range of FFF techniques as Electrical/Asymmetrical FlowFFF, CentriFFF and ThermalFFF along with detection as MALS, DLS, and ICP-MS.

PPD Germany GmbH & Co. KG

CRO

Keywords: Medical Writing, Logistics, Devices, Drug Development

PPD is a leading global contract research organization providing drug discovery, development and lifecycle management services. With offices in 46 countries and more than 23,000 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a commitment to quality to help clients and partners accelerate the delivery of safe and effective therapeutics and maximize the returns on their R&D investments.

PreciPoint GmbH
BIOTECH DEVICES & REAGENTS

Keywords: Microscopy, Automation, Devices

PreciPoint, located in Freising, is a manufacturer of digital microscopes and complex lab automation devices. PreciPoint’s core competency is combining optics, mechanics, electronics, firmware and software to modern micro imaging applications. Currently, the company is focused on Whole Slide Imaging, Digital Pathology and Virtual Microscopy. Our well-rounded engineering staff develops practical, economical and precisely manufacturable solutions for a wide array of complex problems.

PreOmics GmbH
BIOTECH DEVICES & REAGENTS

PreOmics GmbH develops and commercializes tools for mass spectrometry-based proteomics. The main focus are easy and optimized sample preparation methods enabling fast, efficient and sensitive measurements at high throughput. PreOmics further develops instruments for automated fractionation and enrichment to achieve complete proteomics and to facilitate the analysis of signal-transduction pathways. PreOmics addresses customers in research, drug development and diagnostics.

PreSens Precision Sensing GmbH
BIOTECH DEVICES & REAGENTS

Keywords: Devices, Drug Development, Tissue Engineering/Cell Culture, Analytical Chemistry

PreSens is a world leader in the field of chemical-optical sensors and develops, manufactures and distributes microsensors, 2D imaging and non-invasive sensor systems for Biotech & Pharma, Food & Beverage, Scientific Applications and Medical Devices with service all over the world. The out-of-the-box products and the engineering of customized sensors focus on parameters essential for life: oxygen, pH, CO2 and biomass. PreSens is certified EN ISO 13485:2016 and ISO 9001:2015.

Prevec microbia GmbH
PHARMA ANIMAL HEALTH

Prevec microbia is an agri-food biotechnology company specialized in developing technologies and marketing products for improving the health of food animals in order to increase production performance and food safety. Prevec microbia’s mission is to be a world leader in the development and commercialization of products providing an alternative to antibiotics for the prevention of bacterial infections and the improvement of food animal performance. The company has offices in Montreal and Saint-Hyacinthe, Quebec (Canada). Its German based subsidiary is run in conjunction with Klifovet AG.
Special ideas require special protection.

For over 50 years, VOSSIUS & PARTNER has been providing high-end consultancy for innovative companies in all fields of patent, trademark, design and copyright law. VOSSIUS & PARTNER works in your interest: competently, reliably, precisely and creatively.

**Legal areas.** Patents, trademarks and brands, design rights, copyrights, know-how protection, domains, competition law, anticounterfeiting, software and IT, data protection, law on employees’ inventions, licensing, food law, distribution agreements, franchise agreements, R & D agreements, media law, right of publicity, antitrust aspects in licensing, supplementary protection certificates.

**Technical areas.** Mechanical & electrical engineering, IT, physics, chemistry, biotechnology, pharmacology, life sciences.

**Services.** IP prosecution, IP litigation, IP searches, freedom to operate, contracts, annuities, arbitration, mediation, IP portfolio management, due diligence, strategic IP consulting, IP landscaping, IP valuation services.

It is not without reason that VOSSIUS & PARTNER is among Europe’s most renowned law firms in the field of intellectual property.
ProJect Pharmaceutics GmbH
CRO

Keywords: Drug Development, Drug Delivery, AntibodyDrugConjugate ADC, Antibody, Peptide/Protein, Small Molecules, Viruses

ProJect Pharmaceutics transfers delicate pharmaceutical molecules into pioneering drugs with a deep expertise in formulation and pharmaceutical process development for liquid or lyophilized proteins, high-concentration products, ADCs / cytotoxics and live viral vaccines. We develop a quality product and its manufacturing process on a scientific rationale pursuant to international guidelines. Teamed up with manufacturing CMOs, we smooth technology transfer from pre-clinical to large-scale supply.

Proteros biostructures GmbH
BIOTECH PRECLINICAL SERVICES

Keywords: Oncology, Metabolic Diseases, Infectious Diseases, Cardiovascular Diseases, Small Molecules, Fine Chemicals/Reagents, 3D-Structural Analysis

Proteros, Martinsried/Munich, Germany is a private biotechnology company aimed at drug discovery for technically demanding drug targets. Proteros is currently working for most of the big pharma and biotech companies in Europe, US and Japan in different types of service and collaborative relationships. For more information please visit www.proteros.com

PSI CRO Deutschland GmbH
CRO

PSI CRO Deutschland GmbH is a subsidiary of PSI CRO AG (Switzerland), a globally operating service provider specialized in clinical research and development services on behalf of the pharmaceutical and biotechnology industry. With more than 100 employees in Germany and over 2500 worldwide, we plan and execute clinical trials related to the global development of new therapies in many indications like Oncology, Gastroenterology, Haematology, Infectious Diseases, MS and other rare diseases.

PUREN Pharma GmbH & Co. KG, ein Unternehmen der Aurobindo Pharma Ltd.

PHARMA & CHEMICAL INDUSTRY

Already in the 1980s, PUREN Pharma had an important position in Germany thanks to high-quality, inexpensive generics and numerous branded drugs. Over time strategic takeovers have led to diverse company names. The range grew in the area of therapy-relevant generics and branded medicines, the broadest parenteral portfolio for clinics in Germany and attractive OTC specialties. Actavis Germany has been part of the Actavis-Allergan group and belongs now to the globally operating AUROBINDO group.
quattro research GmbH
BIOTECH BIOINFORMATICS

quattro research addresses the needs of life science and chemical industry by providing state-of-the-art solutions to manage all scientific data produced in research projects. Our applications help scientists to optimise the value of their research data, e.g. the compound management solution quattro/CM or the ELN quattro/LJ. quattro research offers software development and consulting services to solve any data management challenges in life science R&D, e.g. Biologics registration.

RAS AG
PHARMA & CHEMICAL INDUSTRY

The RAS AG emerged from the merger of rent a scientist® GmbH and the ras materials GmbH. The task of the new corporation is to develop, produce and sell new materials and technologies. The R&D services are still available as a ‘rent a scientist®’ division.

RAPID Biomedical GmbH
BIOTECH DEVICES & REAGENTS

Keywords: Oncology, CNS, Cardiovascular Diseases, Bone/Joint Diseases, Devices

RAPID Biomedical GmbH is specialised in RF coils for MRI and NMR spectroscopy. Our products include 1H MR resonators for clinical studies at all magnetic field strengths and for all organs. We also supply multi-nuclear (e.g. 1H / 31P) MR-coils for combined MRI and MRS in clinical and basic science investigations. We offer custom made MR probeheads for routine animal research and various accessory devices. Our recent work concentrates on dual tuned coils and multi array coils for parallel MRI both for human as well as for animal studies.

res mechanica
BIOTECH BIOINFORMATICS

res mechanica is a Munich-based company that develops hema.to, a software service for automatic and supportive diagnosis of leukemia based on flow cytometric data using artificial intelligence. hema.to has achieved a level of reliability in the diagnosis of mature B-cell neoplasms that is comparable to the judgment of an experienced diagnostician and is demonstrably world-class.
REMARK GmbH
Pharmaservices & Consulting

CRO

Keywords: Drug Development, Medical Writing, Clinical Trial Management and Monitoring, R&D Service

REMARK is a privately owned pharma services and consulting company founded in 1999. Quality and speed are the decisive factors in the success of a company involved in the healthcare market. To reach your goals we offer the following services: - Strategic Consulting - Project Management - Sponsor Representative - Clinical Trial Liaison / Medical Science Liaison - Medical Affairs Services - Quality Assurance Services For more information visit our web site at www.remark-pharma.com.

Ritter GmbH, Medical
BIOTECH DEVICES & REAGENTS

Keywords: Genomics, PCR, Pharmacogenetics, Proteomics, Devices, Automation, ELISA/EIA

Ritter GmbH was founded 1965. The company is established in Schwabmünchen, Bavaria. On 25,000 m² Ritter develops and produces with about 300 employees sterile and non-sterile laboratory equipment, high precision dispensers, tips and plates, certified according to the current DIN EN ISO 9001 and 13485 standards. In more than 70 countries, millions of Ritter medical products are used in clinical and biotechnological applications every day. Products: Robotic Consumables, Liquid Handling, Clinical Products.

Roche Diagnostics GmbH
BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Peptide/Protein, Antibody, PCR, ELISA/EIA, Automation, Clinical Diagnostics, Drug Development

Roche Diagnostics GmbH is part of Roche, Switzerland, a leader in research-focused healthcare with combined strength in pharma and diagnostics. At Penzberg, Roche runs one of Europe’s largest biotechnology centers for research, development and production as well as a pioneer in digital health. The portfolio comprises test systems for the life science market, diagnosis, patient stratification and therapy monitoring as well as therapeutic proteins with focus on antibodies and biomarkers for oncology.
R-Pharm Germany GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Automation, Logistics

For many years we have been manufacturing and packaging pharmaceuticals for patients in over 150 countries. Innovative technologies and a highly motivated and competent team guarantee highest reliability and quality standards as well as an extraordinary price-performance ratio besides patient safety and customer satisfaction including personal contact. A company history of more than 150 years - both independent and historically within the global production network of Pfizer, Inc. is our pride.

Heinrich-Mack-Str. 35
D-89257 Illertissen
Phone: +49 (0) 7303 12-0
E-Mail: r-pharm-germany@r-pharm.com
Internet: www.germany.r-pharm.com

Clinical Research Services

for national and international clinical research with drugs and medical devices.

TAILORED-MADE

- medicinal products:
  - interventional clinical trials
  - non-interventional studies
  - value dossiers
- medical devices:
  - trials for CE certification
  - PMCF studies

RESULTS-DRIVEN

- medical writing
- regulatory
- project management
- data management
- monitoring
- vigilance
- biostatistics
- medical & statistical advising

www.gkm-therapieforschung.de
SanoLiBio GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

SanoLiBio focuses on automated solutions in blood circulating rare cell enrichment and rare cell analysis. Cost-efficiency, accessibility, scalability, and diagnostic accuracy drive our innovations. Our technology distinguishes itself from any existing rare cell enrichment platform by our no-loss enrichment of desired cells. SanoLiBio’s market priority is non-invasive prenatal testing and cancer diagnostics and ultimately, thriving to pioneer disease prevention by cell-based liquid biopsy.

Sandoz Pharmaceuticals GmbH

PHARMA & CHEMICAL INDUSTRY

Sandoz Pharmaceuticals GmbH belongs to the global Sandoz-Group - number two worldwide in the field of generics. In Germany, we specialize on premium generics, biopharmaceuticals and well known minerals.

SciRhom GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

**Keywords:** Rheumatoid Arthritis, Inflammation, Autoimmune Diseases, Antibody, Drug Development

SciRhom GmbH, a biopharmaceutical start-up company, develops first-in-class antibodies against iRhom2, a key modulator of several crucial pro-inflammatory signaling pathways, including TNF-alpha signaling. Based on a decade of cutting-edge bench research and the successful completion of antibody generation campaigns, SciRhom is now pursuing the preclinical and early clinical development of monoclonal antibodies against iRhom2 for the treatment of autoimmune and other serious diseases.

Secarna Pharmaceuticals GmbH & Co. KG

BIOTECH THERAPEUTICS & DIAGNOSTICS

Secarna Pharmaceuticals is the leading independent European antisense drug discovery and development company. Leveraging its proprietary LNAplus platform, Secarna develops next generation antisense oligonucleotide (ASO) therapies addressing challenging or currently undruggable targets. LNAplus™ is fully validated by over 15 in-house programs and numerous industry collaborations focusing on immuno-oncology, immunology, fibrotic-, viral-, neurodegenerative- and cardiometabolic diseases.
Securetec Detektions-Systeme AG

Keywords: Analytical Chemistry, R&D Service, In-Vitro-Diagnostics, Infectious Diseases, Antibody, Toxicology, Small Molecules

Securetec Detektions-Systeme AG provides specific technologies for the detection of drugs and hazardous substances. We understand the worldwide demands of traffic safety, customs and enforcement authorities. Our competencies are the development and production of test solutions for a highly reliable day-to-day use for a multitude of rapid identification applications of drugs and hazardous substances. We detect to protect - Securetec is proud to play a part in making today’s world a safer one.

selectION Therapeutics GmbH, Martinsried, selectION Inc., San Diego

Keywords: Drug Development, Peptide/Protein, CNS, Pain, Cardiovascular Diseases

selectION is a privately owned biopharmaceutical company focused on the development of new peptide therapeutics for the treatment of severe autoimmune diseases and rare oncology indications. The Company has established an efficient technology platform to develop highly selective peptide blockers for ion channels. The most advanced drug candidate is si-544, a best-in-class Kv1.3 blocker for treatment of effector memory T cell (TEM) driven diseases.

Sension GmbH

Keywords: Clinical Diagnostics, ELISA/EIA, Autoimmune Diseases, Antibody

Sension develops immunoassays and rapid test systems for on-site analysis. The tests find broad applications in the fields of food analysis, environmental analysis, medical diagnostics, reproductive management in agriculture, and in the monitoring of samples for mold. Also technologies for label production to prevent products from counterfeiting are realized. Sension is realizing own product developments, but also performs R&D developments for partners and customers and specifically focus on the specific needs required.

SequiServe GmbH

BIOTECH DNA/PROTEIN ANALYTICS

Sequiserve offers the following custom services in molecular biology: Sanger-DNA-sequencing (plasmids, PCR-products, BACs, PACs, primer-walking, direct sequencing of bacterial pellets), Purification of PCR products and Plasmid-DNA preparation for subsequent sequencing. Sequiserve - your expert in DNA-sequencing since 1994!
SERVIER Deutschland GmbH

**PHARMA & CHEMICAL INDUSTRY**

**Keywords:** Drug Development, Cardiovascular Diseases, Hematology, Neurology, Rheumatoid Arthritis, Oncology

Servier is an international pharmaceutical company governed by a non-profit foundation, with its headquarters in France (Paris-Suresnes). With a strong international presence in 149 countries and a turnover of 4.6 billion euros in 2019, Servier employs 22,000 people worldwide. Entirely independent, the Group reinvests 25% of its turnover (excl. generics) in R&D. Five areas of excellence: cardiovascular, immune-inflammatory, neurodegenerative diseases, cancer, diabetes and generics.

Shivom.io, c/o Axel Schumacher

**BIOTECH BIOINFORMATICS**

Shivom is spearheading the next era of Genomics & Precision Medicine and powering the transition to value-based healthcare. Our focus is on the transformational convergence of OMICS technologies with blockchain, artificial intelligence, cryptography and other real cool technologies to enable secure and personalized medicine with global scalability.

Sigma-Aldrich Chemie GmbH

**BIOTECH DEVICES & REAGENTS**

**Keywords:** Proteomics, Antibody, Genomics, CNS, Small Molecules, Knock Out, PCR

Our biochemical and organic chemical products and kits are used in scientific and genomic research, biotechnology, pharmaceutical development, the diagnosis of disease and as key components in pharmaceutical and other high technology manufacturing. We have customers in life science companies, university and government institutions, hospitals and in industry. Sigma-Aldrich operates in 36 countries and has over 7,600 employees providing excellent service worldwide.

Silantes GmbH

**BIOTECH DEVICES & REAGENTS**

Silantes GmbH, engages in development, manufacturing, marketing and distribution of stable isotopically labeled biomass and bio-molecules. By using a new patented technique for labelling S-isotopic bio-molecules, Silantes is able to offer improved quality and reduced costs for the customers in industrial and academic research fields at the same time. Additionally, international research projects with different scientific groups and close collaboration with NMR-specialists enable synergetic effects.
**SIMFO GmbH**

**BIOTECH THERAPEUTICS & DIAGNOSTICS**

SIMFO GmbH is a research and development facility with advanced expertise in personalized medicine. It focuses particularly on the development of innovative analysis methods in haematological and oncological diagnostics. With maintrac®, simfo GmbH offers an analysis platform for the early detection of circulating tumor cells. In simfo, biotechnology and pharmaceutical companies will find a professional partner for conducting scientific studies and for preclinical phases of drug development.

Kurpromenade 2
D-95448 Bayreuth
Phone: +49 (0) 921 730052-10
Internet: www.simfo.de

**SiNatur GmbH**

**BIOTECH THERAPEUTICS & DIAGNOSTICS**

Keywords: Metabolic Diseases, Diabetics

SiNatur owns the patent rights for the structure, preparation and medicinal applications Sub-Nano-Silicic Acid (SNSA). This recently discovered SNSA is the first biologically active form of silicic acid and of silicon generally. The substance is a potent inhibitor of P-type ATPases and of certain Protein-Phosphatases with IC50 in the nanomolar range. Due to the ubiquitous presence of Si in living organisms the discovery of the first biological active form of this element will have a broad scientific and practical impact. SiNatur is developing medicinal applications of SNSA first of all in the therapy of diabetes and of gastric hyperacidity.

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 856625-55
E-Mail: info@sinatur.net
Internet: www.sinatur.net

**SIRION BIOTECH GmbH**

**BIOTECH DEVICES & REAGENTS**

Keywords: Gene Transfer, R&D Service, Viruses, Cell Therapy, Gene Therapy, Drug Development

SIRION Biotech offers the world’s most comprehensive viral vector AAV-, Lentivirus-, and Adenovirus-based technologies to expedite gene and cell therapy and vaccine R&D. LentiBOOST™ transduction reagent is actively used to improve hematopoietic cell transductions in clinical trials (USA, Europe). Commercial arrangements range from fee-for-service, all the way to milestone & licensing.

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 700961-999
E-Mail: info@sirion-biotech.de
Internet: www.sirion-biotech.com

**siTOOLs Biotech GmbH**

**BIOTECH DEVICES & REAGENTS**

siTools Biotech is a young, innovative Biotech start-up dedicated to provide innovative and superior RNAi reagents to the scientific community. siTools Biotech is located at Munich’s biotech cluster in Planegg/Martinsried. “siPools” are highly complex but accurately defined pools of siRNAs. They enable highly efficient and reliable target gene silencing without detectable off-target effects.

Lochhamer Straße 29a
D-82152 Planegg
Phone: +49 (0) 89 4431 2584
E-Mail: info@sitoolsbiotech.com
Internet: www.sitoolsbiotech.com
Smart4Diagnostics GmbH
BIOTECH DEVICES & REAGENTS

Keywords: Devices, Bioinformatics

Smart4Diagnostics GmbH closes the data gap between blood collection and lab analysis and enables a new quality standard for diagnostic decision making. We change medical diagnostics from a trust-based system into an evidence-based system. Our digital human sample fingerprint is a quantum leap forward for patient safety, the quality of medical decisions and sample turnaround time in the lab. We create a trustworthy and verifiably basis for the personalized medicine of the future.

SMARTEC IngenieurBüro
BIOTECH DEVICES & REAGENTS

Keywords: Devices, Automation, Chip/Array Technology, PCR, Tissue Engineering/Cell Culture

SMARTEC IngenieurBüro is your competent partner for individual system approaches and instrument development in the biological laboratory. SMARTEC IngenieurBüro convinces with know-how within the ranges biotechnology, analytics, genetic engineering, micro technology as well as micro fluidic. SMARTEC IngenieurBüro solves tasks of instrumentation for molecular and immunological process engineering. SMARTEC IngenieurBüro supports you from the idea to all stages of the product.

Sourcia GmbH
CRO

Keywords: Pharmacovigilance, Regulatory Affairs, Drug Development, Clinical Trial Management and Monitoring, R&D Service, Devices

Sourcia is your high-experienced, flexible and independent partner in clinical development. While you are focusing on sciences, we are your partner in project management, operational set-up and execution of your Clinical Development Plan.

SpheroTec GmbH
BIOTECH PRECLINICAL SERVICES

Keywords: Drug Development, Oncology, Tissue Engineering/Cell Culture

SpheroTec is a biotech company offering humanized 3D cell culture models, i.e. 3D microtumor models and immunological models for drug testing. This diagnostic service is preclinically offered to cancer patients to identify the most effective drug treatment (personalized therapy). Drug testing includes chemotherapeutics, antibodies, immune therapeutics and natural compounds. In addition, our 3D models are used from pharma and biotech companies in the process of drug development.
SSS International Clinical Research GmbH

CRO

Keywords: Oncology, Respiratory Diseases, Hematology, Autoimmune Diseases, Ophthalmology, Cardiovascular Diseases

SSS International Clinical Research is a Service Provider for the pharmaceutical, biotechnological and medical device industry since 1993, with headquarters in Germany and subsidiaries in Romania and Poland. We provide high quality, comprehensive and internationally integrated Clinical Operations Services throughout Europe. Our services have been proven for more than 25 years and through many successful projects.

Landsberger Str. 23/25
D-82110 Germering
Phone: +49 (0) 89 800 650-0
E-Mail: info@cro-sss.de
Internet: www.cro-sss.eu

Staburo GmbH – Statistical Consulting

CRO

Keywords: Biomarker Discovery & Development, Bioinformatics, Data Management, Cardiovascular Diseases, Oncology, Data Management and Biostatistics

Staburo is a Munich-based biostatistics company, specialized in statistical consulting and programming in the field of clinical trials. We develop tailor-made client solutions, based on our 6 pillars: Clinical Statistics, Translational Medicine & Biomarkers, PK/PD, HTA, Non-clinical Statistics and Statistical Programming. Our customers are pharmaceutical companies, CROs and biotech companies, with whom we work on a flexible basis.

Aschauer Str. 26b
D-81549 München
Phone: +49 (0) 89 5527 1520
E-Mail: info@staburo.de
Internet: www.staburo.de

SÜD-LABORBEDARF GmbH

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Devices

SLG is a German whole seller for molecular biology research consumables, located in Gauting near Munich since 1980. Our main business is high quality consumables such as gloves, liquid handling products, DNA/RNA kits and plastic ware like racks and cryo boxes. We sell by direct mail to Germany, Austria and Switzerland and through distributors in various European Union countries under our own brands SLG, SafeGrip, SL-Tip, SL-Pette and Hi Yield.

Starnberger Str. 22
D-82131 Gauting
Phone: +49 (0) 89 850 6527
E-Mail: info@suedlabor.de
Internet: www.suedlabor.de
Swedish Orphan Biovitrum GmbH, SOBI

Swedish Orphan Biovitrum is an international company specializing in rare diseases. Our mission is to develop and deliver innovative therapies and services to improve the lives of these patients and their families. The Swedish Orphan Biovitrum GmbH (Sobi) has been active in Germany since 2017. The company is based in Martinsried, Bavaria. Behind the success of Sobi are the nearly 40 employees in Germany whose daily motivation is to help improve the lives of patients with rare diseases.

SYNLAB pharma institute

Keywords: Analytical Chemistry, Bioanalytics, R&D Service, Logistics, Clinical Diagnostics, Laboratory, Biomarker Discovery & Development

SYNLAB Pharma offers a very broad range of laboratory services to the biotechnology and pharmaceutical industries as well as to manufacturers of medical devices. Our portfolio includes global clinical trial services, bioanalytical services, biomarker testing, personalized medicine concepts, logistics, sample storage, production monitoring, product release and stability studies, always working in accordance with the highest standards such as DIN/EN ISO/IEC 17025/15189, GMP, GLP, GCLP or GCP.

Syntacoll GmbH

PHARMA & CHEMICAL INDUSTRY

Syntacoll is a subsidiary company and the only development and production site of Innocoll Pharmaceuticals Limited, an international pharmacy group. Since 1992, Syntacoll is developing and producing innovative, collagen-based absorbable implants and wound dressings at our production site in Saal an der Donau. Our facility is GMP compliant and ISO 13485 certified. Additionally, Syntacoll holds a manufacturing license for collagen-based drugs.

Synteract GmbH

CRO

Keywords: Cardiovascular Diseases, CNS, Metabolic Diseases, Nephrology, Oncology, Pain

Synteract is an innovative mid-size CRO with European HQ in Munich. We are providing international, full-service, Phase I-III clinical trials services to biopharma companies. Over its nearly 35-year history, Synteract has contributed to more than 240 product approvals. Our core development areas are: oncology, dermatology, neuro sciences, general medicine and vaccination, rare/orphan disease, and pediatrics.
Syneos Health Germany GmbH

Keywords: CRO/CMO, Clinical Trial Management and Monitoring, Medical Writing

The coming together of INC Research and inVentiv Health as one global company, called Syneos Health, has created the industry’s only true end-to-end solution. This one entity combines world-renowned clinical research and commercialization capabilities with today’s most advanced science, business and data technologies to make real advances possible. We help you improve performance, reduce risk and expedite delivery of healthcare innovation to patients worldwide.

Systasy Bioscience GmbH

Keywords: R&D Service, Biomarker Discovery & Development, CNS, Personalized Medicine, Small Molecules, Drug Development

At Systasy, we believe that early-on knowledge of perturbed signaling pathways will improve and accelerate the drug discovery process for genetically complex brain disorders. With our ground-breaking tools and technologies, we aim at providing an opportunity for pharma & biotech companies to identify novel drug targets based on disease biology. To achieve this goal we create highly relevant HTS-compatible pathway-centric assays in human 2D/3D disease models for functional screening.

T-CURX GmbH

Keywords: Oncology, Hematology, Personalized Medicine, Cell Therapy, Drug Development

T-CURX develops new generation of CAR T cells for personalized cancer immunotherapy built on proprietary technologies that overcome challenges in safety & efficacy, manufacture & scalability of conventional CAR T therapy. T cells are reprogrammed using virus-free gene transfer technology to destroy tumor cells. CAR T cells are living drugs that persist life-long and aim to provide protection from relapse. T-CURX’s target pipeline addresses several cancer indications in hematology and oncology.
TauroPharm GmbH
PHARMA & CHEMICAL INDUSTRY

TauroPharm GmbH is a healthcare company founded in 2000 and based in Waldbüttelbrunn, Germany. We want to minimize infection risks in global healthcare and thus increase patient safety worldwide. We manufacture products that prevent infections associated with central venous catheters and port systems in a variety of applications like administration of medication in the fields of oncology and haematology as well as other implanted medical devices.

The NCD Company UG
BIOTECH PRECLINICAL SERVICES

Keywords: Toxicology

The NCD Company is an independent project company and provides all services of a non-clinical development department for biotech and pharma companies with an experienced team at highest level. By outsourcing preclinical development, you will increase flexibility, save internal resources and ensure the access to a broad spectrum of knowledge and experience. We provide Drug Development Planning and Management, Safety Testing/Toxicology, ADME/DMPK, Outsourcing, QA (GLP) and Regulatory Submission.

Therawis Diagnostics GmbH
PHARMA & CHEMICAL INDUSTRY

Keywords: In-Vitro-Diagnostics, Oncology

Therawis Diagnostics GmbH was founded by an experienced team with proven track record in oncology, diagnostics, corporate development, capital markets and develops diagnostics to support and guide optimal therapy for cancer patients. Therawis Diagnostics and its partner Qiagen, Hilden, Germany, launched the therascreenPITX2 RGQ PCR Kit in 2018, a novel clinically validated biomarker test to predict outcome to anthracycline-based chemotherapy in high risk breast cancer patients.

Thermo Fisher Scientific GENEART GmbH
BIOTECH DEVICES & REAGENTS

Keywords: Genomics, Combinatorics

Thermo Fisher Scientific supplies innovative solutions for the world’s pharmaceutical and biopharmaceutical industries. With applications that span the drug development process - from drug discovery through large-scale commercial production - we provide a broad range of products and services including single-use technologies, customized fluid transfer systems, high-quality media and sera, freezing and storage equipment, and innovative consumables and reagents, purification, and analytics.
Thermosome GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Oncology, Liposomes, Small Molecules, Drug Development, Drug Delivery

Thermosome is leveraging its technology platform to create products with improved therapeutic index that exploit a novel MoA called intravascular drug release. Drug-loaded nanocarriers are created which after i.v. infusion release their content locally upon the influence of mild heat achieved by various clinically established targeted heating techniques (microwave, ultrasound). As a result, up to 15-fold higher local drug concentrations can be reached to improve therapeutic outcomes.

TRIGA-S stands for excellency and highest quality in clinical and technical studies for more than 20 years and is a preferred full-service CRO partner of global diagnostic companies. Within the framework of the new IVD- and Medical Device-Regulation (IVDR/MDR), we offer tailor-made solutions.

TRIGA-S, YOUR PARTNER FOR SUCCESSFUL CLINICAL TRIALS AND TECHNICAL EVALUATIONS.

Mühltal 5 • D-82392 Habach
Tel. +49 (0) 88 47 - 695 78 0
info@triga-s.de
www.triga-s.de

S2 CONTRACT LABORATORY • STUDY MANAGEMENT
STUDY MONITORING • REGULATORY AFFAIRS

COMPLETE SAMPLE OFFER:
COLLECTION • LOGISTICS • PROCESSING • STORAGE

IVD DEVELOPMENT CAN BE CHALLENGING.
OUR EXPERTISE WILL HELP YOU MASTER IT.
tilibit nanosystems GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Nanobiotechnology, New Materials, R&D Service

tilibit nanosystems is specialized in the development and production of functional DNA nanostructures. We offer the design of custom structures for research applications, as well as collaborative development projects with industry partners for novel commercial applications. Nanostructure application fields comprise fields such as drug delivery, diagnostics, sensors, and analytical devices.

TILL I.D. GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Automation, Microscopy, Imaging, 3D-Structural Analysis

TILL I.D. is a small, innovative company in between research and industry. We develop concepts and prototypes for all areas in light microscopy. Our projects focus on an innovative microscopy platform, which is entirely tailored for digitalization. Its versatility and flexibility does not stem from a number of attachable modules, but from a fundamental design to which different imaging techniques and illumination concepts have contributed right from the start.

TopLab GmbH

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Proteomics

TOPLAB GmbH is a leading ISO 9001/GMP certified and FDA registered service provider having outstanding expertise in proteome analysis, protein identification and characterization with more than 25 years of experience. The vision of TOPLAB is to support our clients from pharma, biotech and academia with highest quality standards, modern technologies and an experienced and highly motivated team, to achieve confident results in compliance with the timelines of our customers with calculable costs.

TRIGA-S e.K. Scientific Support

CRO

Keywords: Regulatory Affairs, Medical Writing, ELISA/EIA, Laboratory, Data Management and Biostatistics, In-Vitro-Diagnostics, Clinical Trial Management and Monitoring

TRIGA-S stands for excellency and highest quality in clinical and technical studies for more than 20 years and is a preferred service partner of global diagnostic companies. Within the framework of the new IVD- and Medical Device-Regulation (IVDR/MDR), we offer tailor-made solutions for clinical and technical trials: - Contract Laboratory (S2) - Study Management & Monitoring - Regulatory Affairs - Sample Collection - Sample Processing - Sample Storage - Study Logistics
TRION Research GmbH
BIOTECH PRECLINICAL SERVICES

Keywords: Drug Development, Immune Therapy, Antibody Production Service

Our services comprise Liquid Biopsy diagnostics with the analysis of virus-infected cells and the detection of disseminated tumor cells in blood, urine and other body fluids. Moreover, we offer the full range of preclinical and clinical support from trial design over immunomonitoring and tumor biology analysis to data management and logistics solutions. We work together with our partners to elucidate the modes of action of new compounds.

Tubulis GmbH
OTHER SERVICES

Keywords: Oncology, AntibodyDrugConjugate ADC, Drug Delivery, Drug Development

Tubulis® generates uniquely matched protein-drug conjugates by combining proprietary novel technologies with disease-specific biology. Our goal is to expand the therapeutic potential of antibody drug conjugates (ADCs) ushering in a new era and delivering better outcomes for patients. We will advance a range of conjugates, unlimited by indication, using our own discovery capabilities and by solving development challenges for partners with both antibody and chemical assets.

UroQuant GmbH
BIOTECH

UroQuant develops non-invasive cancer IVD (In Vitro Diagnostics) enabling precision medicine for clinical routine. Starting with bladder cancer, quantitative measurement of disease-specific proteins (biomarkers) will allow UroQuant to diagnose cancer much earlier and more reliably than competitive test kits. Our IVD test will significantly improve patient treatment and patient compliance leading to a substantial cost reduction for the health care system.

vasopharm GmbH
BIOTECH THERAPEUTICS & DIAGNOSTICS

vasopharm is a pharmaceutical company dedicated to the discovery and development of novel therapeutics for the treatment of cerebro- and cardiovascular diseases and their consequences. The company is focused on the development of therapeutics which permits steering the bioavailability of biological NO, covering the entire NO/cGMP signal cascade and its functional counterpart NOX. vasopharm’s drug candidate VAS203 represents a completely new class of NOS modulators targeting cerebral vessels and cerebral tissue, thus preventing life threatening rises in intracranial pressure after a traumatic brain injury.
Vectura GmbH
MEDTECH

Keywords: Inflammation, Respiratory Diseases, Infectious Diseases, Small Molecules, Peptide/Protein, Devices, Drug Delivery

Vectura, a FTSE250 company listed on the London Stock Exchange (LSE: VEC), is an industry-leading inhaled airways disease focused business with proprietary formulation and devices across DPI, pMDI and smart nebulisation platforms. With our extensive range of technologies, capabilities and collaborations, we believe we can become a leader in the development of inhalation products, increasing our ability to help patients suffering from respiratory diseases. Vectura has seven inhaled, four non-inhaled and ten oral products marketed by partners with growing global royalty streams and a portfolio of drugs in clinical development, a number of which have licence agreements with several global pharmaceutical & biotechnology companies.

Velvio GmbH
BIOTECH THERAPEUTICS & DIAGNOSTICS

Velvio develops Antisense Oligonucleotide compounds to restore organ repair functions as treatment for Orphan Diseases in Neurodegeneration - first of all Amyotrophic Lateral Sclerosis (ALS) and Idiopathic Pulmonary Fibrosis (IPF). Further, Velvio offers new opportunities in Immune-Oncology and treatment concepts in liver and brain tumors. From our broad compound pipeline, we are ready to go first in man with ALS and we are about to finish preclinical drug development in IPF.

vermicon AG
BIOTECH AGRO, FOOD, ENVIRONMENT

Keywords: Microscopy, Laboratory, Bioanalytics, Other Diagnostics

vermicon AG offers innovative solutions for microbiology. The development of VIT® (vermicon identification technology) made FISH accessible not only for academic research but also for the industrial microbiology. Focusing on the direct and cultivation-independent analysis of microorganisms, the company provides fast, highly specific and reliable insight into the microbiological composition of samples. With satisfied customers worldwide, vermicon is driving the evolution of modern microbiology.

Vertex Pharmaceuticals (Germany) GmbH
BIOTECH THERAPEUTICS & DIAGNOSTICS

Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has approved medicines that treat the underlying cause of cystic fibrosis (CF) and has several ongoing clinical and research programs in CF. Vertex has a robust pipeline of investigational small molecule medicines in other serious diseases, as well as a rapidly expanding pipeline of genetic and cell therapies.
Vertis Biotechnologie AG

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: PCR, NGS, Informatics, Genomics

Vertis is a research-oriented company in the field of functional genomics. The strength of our service is customer-oriented flexibility which is based on our innovative technology platform which we have developed in our 20-year history. We offer innovative tools and strategies for the comprehensive qualitative and quantitative analysis of bacterial and eukaryotic transcriptomes, using state-of-the-art Next Generation Sequencing (NGS) of RNA molecules (RNA-seq).

verum.de GmbH

CRO

Keywords: Cardiovascular Diseases, CNS, Dermatology, Diabetics, Oncology, Respiratory Diseases

Verum is a regional CRO specializing in clinical trials management in Germany, Austria as well as in Central and Eastern Europe. Since 2001 Verum served 158 trials in different areas: neuroscience, oncology, cardiology, etc. During last years verum is also focused on biosamples (BS) collection studies, sponsored by developers and manufactures of integrated systems for the analysis of genetic variation and biological function. We are an expert in regulatory and ethic affairs for BS collection.

Vicron gmbh

BIOTECH THERAPEUTICS & DIAGNOSTICS

Therapy optimisation for doctors & patients in real-time: vicron strives for excellence in medical expertise for proprietary algorithms, data analytics and neural networks. Our Decision Support System is designed to empower doctors for expedient and fast data analytics to make better treatment decisions for patients in hospitals. To ensure data integrity, vicron smoothly integrates with EHRs and uses decentralised data management processes.

Vifor Pharma Deutschland GmbH

PHARMA & CHEMICAL INDUSTRY

Vifor Pharma is an internationally active pharma company, which researches, develops, produces and markets its own pharmaceutical products worldwide. The company’s main area of focus is iron replacement therapy, Vifor Fresenius Medical Care Renal Pharma and infectious diseases.
ViGeneron Gmbh

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Neuro-Degeneration, Ophthalmology, Gene Therapy, Industrial Biotechnology, Orphan Drug

ViGeneron is dedicated to developing innovative gene therapies to treat ophthalmic diseases with high unmet medical need, as well as partnering with leading biopharmaceutical players in other disease areas. The company’s pipeline is built on two proprietary adeno-associated virus (AAV) technology platforms. For further information, please visit www.vigeneron.com.

Viramed Biotech AG

BIOTECH DEVICES & REAGENTS

Keywords: ELISA/EIA, Clinical Diagnostics, In-Vitro-Diagnostics, Infectious Diseases

Viramed Biotech AG produces IVD-Products, based on its proprietary research and development. The company focuses on Westernblot-, Stripe- and Elisatetests for serological screening and confirmation of infectious and autoimmune diseases. The major products are Westernblot tests for Borrelia sp., Yersinia, Helicobacter p., Epstein-Barr-Virus, Bordetella pertussis, ENA and autoimmune liver diseases. The company aims to intensify export of existing products worldwide and appreciates further distribution contacts.

vivoPharm Europe Ltd, a CGI company

CRO

Keywords: Bioanalytics, Pharmacokinetics, Oncology, Drug Development, Pharmacology, Toxicology, Vaccines

vivoPharm is a successful and fast-growing precision research organization (CRO) that provides integrated preclinical services worldwide. Using our experience and knowledge, we assist in the planning and performance of tailored studies, from discovery stage through to clinical development and beyond. We’re a unique IO precision service organization, active in preclinical and clinical services. All work is carried in AAALAC accredited and GLP compliant facilities in Australia and the US.
Wacker Chemie AG

PHARMA & CHEMICAL INDUSTRY

Keywords: Fine Chemicals/Reagents, Antibody Production Service, Peptide/Protein, CRO/CMO, Nutraceuticals

WACKER is a globally active chemical company headquartered in Munich, Germany. With a wide range of state-of-the-art specialty products, WACKER is a leader in numerous industrial sectors. Within its bio division, WACKER uses advanced biotech processes to offer innovative and tailored solutions and biotech products for the pharma and the food & nutrition industry. Its products include pharmaceutical proteins, cyclodextrins and fermentation-grade cysteine.

Hansa-Seidel-Platz 4
D-81737 München
Phone: +49 (0) 89 6279-0
E-Mail: info@wacker.com
Internet: www.wacker.com

Winicker Norimed GmbH
Medizinische Forschung

CRO

Keywords: Data Management and Biostatistics, Medical Writing, Clinical Trial Management and Monitoring, Pharmacovigilance, Regulatory Affairs

Winicker Norimed GmbH is an independent contract research organization. We manage projects from the planning through the field phase to the analysis and the clinical study report or publication. We deliver quality services according to applicable laws and international guidelines based on either our own or our clients SOPs. Winicker Norimed manages phase II-IV clinical trials with pharmaceuticals, studies with medical devices as well as non-interventional and epidemiological studies.

Deutschherrnstr. 15-19
D-90429 Nürnberg
Phone: +49 (0) 911 92680-0
E-Mail: wn@winicker-norimed.com
Internet: www.winicker-norimed.com

XL-protein GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: AntibodyDrugConjugate ADC, Drug Development, Drug Delivery, Pharmacokinetics, Peptide/Protein

XL-protein is a biopharmaceutical company commercializing its groundbreaking PASylation® technology, which enables the design of biologics with extended plasma half-life and enhanced action. Based on a strong proprietary technology position, XL-protein focuses at the preclinical as well as clinical development of PASylated proteins in diverse disease areas. XL-protein is engaged in a growing number of partnerships with international pharmaceutical and biotech companies at various levels.

Lise-Meitner-Str. 30
D-85354 Freising
Phone: +49 (0) 8161 53730-90
E-Mail: info@xl-protein.com
Internet: www.xl-protein.com

XL-protein GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: AntibodyDrugConjugate ADC, Drug Development, Drug Delivery, Pharmacokinetics, Peptide/Protein

XL-protein is a biopharmaceutical company commercializing its groundbreaking PASylation® technology, which enables the design of biologics with extended plasma half-life and enhanced action. Based on a strong proprietary technology position, XL-protein focuses at the preclinical as well as clinical development of PASylated proteins in diverse disease areas. XL-protein is engaged in a growing number of partnerships with international pharmaceutical and biotech companies at various levels.

Lise-Meitner-Str. 30
D-85354 Freising
Phone: +49 (0) 8161 53730-90
E-Mail: info@xl-protein.com
Internet: www.xl-protein.com
XVir® Therapeutics GmbH
BIOTECH THERAPEUTICS & DIAGNOSTICS

XVir Therapeutics GmbH is focusing on the clinical development of oncolytic adenoviruses for the treatment of various solid tumors, and in particular of drug-resistant or radiation-resistant tumors. XVir Therapeutics has completed preclinical development of its most advanced product candidate XVir and is preparing a Phase I clinical study in the indication glioblastoma. XVir’s therapeutic approach is covered by proprietary patents and patent applications, respectively.

Zeta GmbH
BIOTECH & PHARMA PRODUCTION

Keywords: Bioinformatics, Data Management and Biostatistics, Devices, Bioprocessing, Industrial Biotechnology

The ZETA group is one of Europe’s largest provider of engineering, automation and process technology for biopharmaceutical aseptic applications. The product range extends from streamlined engineering project execution to state-of-the-art customized process systems for biologic drug substance production plants. Concept, Basic and Detail Engineering Digitalization and Smart Engineering Automation Bioreactors & Fermentation Systems Bioprocessing Skids Freeze & Thaw Systems

Zimmer BioTech GmbH
BIOTECH THERAPEUTICS & DIAGNOSTICS

Zimmer BioTech, a Neu-Ulm, Germany-based start-up is advancing Alevin deep a drug based on 5-Aminolevulinic acid (ALA), used for treatment of actinic keratoses in photodynamic therapy (PDT). New developments show a huge upside potential as the drug could be used to treat Acne. Investors include Zimmer MedizinSysteme GmbH, the medical device producer, and High-Tech Gründerfonds. The company will use the funds to continue to develop a new therapy to combat skin cancer and Acne.
YOUR TRUSTED PARTNER
FROM CONCEPT TO MARKET

Rentschler Biopharma is a leading contract development and manufacturing organization (CDMO), focused exclusively on client projects. From its headquarters in Laupheim, Germany, and its site in Milford, MA, USA, Rentschler Biopharma offers process development and manufacturing of biopharmaceuticals as well as related consulting activities, including project management and regulatory support. Rentschler Biopharma’s high quality is proven by its long-standing experience and excellence as a solution partner for its clients. Rentschler Biopharma offers best-in-class formulation development, considered at every step of the biopharmaceutical process, in a strategic alliance with LEUKOCARE AG. Rentschler Biopharma is a family-owned company with about 1,000 employees.

Rentschler Biopharma SE
Erwin-Rentschler-Str. 21 · 88471 Laupheim · Germany
info@rentschler-biopharma.com · www.rentschler-biopharma.com
Imprint

Editorial staff: Gabriele Klingner, Dr. Georg Käab, Dr. Christina Grimm, Dr. Stephanie Wehnelt, Dr. Ruoyu Sun
Company Profiles: Dr. Christina Grimm, Dr. Georg Käab, Corina Hierl, Nikolaus Repgen
Advertisement: Dr. Andreas Berghammer

Data analysis was compiled together with BIO-Deutschland e.V.

We thank the Bavarian companies and the regional organizations of the Bavarian Biotechnology Cluster for supporting this survey.
July, 2020

Contact

Prof. Horst Domdey, CEO BioM
Spokesman of the Bavarian Biotechnology Cluster

The Bavarian and the Munich Biotechnology Clusters are managed by:

BioM Biotech Cluster Development GmbH
Am Klopferspitz 19a
D-82152 Martinsried
Phone: +49(0)89-899679-0
Fax: +49(0)89-899679-79
E-Mail: info@bio-m.org
www.bio-m.org

Cover: iStock by Getty Images
The layout, graphics and other contents of this brochure of the Bavarian Biotechnology Cluster are protected by copyright law.

Layout-Design: MxM, Munich, www.mxm.de
Pictures copyright as indicated

Supported by the Bavarian Ministry of Economic Affairs, Regional Development and Energy
www.stmwi.bayern.de/en/

Weitere Informationen über Amgen finden Sie unter: www.amgen.de
YOU HAVE THE IDEA—
WE HAVE THE LOCATION

→ Site: 26,000 m², S1 laboratories
→ Real estate and facility management on site
→ Faculty Club and conference rooms for up to 100 people
→ Kindergarten (Bio Kids), Chemistry School Elhardt
→ Hotel CAMPUS AT HOME
→ Restaurant SEVEN AND MORE, Café Freshmaker
→ On the Martinsried Campus: over 50 start-ups in the IZB, two Max Planck Institutes, ten faculties of the LMU, Clinic of the University Munich

WHERE THE FUTURE BECOMES REALITY